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General introduction
INTRoduCTIoN
“Sometimes fracture of the neck of the femur occurs at the hip joint, which I saw when called 
to treat a good woman. Seeing that the leg was shorter than the other, with a prominence 
the trochanter makes externally and below the joint of the ischium, I assumed this was the 
head of the bone, dislocated and not fractured. Then I pulled and set the bone, it seemed, 
in its socket, after which the two legs were equal in length and contour, and I dressed and 
treated it as a dislocation. Two days later I found her in great pain, the leg short again and 
the foot turned inward. I removed the bandages and found that the prominence had reap-
peared. Then I tried again to replace the bone in its socket and I felt the bone crepitate. Then 
I found there was no joint cavity, so I knew this was a fracture and not a dislocation.”
This first report in medical literature of a femoral neck fracture was written by Ambroise 
Paré (1510-1590) and published in 1575 (1). Besides being the first and the notification 
of the inward turned foot (mostly the foot is turned outward), also notable in this report 
is Paré’s transparency about the initial misdiagnosis. An even longer delay in diagnosing 
a femoral neck fracture is in the probably oldest documented case: a woman living in 
the XIIth Dynasty (1990–1786 B.C.) in Egypt, who was diagnosed by researchers about 
4000 years after the fracture (2). The discovery of X-rays in 1895 by the first winner of 
the Nobel Prize in physics (1901), Wilhelm Conrad Röntgen (1845-1923), made it sub-
stantially easier to identify femoral fractures. Another landmark in hip fracture history 
is the creation of the first classification in 1822 by Sir Astley Cooper (1768-1841). He 
classified proximal femoral fractures in intra- and extracapsular fractures on specimens 
(3). Nowadays the intracapsular fractures are classified on X-rays as undisplaced (type 
1 and 2) and displaced (type 3 and 4), according to Robert Symon Garden (1910-1982) 
(Figure 1) (4).
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Figure 1. Classification according to Garden (4).
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Almost 60% of all proximal femoral fractures are femoral neck fractures of which 80% 
is displaced (5).
The optimal individual treatment is under scientific debate and the famous term “the 
unsolved fracture”, introduced by Kellog Speed (1879-1955) in 1935, is still accepted 
(6). The individual characteristics of both the fracture and the patient together with 
the preference of the surgeon determine the treatment mostly being either internal 
fixation or arthroplasty. This thesis focuses on the treatment of elderly patients with 
a displaced femoral neck fracture using arthroplasty. Surgical options for arthroplasty 
include total hip arthroplasty (THA) and hemi-arthroplasty (HA). The variable practice 
is demonstrated by a survey among an international group of orthopedic trauma sur-
geons (7). In order to identify the most favorable type of arthroplasty and finally develop 
an evidence based practice guideline the HEALTH trial (NCT00556842) was started in 
2008. This international multicenter randomized controlled trial compares THA and HA 
by evaluating secondary interventions, complications, functional outcome and quality 
of life of 1,434 elderly patients with a displaced femoral neck fracture (8). Appendix 
1 provides a summary of the aims and the protocol of the HEALTH trial. Data of the 
Dutch subset of the HEALTH trial form the base of this thesis. In general, hospitalization, 
long term rehabilitation, reduced quality of life, large healthcare expenses, and a high 
one year mortality make hip fractures a major public health issue. Despite declining 
trends for hip fractures in Western countries (9-13), a continued worldwide increase is 
expected because of the aging of populations by improving global healthcare and in-
creasing industrialization and urbanization (14). Another important societal focus is on 
the health care related costs of femoral neck fractures. Hospital stay is one of the most 
important direct cost determinants in the treatment of femoral neck fractures (15). The 
implementation of multidisciplinary clinical pathways is related to with positive effects 
on mortality, postoperative complications, and in-hospital stay, leading to reduced costs 
(16-18). Consequently, the Dutch Ministry of Health, Welfare and Sport propagates early 
transfer to medical rehabilitation facilities (15).
AIms oF ThIs ThesIs
The aim of this thesis is threefold. The first aim is to study the cumulative incidence of 
bilateral femoral neck fractures and the use of two types of arthroplasty for these frac-
tures. The second aim is to investigate the reliability and validity of the Western Ontario 
and McMaster Universities Osteoarthritis Index (WOMAC) in a femoral neck fracture 
population. Finally, the third aim is to evaluate health care costs and functional results 
after treatment with arthroplasty for femoral neck fractures.
13
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ouTlINe oF ThIs ThesIs
Chapter 2 includes the results from time trends in numbers and incidence rates of hip 
fracture related hospitalizations and admission time in the older Dutch population from 
1981 throughout 2008 using the National Hospital Discharge Registry. It is known that a 
first hip fracture is a risk factor for a second, contralateral fracture. Data on the similarity 
of the treatment of bilateral femoral neck fractures are however only scarcely available. 
This information can be relevant to inform patients about the measures to be taken in 
order to minimize the risk of a second fracture in the future. Chapter 3 describes the 
cumulative incidence of non-simultaneous bilateral femoral neck fractures, including 
patient and treatment characteristics. There is still no consensus on the optimal type of 
arthoplasty, despite multiple clinical comparative studies. Therefore, a systematic review 
and meta-analysis of data from randomized trials concerning THA versus HA is included 
in chapter 4. This chapter forms another important base for the rationale of performing 
the multicenter HEALTH trial. Multicenter trials can be organized in different ways. For 
the Dutch sites most study tasks were managed by a central trial coordinator (central 
coordination), Canadian and US sites used local study coordinators (local coordination). 
Chapter 5 describes the results of a prospective observational study that analyses how 
these different strategies affected trial performance.
The main question when treating patients is to what extent patients are able to regain 
the functional ability they had prior to the fracture. Traditionally, objective determinants 
like mortality, complications, and revision surgery were used to assess treatment out-
comes after hip fracture surgery. Nowadays, methods to assess the patient’s perspective 
of treatment results are gaining importance as an indicator of the quality of care. These 
subjective functional outcomes and quality of life are quantified using patient reported 
outcome measures (PROMs). A validated questionnaire in the hip fracture population 
however was not available. Chapter 6 aims to determine the reliability, validity, and re-
sponsiveness of the WOMAC, compared with a known functional outcome questionnaire 
(SF-12) and a quality of life questionnaire (EQ-5D), in elderly patients who sustained a 
femoral neck fracture.
Quality of care of patient populations can be improved by implementing clinical 
pathways. Chapter 7 describes the effect of the implementation of a clinical hip fracture 
pathway on admission duration and complication rates in a Dutch teaching hospital. 
Cost awareness be-comes more important in today’s healthcare. In times of financial 
distress, surgeons are ex-pected to have a general idea about the costs of the treatments 
they provide. Chapter 8 is a comprehensive overview of the costs of Dutch patients with 
a femoral neck fracture treated with arthroplasty.
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Chapter 9 summarizes the main results and conclusions of the studies in this thesis, a 
Dutch translation is provided in chapter 10. Finally, chapter 11 provides a general discus-
sion of the main findings in this thesis and its consequences on treatment of patients 
with a femoral neck fracture, including future perspectives.
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ABsTRACT
Background: Hip fractures are a public health problem, leading to hospitalization, 
long term rehabilitation, reduced quality of life, large healthcare expenses, and a high 
1-year mortality. Especially older adults are at greater risk of fractures than the general 
population, due to the combination of an increased fall risk and osteoporosis. The aim of 
this study was to determine time trends in numbers and incidence rates of hip fracture 
related hospitalizations and admis sion duration in the older Dutch population.
Methods and Findings: Secular trend analysis of all hospitalizations in the older 
Dutch population (≥65 years) from 1981 throughout 2008, using the National Hospital 
Discharge Registry. Numbers, age-specific and age-adjusted incidence rates (per 10,000 
persons) of hospital admissions and hospital days due to a hip fracture were used as 
outcome measures in each year of the study. Between 1981 and 2008, the absolute 
number of hip fractures doubled in the older Dutch population. Incidence rates of hip 
fracture-related hospital admissions in creased with age, and were higher in women 
than in men. The age-adjusted incidence rate increased from 52.0 to 67.6 per 10,000 
older persons. However, since 1994 the incidence rate decreased (percentage annual 
change 20.5%, 95% CI: 20.7; 20.3), compared with the period 1981–1993 (percentage 
annual change 2.3%, 95% CI: 2.0; 2.7). The total number of hospital days was reduced by 
a fifth, due to a reduced admission duration in all age groups. A possible limitation was 
that data were obtained from a linked administrative database, which did not include 
information on medication use or co-morbidities.
Conclusions: A trend break in the incidence rates of hip fracture-related hospitaliza-
tions was observed in the Netherlands around 1994, possibly as a first result of efforts 
to prevent falls and fractures. However, the true cause of the observation is unknown.
Funding: Grants from the Netherlands Organization for Health Research and Develop-
ment (ZonMw, project number 170.885.607 and 170.882.503) and a grant from NutsOhra 
(project number T-0602-43) were received. The funders had no role in study design, data 
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: A grant from NutsOhra (project number T-0602-43) was received. 
This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data 
and materi als.
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INTRoduCTIoN
Fall incidents and fall related injuries among older people are a major public health 
problem in ageing societies worldwide (1-3). Of people aged ≥65 years approximately 
one third fall each year (4-7). Especially older individuals are at an increased risk of 
sustaining fractures after a low energetic trauma, e.g. a fall incident, due to underlying 
medical conditions, especially osteoporosis (8).
Osteoporosis, a highly prevalent condition in the older population, is characterized by 
low bone mass and microarchitectural deterioration of bone tissue. Osteoporosis results 
in an increased bone fragility and increased susceptibility to fractures (8). Typical sites 
of osteoporotic fractures include those of the hip, wrist, vertebrae, and upper arm (9). 
Approximately 85% of all hip fractures occur in individuals aged ≥65 years (10). Hip frac-
tures are, more than any other type of fracture, associated with a loss of independence 
(11), morbidity (12), and mortality (13).
Besides the health impact on the individual patient, the socioeconomic impact of 
osteoporosis and of hip fractures in particular is substantial (14). Hip fractures are cur-
rently leading to nearly half (46%) of all injury related healthcare costs in older adults in 
the Netherlands (15, 16). In a global perspective, the annual estimated worldwide direct 
and indirect costs of hip fractures amounted to $34.8 billion in 1990, and are expected 
to rise to an estimated $131 billion by 2050 (17). With the expected continuing ageing 
of populations worldwide (18), it might be expected that the number of hip fractures 
will increase accordingly, making it necessary to prepare our healthcare systems for 
this burden. In order to optimize healthcare use and healthcare planning in an ageing 
society, accurate numbers in hip fracture incidence are mandatory.
The aim of this study was to provide secular trends of age- and gender specific num-
bers, incidence rates and length of hospital stay (LOS) of hip fractures in the older Dutch 
population.
mATeRIAls ANd meThods 
For this study all data of hospital admissions due to a hip fracture in persons aged 
≥65 years were collected from 1981 throughout 2008 in the Netherlands. The data 
were retrieved from Statistics Netherlands (CBS, The Hague, the Netherlands), which 
combines information of the National Medical Registration (LMR) (19) and the National 
Hospital Discharge Registry. Data regarding hospital admissions, admission diagnosis, 
LOS in days, age, and gender are stored in this database. The LMR database has a high 
nationwide coverage and nearly all admissions are stored in this database (less than five 
percent missing). Hospital admissions data and population numbers were verified with 
Chapter 2
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the national Birth-Registry (19). The Birth-Registry is used to identify individual patients 
in the National Medical Registry. Data were corrected for missing values by the Statistics 
Netherlands, and extrapolated to full national coverage (20). A uniform classification 
and coding system is used by the LMR for all hospitals and did not change during the 
study period. Official coding clerks register the diagnosis and injury mechanism of all 
hospital admissions, based on data obtained from medical records. Throughout the 
study period, a hip fracture was defined by using the International Classification for 
Diseases, 9th revision of the World Health Organization, code 820. Older persons were 
defined as persons aged 65 years and older. Demographic numbers were retrieved from 
the Statistics Netherlands. In this study the mid-year population was used. The medical 
ethical review board of the Erasmus MC, University Medical Center, Rotterdam, approved 
the study (MEC-2010-402) and provided a waiver for ‘informed consent’, because the 
data were retrieved from a large public accessible database, containing anonymous data 
on admissions, which cannot be traced to individuals.
Numbers of hospitalizations due to hip fractures were specified for age and gender. 
The age-specific incidence rates were calculated in 5-year age groups using the number 
of hip fractures in that specific age group, divided by the population size within that 
specific age-group for male and female patients, and was expressed per 10,000 persons 
in that age-group. Age-adjusted incidence rates allowed us to compare the incidence 
rate for a standardized population during the study period, and were performed by ‘Di-
rect Standardization’ to correct for demographic changes throughout the study period. 
Growth in the numbers of hospital admissions and LOS were calculated in percentages 
compared to the index year 1981.
Data were analyzed using a Poisson regression analysis for annual growth in overall 
hospital admissions for older persons, corrected for population size and age composi-
tion. In order to model the trend in hospital admissions, a linear regression model with 
Poisson error and log link was built with log (mid year population size of each year of the 
study) as offset factor. To assess if the annual growth changed during the study period 
for both genders, the Joinpoint Regression Program, Version 3.4.3. (Statistical Research 
and Applications Branch, National Cancer Institute, USA) was used. This program showed 
the necessity for assuming a spline instead of a simple linear model, for men and women 
separately, and determines where to place the knot. The spline function accommodated 
two piecewise linear fits, connected with one another at the knot. Comparison of these 
two periods enabled us to detect and quantify changes in the secular trend in admission 
rates such as stagnation or an increase in admission rates. The best knot was found to be 
January 1, 1994. The parameter for calendar year, corrected for gender and age-group 
was transformed into Percentage Annual Change (PAC). The analysis including splines 
yielded estimates of annual changes in admission rates within each period (1981–1993 
and 1994–2008). All statistical analyses were performed using the Statistical Package for 
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the Social Sciences (SPSS) software (version 16.1.1). A. p-value < 0.05 was considered 
statistically significant.
ResulTs
During the study period from 1981 throughout 2008, 355,320 patients aged ≥65 years 
were admitted due to a hip fracture in the Netherlands. The annual number of hip 
fracture-related hospitalizations doubled in both men and women, from 7,614 cases in 
1981 to 16,049 cases in 2008 (Table 1). The male:female ratio remained 1:3 throughout 
the study period. The crude incidence rate increased, from 46.4 per 10,000 older adults 
in 1981 to 66.5 per 10,000 in 2008 (an increase of 43.3% compared to 1981), and peaked 
in 1995 (70.4 per 10,000 older adults). For older men the crude incidence rate increased 
from 27.6 to 39.5 (an increase of 43.3%) and for older women from 59.5 to 86.8 (an 
increase of 46.0%) from 1981 to 2008 respectively.
Gender and age-specific incidence rates of hip fracture-related hospital admissions 
are shown in Table 2. For men and women aged 65–74 years the age-specific incidence 
rates of hip fractures did not change significantly when comparing 2008 to 1981. How-
ever, a strong increase (>50%) in the incidence rate of hospital admissions due to hip 
fracture was seen in men aged ≥80 years since 1981, up to an increase of 127% in men 
aged ≥95 years (from 156.3 per 10,000 in 1981 to 354.7 per 10,000 in 2008). Age-specific 
incidence rates for women aged ≥75 years showed growth of one sixth to a quart.
The overall age-adjusted incidence rate of hip fractures increased (Figure 1) from 52.0 
per 10,000 older adults in 1981 to 62.7 in 2008 (an increase of 20.6%).
Table 1. Population characteristics of persons aged ≥65 years, number, incidence and mean admission 
duration of hip fracture related hospitalizations in persons aged ≥65 years (the Netherlands, 1981-2008).
Characteristic 1981 1986 1991 1996 2001 2006 2008
Population ≥65 year (*1,000) 1,642 1,769 1,934 2,061 2,175 2,330 2,415
Female (%) 59.0% 61.2% 60.2% 59.8% 58.9% 57.6% 57.0%
Admissions overall (n) 7,614 9,958 12,565 14,508 14,810 15,249 16,049 
- males (n) 1,857 2,281 2,879 3,326 3,385 3,845 4,105 
- females (n) 5,757 7,677 9,686 11,182 11,425 11,404 11,944 
Incidence rate† 46.4 56.3 65.0 70.4 68.1 65.4 66.5
Mean admission duration, day 37.0 32.1 30.0 23.8 23.1 15.4 14.0 
† Crude incidence rate, expressed per 10,000 older adults.
Throughout the study period, the age-adjusted incidence rate for women (68.6 per 
10,000 older women in 1981 and 79.9 in 2008) remained twice as high compared to men 
(27.9 per 10,000 older men in 1981 and 37.8 in 2008).
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The PAC, change per year, of the age-adjusted incidence rate was 1.13% (CI 95%: 0.80; 
1.45) for men versus 0.52% (CI 95%: 0.24; 0.81) for women over the whole study period. A 
joint-point regression analysis showed that the change in age-adjusted incidence rates 
was not constant over time and could be divided into two phases: first, the incidence of 
hospital admissions due to a hip fracture in older patients increased between 1981 and 
1993, and second, decreased between 1994 and 2008 (Figure 1). The annual growth in 
men was 2.46% (CI 95%: 1.98; 2.94) and in women 2.16% (CI 95%: 1.89; 2.43) in the period 
1981–1993. The PAC decreased in the period 1994–2008 to a nega-tive annual growth of 
20.34% (CI 95%: 20.86; 0.19) in men and 20.64% (CI 95%: 20.83; 20.46) in women.
Also the mean LOS decreased throughout the study period in both men and women, 
from 37.0 days in 1981 to 14.0 days in 2008 (Figure 2). The admission duration decreased 
over 60% in male and female patients of 65–79 years. Reduction in LOS was smaller in the 
older patient groups. In patients ≥80 years the LOS per admission was reduced by a third. 
In general, the LOS was age-related: the higher the age, the longer the admission dura-
tion (Figure 2). Although the total number of hip fracture-related hospital admissions 
increased, the total number of hospital-beddays decreased due to a reduced LOS per 
admission. The total numbers of hospital-bed-days are shown in Figure 3 and decreased 
from 281,396 days in 1981 to 224,002 days in 2008 (a decrease of 20%). For all men aged 
≥65 years, the total number of hospital days decreased with 8% (from 62,980 days in 
1981 to 58,146 days in 2008). In women aged 65–79 years, a reduction of 54% in hospital 
days was seen (from 94,903 days in 1981 to 43,474 days in 2008). In women aged ≥80 
years the number of hospital days increased until 1991 to 194,264 days and from there 
on started to decrease, with the total number of hospital days in 2008 (122,382 days) just 
below (21%) the total number of hospital days in 1981 (123,513 days).
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Figure 1. Numbers, crude and age-specific incidence rates of hip fracture-related hospitalizations in the 
Dutch population ≥65 years (1981-2008) . Period 1 (blue line): 1981-1993, percentual annual change 2.30%, 
(95% CI: 2.00; 2.59). Period 2 (red line): 1994-2008, percentual annual change -0.50% (95% CI: -0.70; -0.30).
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dIsCussIoN
In order to determine trends in hip fractures in the older Dutch population, all hip 
fracture-related hospitalizations were analyzed from 1981 throughout 2008. The age-
adjusted incidence rates of hip fractures increased until the end of 1993 in the popu-
lation ≥65 years. After that year, a trend break was observed and the incidence rates 
started to decrease. Although an encouraging decrease in the age-adjusted incidence 
4 
 
 
 
 
 
1980 1990 2000 2010
0
4,000
8,000
12,000
16,000
20,000
0
15
30
45
60
75
Age-adjusted rate
Crude rate
Men (η)
Women (η)
Joint Point Regression
Period 1 Period 2
Year
N
um
be
r 
of
 fr
ac
tu
re
s
Incidence per 10,000 older persons
65-69 70-74 75-89 80-84 85-89 90+
0
10
20
30
40
1981*
1986*
1991
1996
2001
2006
2008
Age group (years)
Ad
m
is
si
on
 d
ur
at
io
n 
(d
ay
s)
Figure 2. Mean hospital admission duration in persons aged ≥65 years in the Netherlands 
between 1981-2008. * No SD data were available before 1991.
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Figure 3. Total number of hip fracture-related hospital-bed-days in persons of ≥65 years in the Netherlands 
between 1981-2008.
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rates was observed, the absolute number of hip fractures continued to increase due to a 
rising number of older persons in the population.
Comparable trends of decreasing incidence rates for hip fracture-related hospitaliza-
tions since the mid-nineties have been reported in several countries around the globe, 
such as the United States (21), Canada (22), and Finland (23). However, not all findings 
across western countries are consistent. A recent study from Germany failed to demon-
strate a decline in hip fracture incidence rates (24). Since most studies on hip fracture 
incidence from multiple countries point in the same direction, there might be a causal 
explanation for this observation. However, there is no simple answer to this question, 
because risk factors for hip fractures are multifactorial, as mentioned by Leslie et al. (22). 
Important developments over the last two decades include: the increasing awareness 
of falls (25, 26), the implementation of guidelines for the diagnosis and treatment of 
osteoporosis (27, 28), increasing availability and use of bisphosphonates (29), and an 
improvement of calcium intake and vitamin D status, although the latter is argued by 
some (22). Other nationwide changes, such as the prevention and improved treatment 
of cardiovascular diseases in the general population may also have contributed to the 
observed trend break. A large Finnish twin-study recently demonstrated that cardiovas-
cular diseases are associated with the development of hip fractures (30). However, the 
exact mechanism behind this association is not clear yet (30). Another possibility might 
be that general health (31) and bone quality (32) have improved since smoking has been 
discouraged. The proportion of smokers is decreasing rapidly in the Netherlands (31, 
33) as well as in other countries (34, 35). Furthermore, the Statistics Netherlands (CBS) 
reported that the mean body weight has increased in the Dutch population (33). An 
increased Body Mass Index is associated with a lower fracture risk (36).
A remarkable difference was observed between the younger and older age-groups. 
Whereas incidence rates decreased in persons <80 years, the incidence rate stabilized 
in females aged ≥80 years, and continued to increase in males ≥80 years. This finding is 
worrisome because the population of 80 years and over is the fastest growing segment 
in the ageing population (37) and because mortality and morbidity associated with hip 
fractures are greater for the oldest old, and are higher in men than in women in the first 
year after sustaining a hip fracture (38, 39). A possible explanation for this observation 
might be that life expectancy increased more rapidly in men compared to women over 
the past decades, resulting in a smaller gap in life expectancy between men and women 
(40). Consequently, men have become more vulnerable for age-related (co)morbidities, 
such as osteoporosis and hip fractures, which were previously frequently seen in older 
women. This assumption is supported by a previous report on a more rapid increase in 
fall-related injures, hospitalizations, and mortality in older men than in older women in 
the Netherlands over the past decades (2, 41). Another possible explanation might be 
that osteoporosis in men is frequently underdiagnosed and undertreated (42).
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The number of hospital-bed-days per admission is considered to be one of the most 
important determinants of total costs per hip fracture in an individual patient (43). 
Therefore, a reduced LOS is necessary in order to reduce hospital care demands and 
to limit related healthcare costs. During the study period the LOS decreased by two-
thirds. Several factors might have contributed to this impressive reduction: the rapid 
improvement of surgical and anesthetical care over the last decades, resulting in less 
invasive surgical procedures; the introduction of new hip prostheses, and implants; pro-
tocols for early timed surgery after a hip fracture; better pain management and better 
post-operative care with early mobilization; early discharge to designated rehabilitation 
places and skilled nursing homes; and the implementation of hip fracture treatment 
guidelines (44-46). In addition, during the final years of the study period a change in the 
financing structure of Dutch hospitals, which was introduced in 2004, may have led to a 
further decline in LOS.
A strength of the present study is the availability of populationbased in-hospital data, 
covering a period of 28 years. The Dutch healthcare system is characterized by full health 
insurance coverage and full accessibility for the whole population during the study 
period. Since 1981 absolute numbers of hip fracture related hospital admissions and 
hospital-bed-days in all hospitals in the Netherlands have been recorded with nearly 
complete national coverage in a highly accurate electronic database. Throughout the 
study period, the coding system of the National Medical Registry did not change and 
no major policy changes were introduced in the Netherlands which might have affected 
the increase in admission rates. However, this study has some limitations. A possible 
limitation is that these data describe the situation in one country, which may not directly 
translate to other western countries, because of differences in healthcare system charac-
teristics and demographics. Nevertheless, since hip fracture trends (21, 22, 47) in other 
western populations are comparable with the trends in the Netherlands, there is no 
reason to assume that hip fractures trends will be substantially different in other coun-
tries. This study is based on a linked administrative database, which does not contain 
clinical data regarding underlying diagnosis, comorbidity, injury severity, lifestyle, or 
medication use of the patients. This limits the interpretation of the causal mechanisms 
behind the observed trends. Furthermore, readmissions in one calendar year were not 
excluded and could potentially lead to some ‘double registration’. However, it is unlikely 
that readmissions influenced our results, since readmissions for injuries constitute at the 
most 2.6% (at the maximum) in the Netherlands, as was found in a study by Polinder et 
al. (48) 
In summary, the increase in hip fracture incidence rates slowed down between 1981 
and 1993, and the incidence rates started to decrease over the last 14 years. However, 
incidence rates nowadays remain higher than in 1981, suggesting that there is still room 
for improvement. Furthermore, the continuing increasing incidence rates in the oldest 
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men is a worrying trend that deserves specific attention, since the group of persons 
aged 80 years and older are the fastest growing segment of aging societies. With the 
expected ageing of societies worldwide, continued attention is needed in order to cope 
with the demand of hip fracture related care in the near future.
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ABsTRACT
Purpose: In the Netherlands, over 20,000 patients sustain a hip fracture yearly. A first 
hip fracture is a risk factor for a second, contralateral fracture. Data on similarity of the 
treatment of bilateral femoral neck fractures are only scarcely available. The objectives 
of this study were to determine the cumulative incidence of non-simultaneous bilateral 
femoral neck frac tures and to describe the patient characteristics and treatment char-
acteristics of these patients. Methods: A database of 1,250 consecutive patients with a 
femoral neck fracture was available. Patients with a previous contralateral femoral neck 
fracture were identified by
27 reviewing radiographs and patient files. Patient characteristics, previous fractures, 
hip frac ture type and details on treatment were collected from the patient files.
Results: One hundred nine patients (9 %, 95 % confidence interval 7–10 %) had 
sustained a non-simultaneous bilateral femoral neck fracture. The median age at the 
first fracture was 81 years; the median interval between the fractures was 25 months. 
Overall, 73 % was treated similarly for both fractures in terms of non-operative treat-
ment, internal fixation or arthroplasty. In patients with identical Garden classification (30 
%), treatment similarity was 88 %.
Conclusions: The cumulative incidence of non-simultaneous bilateral femoral neck 
fractures was 9 %. Most patients with identical fracture types were treated similarly. The 
relatively high risk of sustaining a second femoral neck fracture supports the importance 
of secondary prevention, especially in patients with a prior wrist or vertebral fracture.
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INTRoduCTIoN
Hip fractures are a global public health problem. In the Netherlands, over 20,000 pa-
tients sustain a hip fracture annually (1). The incidence of hip fractures is expected to 
increase, mainly due to the aging of the population. A first hip fracture is a risk factor 
for sustaining a second hip fracture at the contralateral side. Other reported predictors 
for a second hip fracture include age, female gender, living alone, alcoholism, any prior 
fracture, functional status, dementia, and osteoporosis (2-6).
Despite a declining trend in hip fractures in western countries (7-11), a worldwide 
increase is expected as a result of aging of populations by improving health care glob-
ally and increasing industrialization and urbanization (12). An increase in incidence of 
the first hip fracture implies that an increase in incidence of a subsequent hip fractures 
is to be expected as well. The latter is associated with an increased mortality risk; the 
one-year mortality ranges from 9 % to 27% following a first hip fracture and 8% to 32% 
after a second hip fracture (2, 13, 14). The 5-year mortality rate after a first and second 
hip fracture is 46% and 67%, respectively (2).
The overall cumulative incidence of non-simultaneous bilateral hip fractures, regard-
less of fracture location or subtypes, is reported to range from 2% to 15% (2-4, 6, 15-22). 
The reported interval between both fractures is 2-5 years (2-4, 6, 13, 15, 18, 21, 22). In 
60-81% of the patients with bilateral hip fractures the second fracture is of the same 
type as the first hip fracture (i.e., trochanteric or femoral neck) (3, 4, 13, 14, 18, 21, 23). 
Most reports on characteristics of bilateral hip fractures involved patients with both 
trochanteric and femoral neck fractures. A minority of patients with a primary trochan-
teric fracture sustains a subsequent contralateral femoral neck fracture. The opposite, 
a femoral neck fracture as a second fracture with a first trochanteric fracture, is even 
rarer (14, 17). Especially the treatment of non-simultaneous femoral neck fractures has 
received little attention in previous studies.
Controversy on the treatment of active patients with a displaced femoral neck frac-
ture still exists, particularly on the type of implant (i.e., sliding hip screw or cannulated 
screws) or prosthesis (i.e., hemi-arthroplasty or total hip arthroplasty). One would expect 
that two fractures of the same type in patients with unchanged characteristics would be 
treated the same. In addition to these patient and fracture characteristics, preferences 
of the surgeon may also contribute to the treatment selection. Detailed information on 
the treatment of patients with non-synchronous femoral neck fractures is limited, to the 
best of our knowledge.
Therefore, the objectives of this study were to determine the cumulative incidence of 
non-simultaneous bilateral femoral neck fractures and to describe patient characteris-
tics, mortality and treatment characteristics of these patients.
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PATIeNTs ANd meThods
This study was conducted as a multicenter retrospective cohort study of patients who 
sustained non-simultaneous bilateral femoral neck fractures. The study was approved 
by the local medical research ethics committee (ref. No MEC-2011-419, approval date 
November 4, 2011). In a previous retrospective multicenter study a database was de-
veloped, containing data for 1,250 consecutive patients with a femoral neck fracture 
who were treated in 14 Dutch hospitals between February 2008 and August 2009 (24). 
Patients were identified by searching the electronic hospital databases for DBC code (Di-
agnosis Treatment Combination; comparable to the North-American Diagnosis Related 
Groups), surgical codes and ICD-codes (International Classification of Diseases, version 
9 and 10).
Two investigators (PTPWB and AKEM) independently assessed pelvic and hip X-rays of 
all patients for the presence of any sign of a previous fracture at the contralateral side 
(i.e. implant, arthroplasty, or healed fracture). Presence of a non-simultaneous bilateral 
femoral neck fracture was confirmed with data in the patient files.
Patients were eligible for enrolment if details on the treatment (i.e., non-operative 
treatment, type of implant or arthroplasty) of both femoral neck fractures were avail-
able from radiographs or medical correspondence. Pathological fractures, simultaneous 
bilateral fractures, and fractures following a high energetic trauma were excluded.
The following data were collected for both fractures:
- Patient characteristics: age at fracture, gender, ASA (American Society of Anesthesi-
ologists) class, prior and concomitant fractures;
- Fracture characteristics: Garden classification (i.e., undisplaced or displaced);
- Treatment characteristics: type of treatment, and for internal fixation: quality of 
reduction and positioning of the implant (i.e., acceptable or unacceptable);
- Post-treatment details: length of hospital stay and in-hospital mortality.
The Garden classification was assessed independently by two senior trauma surgeons 
(MJH and MHJV) from blinded preoperative, peroperative and postoperative X-rays; 
classifications were done according to the description made in 1961 (25). These sur-
geons also rated the quality of reduction and positioning of the implant (for internal 
fixation), using the criteria as defined in the guideline of the Association of Surgeons of 
the Netherlands (26) (Table 1), as described elsewhere (24). If two out of three criteria 
were met, fracture reduction and positioning of implants were scored as ‘acceptable’. 
Disagreement was solved by a third senior trauma surgeon (GRR), who independently 
reviewed the X-rays in order to reach a final decision.
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Table 1. Criteria for acceptable reduction and positioning of the implant for internal fixation of a femoral 
neck fracture, according to the guideline of the Association of Surgeons of the Netherlands (26).
Acceptable reduction Varus- valgus dislocation: maximum Garden index: 160–180° +
Femoral neck shortening neutralized+ 
Dorsoventral dislocation: maximum 10° retroversion - 5° anteversion++
Acceptable position 
cannulated screws
One screw placed caudally over the calcar femoris+
One screw placed over the dorsal cortex++ 
Screws positioned into the subchondral bone (maximum distance  between 
screw tip and femoral head lining: 5-10 mm)+ 
Acceptable position 
sliding hip screw
Screw positioned in the central or caudal 1/3 part of femoral head+
Screw positioned in the central or dorsal part of femoral head++ 
Screw positioned into the subchondral bone (maximum distance  between 
screw tip and femoral head lining: 5-10 mm)+ 
+ On AP (Anterior-Posterior) view. ++ On axial view.
statistical Analysis
Statistical analyses were conducted using SPSS (SPSS Inc. Released 2007. SPSS for Win-
dows, Version 16.0. Chicago, SPSS Inc). Normality of continuous data was tested with the 
Shapiro Wilk test and by inspecting frequency histograms (Q-Q plots).
All continuous variables were non-parametric and are therefore presented as medians 
with the first and third quartiles. Categorical variables are presented as numbers with 
percentages. The traditional Wald confidence interval formula for proportions was used 
for calculating the 95% confidence interval around the cumulative incidence of bilateral 
femoral neck fractures. Descriptive analyses were performed in order to describe the 
patient, treatment and post-operative variables for the first and second fracture. An 
additional analysis of treatment was performed for a subgroup of patients in whom the 
Garden class of the first and second fracture were of the same type.
ResulTs
Patient demographics
The total population consisted of 1,250 patients with a femoral neck fracture. Of these, 
176 patients showed radiographic signs of bilateral femoral neck fractures. After review-
ing the medical files, 67 patients were excluded; 29 patients underwent arthroplasty 
because of arthrosis rather than a fracture, 32 patients had a subtrochanteric or pertro-
chanteric fracture, and six patients were treated for another reason than for osteopo-
rotic femoral neck fracture (Figure 1). In the remaining 109 patients the occurrence of 
non-simultaneous bilateral femoral neck fractures (9%, 95% CI 7 to 10%) was confirmed.
Patient characteristics of these 109 included patients are shown in Table 2. The median 
age was 81 years (P25-P75 74-86 years) at the time of the first fracture and 86 years (P25-P75 
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79-89 years) at the time of the second fracture. Seventy-six patients (70%) were female. 
The median time between the first and the second fracture was 25 months (P25-P75 12-62 
months). The shortest interval between the two fractures was three days (and occurred 
following a fall) and the longest was 20 years. The right hip was the first affected side in 
51 patients (47%). At the time of the first fracture 30 of 41 patients (73%) for whom data 
were available lived at home. At the time of the second fracture 49 of 80 patients (61%) 
lived at home. Concomitant fractures were found in 5% of patients at the time of the first 
 
N = 29
Figure 1. Flowchart of enrolled patients.
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fracture and in 7% of patients at the time of the second fracture. Twenty-two patients 
(20%) had sustained another type of fracture prior to the second femoral neck fracture, 
with a median interval of seven years . Especially fractures of the wrist (6%), humerus 
(7%), spine (1%), rib (2%), olecranon (2%), and foot (2%) were found. The median hospital 
length of stay was 10 days (P25-P75 7-17 days) after the first fracture and nine days (P25-P75 
5-13 days) after the second. One patient (1%) died during admission for treatment of the 
second fracture. Of the 1141 excluded patients, 42 (3.7%) died in hospital.
Table 2. Patient characteristics by first and second fracture
Characteristic overall
N= 109
First Fracture
N=109
second fracture
N=109
Age 1 (year) 81 (74-86) 86 (79-89)
Female gender 2 76 (70)
Right side affected 2 51 (47) 58 (53)
Additional injuries at presentation2 5 (5) 8 (7)
Wrist/hand fracture  4 (4) 1 (1) 
Humeral fracture  0 (0) 3 (3) 
Tibia fracture  0 (0) 1 (1) 
Head injury/wound  1 (1) 3 (3) 
Not documented  34 (31) 3 (3) 
Prior other fracture 2 23 (21)
Not documented 27 (25)   
Pre-operative ASA-class 2
ASA I-II  21 (19) 65 (57) 
ASA III-IV  12 (11) 34 (31) 
Unknown  76 (70) 13 (12) 
1 Data are displayed as median, with the first and third quartile given within brackets;
2 Patient numbers are displayed with percentages within brackets
Fracture and treatment characteristics of the first and second femoral neck fracture
Details of the fractures and treatments of the total population of 109 patients are shown 
in Table 3. Data on the Garden classification of the first fracture were available in 50% of 
the patients. In patients for whom data were available, the first fracture was displaced 
in 72% of the patients (39 of 44); the second fracture (with 90% data availability) was 
displaced in 68% (67 of 98). Arthroplasty was performed in 65% of the first fractures and 
in 70% of the second fractures. The majority was treated with a hemi-arthroplasty (92% 
and 99% of the first and second fractures, respectively). Internal fixation was applied in 
35 patients for the first fracture (32%) and in 30 patients (28%) for the second fracture. In 
these patients, cannulated hip screws (CHS) were then used in 49% of the first fractures 
and 70% of the second fractures. A sliding hip screw (SHS) was used in 49% and 30% of 
the first and second fractures, respectively.
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Table 3. Fracture and treatment characteristics by first and second fracture
Characteristic First fracture
N=109
second fracture
N=109
Garden classification
Non-displaced (Garden I-II) 15 (14) 31 (28) 
Displaced (Garden III-IV) 39 (36) 67 (62) 
Missing* 55 (51) 11 (10) 
Therapy
Non-operative treatment 3 (3) 3 (3) 
Internal Fixation 35 (32) 30 (28) 
Cannulated screws 17 (16) 21 (19) 
Sliding hip screw 17 (16) 9 (8) 
PFN-A 1 (1) 0 (0) 
Arthroplasty 71 (65) 76 (70) 
Hemi-arthroplasty 65 (60) 75 (69) 
Total hip arthroplasty 6 (6) 1 (1) 
Internal fixation: Reduction
Adequate 20 (57) 28 (93) 
Not adequate 0 (0) 2 (7) 
Not able to determine 4 (11) 0 (0) 
Missing 11 (31) 0 (0) 
Internal fixation: Implant position
Adequate 19 (54) 26 (87) 
Not adequate 1 (3) 4 (13) 
Not able to determine 4 (11) 0 (0) 
Missing 11 (31) 0 (0) 
Implant position Cannulated screws 
Adequate 8 (47.1) 17 (81.0) 
Not adequate 1 (5.9) 4 (19.0) 
Not able to determine 2 (11.8) 0 (0.0) 
Missing 6 (35.3) 0 (0.0) 
Implant position Sliding Hip Screw
Adequate 11 (64.7) 9 (100.0) 
Not adequate 0 (0.0) 0 (0.0) 
Not able to determine 1 (5.9) 0 (0.0) 
Missing 5 (29.4) 0 (00.0) 
Patient numbers are displayed, with the percentages given within brackets.
* Garden classification could not be determined if adequate diagnostic images were not available, e.g., if 
trauma diagnostic had been done at another hospital.
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An overview of similarity in characteristics and treatment of the first and second frac-
ture is shown in Table 4. Data are presented for the entire group of 109 patients as well as 
for a subgroup of 33 patients in whom both fractures had the same Garden classification. 
This subgroup was treated identically in 88% of the patients in terms of non-operative 
treatment, internal fixation or arthroplasty. When the type of implant and arthroplasty 
were also taken into account, bilateral fractures of the same Garden classification were 
treated similarly in 73%. If arthroplasty was used, the same type of device was used in 
100% of patients, whereas only in two out of seven patients (27%) treated with internal 
fixation the same type of implant was used. Table 5 shows the relation between Garden 
classification and treatment for the total population of 109 patients. Undisplaced frac-
tures were mostly treated with internal fixation; 67% of the first fractures, 58% of the 
second fractures. Displaced fractures were treated with arthroplasty in 82% of first and 
in 81% of second fractures.
Table 4. Identical characteristics and treatment of first and second fracture
entire group
(N=109)
same Garden classification for both fractures 
(N=33)
N (%) N (%)
ASA classification 15/109 (14) 10/33 (30)
Garden class 33/109 (30) N.A.
Treatmenta 62/109 (57) 24/33 (73)
Treatmentb 80/109 (73) 29/33 (88)
Type of prosthesisc 54/60 (90) 22/22 (100)
Type of implantc 8/20 (40) 2/7 (29)
Reductionc 11/20 (55) 5/7 (71)
Position implantc 9/20 (45) 6/7 (86)
Position cannulated screwsc 2/4 (50) 2/2 (100)
Position SHSc 2/4 (50) N.A.
Data are shown as numbers with the percentage within brackets.
N.A.; not applicable.a Treatment separated into non-operative, CHS, SHS, PFN-A, hemiarthroplasty and total 
hip arthroplasty.b Treatment separated into non-operative, internal fixation, and arthroplasty.c Data are 
shown for the subgroup of patients (denominator) where this applies to and for which data were available 
for both fractures.
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Table 5. Association between the Garden classification and treatment (all 109 patients)
Treatment Garden I-II Garden III-IV unknown
First fracture N=15 N=39 N=55
Non-operative 2 0 1 
Internal fixation 10 7 18 
Arthroplasty 3 32 36 
Second fracture N=31 N=67 N=11
Non-operative 1 1 1 
Internal fixation 18 12 0 
Arthroplasty 12 54 10 
Data are shown as numbers.
dIsCussIoN
Out of 1,250 patients with a femoral neck fracture, 109 had previously sustained a con-
tralateral femoral neck fracture. The cumulative incidence of non-simultaneous bilateral 
fractures was 9%. This result is comparable with the recent literature, reporting a cumula-
tive incidence of bilateral proximal femur fractures between 2% and 20% depending on 
the follow up period (2-6, 13, 15, 17). These studies however included both trochanteric 
and femoral neck fractures, implying that the cumulative incidence of bilateral femoral 
neck fractures in these studies had been lower than the percentages reported.
The median time between the first and second fracture in the current study was 25 
months (P25-P75: 12.4-61.8 months). This is in line with literature data, where intervals 
from 2 to 5 years between the first and second hip fracture are reported (2, 4, 6). Given 
this short period, substantial changes in patient characteristics were not very likely.
Additional injuries, especially fractures, are likely to impair postoperative rehabilita-
tion, to prolong hospital stay, and to increase the total health care costs. In the current 
study concomitant additional significant injuries such as a wrist fracture, head injury, 
or humeral fracture were seen in 5% and 7% of the patients at the time of the first and 
second hip fracture, respectively. Approximately a quarter of patients had already had 
a fracture in their medical history, prior to their femoral neck fracture (28%), which cor-
responds with a previous study on non-simultaneous bilateral femoral neck fractures 
(30%) (16). These results emphasize the vulnerability of this population, as a prior frac-
ture increases the risk of a hip fracture and the occurrence of a first hip fracture increases 
the risk of subsequent (hip) fracture (5, 23). In the growing, fragile population that often 
suffers from multiple risk factors for falling and sustaining subsequent fractures, there 
might be great potential for multidisciplinary secondary prevention strategies. In this 
retrospective study documentation of osteoporosis screening was found in only 19% 
of the patients and anti-osteoporosis medication was prescribed in only 24% (data not 
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shown). This indicates too little attention has been paid to osteoporosis screening and 
management. Although circumstances and protocols differ between hospitals, there is 
a clear need for better compliance to the Dutch guideline on osteoporosis and fracture 
prevention (27). Regular evaluation of the local progress of the implementation should 
ensure a stricter protocol compliance and ultimately a better quality of fracture care 
(28). Also, independent community dwelling elderly have an increased risk of sustaining 
a second hip fracture (2). This emphasizes that the environment of the patient (i.e., modi-
fications in their home) and adequate rehabilitation (i.e., appropriate use of walking aids 
and physical therapy) deserve attention to minimize the risk of falling and sustaining a 
new fracture as much as possible.
Over 80% of the displaced fractures were treated with arthroplasty and about 60% of 
the undisplaced fractures were treated with internal fixation. It seems that trauma and 
orthopedic surgeons generally agree on the treatment of the different types of femoral 
neck fractures, as 88% of the patients with a bilateral femoral neck fracture with similar 
Garden classification were treated similarly in terms of a non-operative treatment, inter-
nal fixation, or arthroplasty.
However, heterogeneity in the use of the specific type of implant or prosthesis re-
mains. This is supported by the finding that in only 27% of the patients with an identical 
Garden classification of both fractures the type of treatment was not the same when the 
type of implant/ arthroplasty was also considered. Heterogeneity was especially high in 
the use of implant for internal fixation. This was not unexpected, as insufficient evidence 
on the use of implant or arthroplasty type for femoral neck fractures is known (29). It 
was however unexpected, that the controversy in the essential details of treatment 
seemed larger in undisplaced fractures (67 versus 58% internal fixation in first and sec-
ond fracture), than in displaced fractures (82 versus 81% arthroplasty in first and second 
fracture). Diverging treatment decisions may however partially be explained by other 
variables such as coxarthrosis, comorbidity, surgeons preferences, material availability.
The strength of the current study is that a database of a large number of 1,250 con-
secutive patients treated in fourteen different hospitals was used (24). However, due to 
the retrospective design data were incomplete from a substantial number of patients. 
Data concerning the first fracture were often missing for patients in whom the first 
fracture was treated at another hospital. In addition, some radiographs were not avail-
able, e.g., when they were made analogous, during external storage, or during digital 
exportation. There are no indications for a selective pattern of missingness of data. As a 
consequence, a reliable multivariable analysis was not possible. For the same reason the 
one year mortality could not be calculated, therefore the in-hospital mortality was used 
as a relevant alternative. Moreover, as no data on the cumulative incidence in a matched 
control cohort were available, it was not possible to carry out a risk assessment. Due to 
the relatively small number of patients per hospital, a subgroup analysis of similarity 
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of management for both fractures if treated at the same hospital was not possible. It is 
unfortunate that data on osteoporosis or osteoporosis treatment were often not docu-
mented. As discussed above, attention for osteoporosis screening and treatment can still 
be improved. For this reason, osteoporosis guidelines have been implemented in 1999 
and were revised in 2002 and 2011 (28). Despite duplicate assessment of radiographic 
images, non-operatively treated fractures or fractures in which implants are removed 
could have been missed. However, if only the slightest doubt existed patient files were 
checked; in none of those patients a previous fracture was confirmed. Therefore it is 
unlikely that bilateral fractures were missed.
CoNClusIoN
In a population of 1,250 patients who sustained a femoral neck fracture during the study 
period, 9% had previously sustained a femoral neck fracture at the contralateral side. 
The median time interval between both fractures was 25 months. If both fractures were 
undisplaced or both were displaced, the same treatment was applied in 88% of patients. 
Surgeons generally agreed on the use of internal fixation or arthroplasty for the different 
types of femoral neck fractures. The relatively high risk of sustaining a second femoral 
neck fracture supports the importance of national secondary prevention guidelines, 
especially in patients with a prior wrist or vertebral fracture.
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ABsTRACT
Purpose: Displaced femoral neck fractures in healthy elderly patients have traditionally 
been managed with hemiarthroplasty (HA). Recent data suggest that total hip arthro-
plasty (THA) may be a better alternative.
Methods: A systematic review of the English literature was conducted. Randomized 
con trolled trials comparing all forms of THA with HA were included. Three authors inde-
pendently extracted articles and predefined data. Results were pooled using a random 
effects model.
Results: Eight trials totalling 986 patients were retrieved. After THA 4 % underwent re-
vision surgery versus 7 % after HA. The one-year mortality was equal in both groups: 13 
% (THA) versus 15 % (HA). Dislocation rates were 9 % after THA versus 3 % after HA. Equal 
rates were found for major (25 % in THA versus 24 % in HA) and minor complications (13 
% THA versus 14 % HA). The weighted mean of the Harris hip score was 81 points after 
THA versus 77 after HA. The subdomain pain of the HHS (weighted mean score after THA 
was 42 versus 39 points for HA), the rate of patients reporting mild to no pain (75 % after 
THA versus 56 % after HA) and the score of WOMAC (94 points for THA versus 78 for HA) 
all favored THA. Quality of life measured with the EQ-5D favored THA (0.69 versus 0.57).
Conclusions: Total hip arthroplasty for displaced femoral neck fractures in the fit el-
derly may lead to higher patient-based outcomes but has higher dislocation rates com-
pared with hemiarthroplasty. Further high-quality randomized Total hip arthroplasty 
for displaced femo ral neck fractures in the fit elderly may lead to higher patient-based 
outcomes but has higher dislocation rates compared with hemiarthroplasty. Further 
high-quality randomized clinical trials are needed to provide robust evidence and to 
definitively answer this clinical question.
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INTRoduCTIoN
The optimal surgical management of displaced femoral neck fractures in the elderly is 
the subject of an ongoing scientific and clinical debate (1, 2). About 50 % of the total 
hip fracture population has a displaced femoral neck fracture. Determining the optimal 
therapy is important as in the year 2000 an estimated 1.6 million hip fractures occurred 
(3), and this incidence is expected to increase to over six million hip fractures worldwide 
by the year 2050 (4). Reported causes are the changing demography and an increasing 
contribution of developing countries (5).
Patients with a hip fracture have high mortality and disability (6). As a consequence 
these fractures have a significant impact both on the patients’ personal dependence, 
mobility and quality of life as well as on global economic health costs. Especially, the 
one-year mortality after a femoral neck fracture, even in selected patients, ranges from 
14 % to 36 % (7), so the actual numbers are even higher. Moreover, worldwide 4.5 million 
persons are living with disability from hip fractures yearly. This number is expected to 
increase to 21 million persons in the next 40 years. The costs of treating a hip fracture 
patient are about three times higher than those of caring for a patient without a fracture 
(8). The worldwide direct and indirect annual costs of hip fractures in 1990 were esti-
mated at US$34.8 billion (9).
Hemiarthroplasty (HA) and total hip arthroplasty (THA) remain as widely accepted 
methods of hip replacement after fracture. In the long run some patients treated with 
HA require conversion to THA because of activity limiting thigh pain due to acetabulum 
wear. Reported advantages of HA compared with THA are reduced dislocation rates, less 
complex surgery, shorter operation times, less blood loss, and lower initial costs (10). 
Therefore, a number of authors prefer HA for displaced femoral neck fractures (11-13). In 
contrast, evidence is accumulating to support better function and superior patient sat-
isfaction for patients treated with THA(10, 14-17). Consequently, after weighing the pros 
and cons other authors advocate THA as preferable treatment for displaced fractures in 
the elderly (18-20). In two previous systematic reviews (2, 21) it was concluded that large 
well-designed randomized trials are needed in order to draw a definitive conclusion as 
the scientific evidence is still insufficient. Since the publication of these reviews, data of 
the largest trial (N= 250) (13) became available; these are included in the present study.
The aim of the present study was to conduct a systematic review and meta-analysis 
using the best available evidence in order to determine primarily the outcomes of 
reoperations; secondary outcomes were dislocation rates, mortality rates, complica-
tions, function, and pain of total hip arthroplasty versus hemiarthroplasty for displaced 
femoral neck fractures in the healthy elderly.
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mATeRIAls ANd meThods
The present review and meta-analysis were reported according to the PRISMA statement 
(22). Methods used for the analysis, search strategy, and inclusion criteria were specified 
in advance and documented in an unpublished protocol.
search strategy
An electronic search of the literature was independently performed in duplicate by two 
clinical librarians at different time points from inception to February 22, 2011 in the fol-
lowing databases: MEDLINE (PubMed), EMBASE, World of Science and Cochrane Central 
Register of Controlled Trials. The electronic search was individually tailored to each 
database aiming at maximizing the sensitivity of the search when identifying studies 
having terms relevant to “hemiarthroplasty”, “total hip arthroplasty” and “intracapsular 
hip fracture.” The complete search terms are shown in Appendix 1. In addition, bibliog 
raphies were reviewed of all selected full text articles to identify additional articles. In 
order to evaluate any ongoing randomized trials, the international trial registries (www.
clinicaltrials.gov, www.trialregister.nl and www.apps.who.int/ trialsearch) were accessed 
(last visit: March 11, 2011).
eligibility criteria
Three reviewers (PTPWB, ARG and BB) independently identified titles and abstracts 
relevant to total hip arthroplasty versus hemiarthroplasty for dislocated femoral neck 
fractures. Full text published articles and unpublished data of completely finished and 
analysed studies were included. Authors of studies for which only the abstract was 
available were contacted for availability of study data. The following eligibility criteria 
had to be met: (1) use of (quasi) random allocation of treatments, (2) patients aged 50 
years or older with a displaced femoral neck fracture, (3) inclusion of a treatment arm 
receiving any form of hemiarthroplasty, (4) inclusion of a treatment arm receiving any 
form of total hip arthroplasty, and finally all papers had to report data on the primary 
outcome, being revision surgery. No restrictions related to the length of follow-up or 
languages were defined. The reviewers obtained consensus on inclusion status with any 
found discrepancies.
The primary endpoint was defined as revision surgery within the different study peri-
ods. Secondary outcomes were mortality, dislocation, major and minor complications, 
functional outcome, pain, and quality of life. The minor and major complications were 
arbitrarily defined by two authors (PTPWB and ARG) as specified in Appendix 2.
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data extraction and analysis
Three reviewers (PTPWB, ARG and BB) independently extracted the inclusion criteria 
data from each study meeting. Data included demographics, methodology, details on 
intervention, and reported outcomes. Data for the primary and secondary outcomes 
were extracted and collected on a predefined standardized electronic data collection 
form. In case of differences, the reviewers discussed this item in order to meet consen-
sus; if no agreement could be reached, a third author (RWP) decided. Methodological 
study quality was gauged by noting the specifics of randomization, concealment of 
allocation, blinding, adherence to the intention to treat principle and the extent of 
follow-up (Table 2) (23). Review Manager software (RevMan Version 5.0.22, Copenhagen: 
The Nordic Cochrane Center, The Cochrane Collaboration, 2008.) was used for statistical 
analysis and for generating figures. For combining the results found in the different trials 
the statistical method of Mantel-Haenszel with random effects method was used for 
dichotomous outcomes, and risk ratios for THA variance method was used with random 
effects analysis model and mean differences were calculated. Heterogeneity between 
studies was assessed by using I2 statistics. The quality of the individual parameters was 
assessed with Grade profiler software (GRADEpro. Version 3.2.2. for Windows. Jan Brozek, 
Andrew Oxman, Holger Schünemann, 2008) (24).
ResulTs
After applying the search strings 628 potentially eligible articles were identified, of which 
473 were excluded based upon title, and 52 studies were duplicates of these reports. 
Another 67 manuscripts were excluded after reviewing the abstract. Contact with the 
author of one abstract revealed that the trial was still actively recruiting patients. In the 
next phase of the selection procedure 35 full articles were reviewed of which 24 articles 
did not meet the predefined eligibility criteria. Two studies were published twice (10, 16, 
25, 26). One report was considered the index report, the other article was searched for 
additional information. Data from both articles were included in this study. One manu-
script was a 13-year follow-up (27) of a previously conducted RCT (28). Data from both 
reports were included in the analysis. In conclusion, a total of 11 articles about eight 
studies were included for the present review and meta-analysis which involved a total of 
986 patients (13-17, 25-29) (Figure 1). Tables 1, 2, 3 and 4 summarize the methodological 
quality, the methodological characteristics, the characteristics of the interventions and 
the characteristics of individual studies. Two studies had also included a third (internal 
fixation) arm (17, 27, 28). These data were not taken into account, as internal fixation 
was not assessed in the present study. In all studies inclusion and exclusion criteria were 
clearly defined prior to the study in order to select patients with an ambulatory and cog-
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Table 1. Methodological quality of individual selected studies
Quality assessment
summary of findings
Importance
No of patients effect
QualityNo of 
studies
design limitations Inconsistency Indirectness Imprecision
other 
considerations
Total hip hemiarthroplasty
Relative
(95% CI)
Absolute
1 year mortality 
61 randomized trials very serious2 no serious 
inconsistency3
serious4 serious1,5 none3
53/393 
(13.5%)
64/423 (15.1%)
RR 0.91
(0.65 to 1.27)
14 fewer per 1000 (from 
53 fewer to 41 more)
VERY LOW CRITICAL
13.6%
12 fewer per 1000 (from 
48 fewer to 37 more)
revision surgery 
83 randomized trials very serious2 no serious 
inconsistency3
serious4 serious6 none3
19/472 (4%)
7.1%
36/514 (7%)
RR 0.59 
(0.32 to 1.09)
29 fewer per 1000 (from 
48 fewer to 6 more)
VERY LOW
29 fewer per 
1000 (from 48 
fewer to 6 more)
IMPORTANT
dislocation 
67 randomized trials very serious2 no serious 
inconsistency3
serious4 serious8,9 none3
33/369 
(8.9%)
14/411 (3.4%)
RR 2.53 
(1.05 to 6.1)
52 more per 1000 (from 2 
more to 174 more)
VERY LOW IMPORTANT
0%
0 more per 1000 (from 0 
more to 0 more)
major complications 
510 randomized trials very serious2 no serious 
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Bhandari M, Poolman RW. Total Hip Arthroplasty versus HemiArthroplasty for displaced femoral neck frac-
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2 Allocation concealment: 3/8 study used sealed envelopes, 1/8 hospital number, 2/8 computerized, 1/8 
order of admission, 1/8 not specified blinding: none of studies blinded the patients, only 3/8 studies report 
on a blinded outcome assessor failure to adhereto the intention to treat principle: 5/8 studies. 3 No expla-
nation was provided. 
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Table 1. Methodological quality of individual selected studies
Quality assessment
summary of findings
Importance
No of patients effect
QualityNo of 
studies
design limitations Inconsistency Indirectness Imprecision
other 
considerations
Total hip hemiarthroplasty
Relative
(95% CI)
Absolute
1 year mortality 
61 randomized trials very serious2 no serious 
inconsistency3
serious4 serious1,5 none3
53/393 
(13.5%)
64/423 (15.1%)
RR 0.91
(0.65 to 1.27)
14 fewer per 1000 (from 
53 fewer to 41 more)
VERY LOW CRITICAL
13.6%
12 fewer per 1000 (from 
48 fewer to 37 more)
revision surgery 
83 randomized trials very serious2 no serious 
inconsistency3
serious4 serious6 none3
19/472 (4%)
7.1%
36/514 (7%)
RR 0.59 
(0.32 to 1.09)
29 fewer per 1000 (from 
48 fewer to 6 more)
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29 fewer per 
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fewer to 6 more)
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order of admission, 1/8 not specified blinding: none of studies blinded the patients, only 3/8 studies report 
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4 In the different trials, different approaches and materials, eg: cement vs uncemented were used. This may 
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nitive fit pre-fracture status. The quality of the individual parameters ranged from low to 
very low (Table 1). In three studies, sealed envelopes were used as randomization system 
(14-16, 26); one of which was stated as block randomization(16). A fully automated com-
puterized allocation system was used in two studies (10, 13). Other methods used for 
treatment allocation were by hospital number (29), fixed treatment sequence (28), and 
according to the order of admission (17) . The outcome assessor was blinded for the al-
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Citations identified by 
electronic and manual 
search 
628 
628 
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based upon title 
52 duplicate studies 
103 
67 did not meet inclusion 
criteria based upon abstract 
1 full article not available 
 
35 
24 did not meet inclusion 
criteria Article reviewed in full 
11 
Articles meeting 
inclusion criteria 
Figure 1. Flow diagram for selection process for randomized controlled trials evaluating the effect of Total 
Hip Arthroplasty versus HemiArthroplasty in displaced femoral neck fractures in the healthy elderly.
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located treatment in only one study (17). Patients were not blinded for treatment in any 
of the studies. Three studies (10, 15, 16, 25, 26) stated an intention to treat analysis, one 
a per protocol analysis (13) and four studies did not specify the data analysis method (14, 
17, 27-29). For all eight studies (13-17, 25-29) the follow-up period was at least one year 
(Table 2). All patients in the THA arm were treated with a cemented stem, except in one 
study (16) where both cemented and uncemented stems were used. For patients treated 
with hemiarthroplasty in two studies (16, 29) both cemented and uncemented stems 
were used; in one study (17) cementing of the stem was not specified. In four studies 
cemented stems were used; in one study uncemented stems were used. In three stud-
ies (13, 14, 28) only unipolar heads were used, in three studies (10, 15, 29) only bipolar 
heads were used, in one study (16) both types of heads were used and one study (17) 
did not specify the polarity of the head component of the hemiarthroplasty (Table 3).
Table 2. Methodological characteristics of individual selected studies
study Type of 
randomization
Allocation 
concealment
Patient 
blinding
Intention to 
treat
Follow-up 
period (years)
Baker(14) Sealed envelopes NS No NS 3
Blomfeldt(15) Sealed envelopes No No Yes 1
Dorr(29) Hospital number No No NS 4
Keating(10) Computerized No No Yes 2
Macaulay(16) Sealed envelopes NS No Yes 2
Mouzopuolos(17) Order of admission Yes No NS 4
Skinner(28) Day of the week No No NS 1
Van den Bekerom(13) Computerized No No Per protocol 5
Table 3. Intervention characteristics of individual selected studies
study ThA hA Type surgical approach surgeon’s grade
Baker(14) Cemented Cemented Unipolar lateral Staff and residents
Blomfeldt(15) Cemented Cemented Bipolar anterolateral* Staff
Dorr(29) Cemented Cemented or 
uncemented
Bipolar posterior NS
Keating(10) Cemented Cemented Bipolar Posterior or lateral Staff, residents and 
SHO
Macaulay(16) Cemented or 
uncemented
Cemented or 
uncemented
Uni- or 
bipolar
Posterolateral or 
anterolateral*
Staff and fellows
Mouzopuolos(17) Cemented NS NS NS NS
Skinner(27) Cemented Uncemented Unipolar Posterolateral Registrars and 
consultans and SHO’s
Van den 
Bekerom(13)
Cemented Cemented Unipolar Posterolateral, lateral 
or anterolateral
Staff and residents
NS, Not specified; *via Modified Hardinge; SHO, senior house officers NS= Not specified
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The exact recruitment period was not specified in three studies (14-16). The number 
of patients per arm ranged from 17 to 137. Three studies (15, 28, 29) used a single center 
design; five studies (10, 13, 14, 16, 17) were performed with a multicenter approach 
(Table 4).
Table 4. Study characteristics of individual selected studies
study Recruitment period
ThA 
number 
(N)
hA 
number 
(N)
single-/ multicenter
(N of sites)
ThA 
mean 
age
hA 
mean 
age 
Baker(14) NS 40 41 Multicenter (3) 74 76
Blomfeldt(15) NS 60 60 Single-Center 81 81
Dorr(29) March 1980- July 1982 39 50 Single-Center 69
Keating(10) Sep 1996 - June 2000 69 69 Multicenter (11) 75 75
Macaulay (16) 18 months (NS) 17 23 Multicenter (5) 82 77
Mouzopoulos(17) April 1999-April 2002 43 43 Multicenter (NS) 73 74
Skinner (27) Dec. 1984- Dec. 1986 89 91 Single-Center 81 82
Van den Bekerom(13) Jan 1995-Dec. 2001 115 137 Multicenter (8) 82 80
NS, Not specified
Clinical outcomes
Revision surgery
Data on revision surgery and reported planned revision surgery were pooled, totaling 
986 patients and 55 events (5 %). Revision surgery was performed in 4 % in the THA-arm 
versus 7 % in the HA-arm (Figure 2).
There was low evidence of heterogeneity across the studies (I2=9 %, P= 0.36). No 
statistically significant difference in revision sur gery between the two groups (relative 
risk, RR 0.59, 95 % confidence interval CI 0.32–1.09, absolute risk difference, ARD −0.02, 
95 % CI −0.06 to 0.01) could be found. However, the pooled data showed a trend towards 
less revision surgery for patients who had undergone total hip arthroplasty compared 
with those who had undergone hemiarthroplasty.
One-year mortality
Data for mortality at one year were pooled. Six out of the eight selected studies provided 
adequate data on one-year mortality (10, 13, 15-17, 28) which involved a total of 816 
patients and 117 deaths (overall 14 %; Figure 3). The one-year mortality was 13 % in the 
THA-arm versus 15 % in the HA-arm. There was no evidence of heterogeneity (I2=0 %, 
P= 0.79). The pooled one-year mortality data did not differ between patients who had 
undergone total hip arthroplasty or hemiarthroplasty (RR 0.91, 95 % CI, 0.65–1.27, ARD 
−0.01, 95 % CI −0.05 to 0.03).
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Figure 2. Forest plot comparing risk ratios of revision and planned revision surgery after Total Hip Arthro-
plasty versus HemiArthroplasty in displaced femoral neck fractures in the healthy elderly. Mantel-Haenszel 
statistical method was used with the ‘random effects’ analysis method for dichotomous data.
M-H, Mantel-Haenszel; THA, Total Hip Arthroplasty; HA, HemiArthroplasty
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Figure 3. Forest plot comparing risk ratios of one year mortality after Total Hip Arthroplasty versus Hemi-
Arthroplasty in displaced femoral neck fractures in the healthy elderly. Mantel-Haenszel statistical method 
was used with the ‘random effects’ analysis method for dichotomous data. M-H, Mantel-Haenszel; THA, To-
tal Hip Arthroplasty; HA, HemiArthroplasty
Dislocation
Six of the included studies provided data on dislocation (10, 13, 14, 16, 28, 29) (Figure 4). 
Another study did not report on dislocation (17), and one study reported that in both 
treatment arms there were no cases of dislocation (15). The risk of dislocation was 9 % in 
the THA-arm versus 3 % in the HA-arm. There was low evidence of heterogeneity across 
the studies (I2=30 %, P= 0.21). Pooling the data of these 780 patients and 47 events (6 
%) revealed a significant risk for dislocation after treatment with total hip arthroplasty 
for dislocated femoral neck fractures (RR 2.53, 95 % CI 1.05–6.10, ARD 0.05, 95 % CI 
0.02–0.08).
Chapter 4
60
19 
 
 
 
 
 
 
 
Study or Subgroup
Baker 2006
Blomfeldt 2007
Dorr 1986
Keating 2006
Macaulay 2007
Mouzopoulos 2008
Skinner 1989
Van den Bekerom 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.35; Chi² = 7.19, df = 5 (P = 0.21); I² = 30%
Test for overall effect: Z = 2.07 (P = 0.04)
Events
3
0
7
3
1
0
11
8
33
Total
40
60
39
69
17
43
89
115
369
Events
0
0
2
2
0
0
10
0
14
Total
41
60
50
69
23
43
91
137
411
Weight
7.8%
21.2%
17.4%
6.9%
38.6%
8.2%
100.0%
M-H, Random, 95% CI
7.17 [0.38, 134.53]
Not estimable
4.49 [0.99, 20.41]
1.50 [0.26, 8.70]
4.00 [0.17, 92.57]
Not estimable
1.12 [0.50, 2.52]
20.22 [1.18, 346.66]
2.53 [1.05, 6.10]
THA HA Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favors THA Favors HA
Study or Subgroup
Baker 2006
Blomfeldt 2007
Dorr 1986
Keating 2006
Macaulay 2007
Mouzopoulos 2008
Skinner 1989
Van den Bekerom 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.03; Chi² = 4.82, df = 4 (P = 0.31); I² = 17%
Test for overall effect: Z = 0.39 (P = 0.70)
Events
0
4
0
23
4
0
14
45
76
Total
40
60
39
69
18
43
89
115
302
Events
4
4
0
24
1
0
19
47
80
Total
41
60
50
69
23
43
91
137
330
Weight
1.4%
6.1%
35.8%
2.6%
0.0%
54.2%
100.0%
M-H, Random, 95% CI
0.11 [0.01, 2.05]
1.00 [0.26, 3.81]
Not estimable
0.96 [0.60, 1.52]
5.11 [0.62, 41.85]
Not estimable
0.75 [0.40, 1.41]
1.14 [0.82, 1.58]
1.07 [0.76, 1.50]
THA HA Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.5 0.7 1 1.5 2
Favors THA Favors HA
Study or Subgroup
Baker 2006
Blomfeldt 2007
Dorr 1986
Keating 2006
Macaulay 2007
Mouzopoulos 2008
Skinner 1989
Van den Bekerom 2010
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.14; Chi² = 6.56, df = 4 (P = 0.16); I² = 39%
Test for overall effect: Z = 0.24 (P = 0.81)
Events
12
5
0
8
7
0
0
6
38
Total
40
60
39
69
18
43
89
115
302
Events
5
4
0
15
11
0
0
10
45
Total
41
60
50
69
23
43
91
137
330
Weight
19.1%
12.8%
23.7%
26.1%
18.3%
100.0%
M-H, Random, 95% CI
2.46 [0.95, 6.35]
1.25 [0.35, 4.43]
Not estimable
0.53 [0.24, 1.18]
0.81 [0.40, 1.67]
Not estimable
Not estimable
0.71 [0.27, 1.91]
0.94 [0.56, 1.58]
THA HA Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.2 0.5 1 2 5
Favors THA Favors HA
Figure 4. Forest plot comparing risk ratios of dislocation after Total Hip Arthroplasty versus HemiArthro-
plasty in displaced femoral neck fractures in the healthy elderly. Mantel-Haenszel statistical method was 
used with the ‘random effects’ analysis method for dichotomous data.
M-H, Mantel-Haenszel; THA, Total Hip Arthroplasty; HA, HemiArthroplasty
Complications (Appendix 2)
Data on major complications were retrieved from five studies (10, 13-16) (Figure 5). In 
addition, one study reported data on both minor and major complications, and these 
data had to be excluded as these were not specified to both treatment groups (29). The 
outcome measures of two other studies were focused on functional recovery only and 
dat  on general complications were not presented (1 , 28). In 25 % major complica-
tions were found after THA versus 24 % after performing HA. No significant difference 
in major complication rates was found after either form of arthroplasty (RR 1.07, 95 % CI 
0.76–1.50, ARD 0.00 95 % CI −0.08 to 0.08). Heterogeneity across the studies was 17 % 
(P=0.31). The same five studies described in the section above on major complications 
presented data on general minor complications (10, 13-16) (Figure 6).
Heterogeneity across the five studies was 39 % (P=0.16). In 13 % minor complications 
wer  found after THA versus 14 % after performing HA. After excluding the mentioned three 
studies for analysis, pooled data for general complications showed no significant difference 
in ge eral minor complications (RR 0.94, 5 % CI 0.56–1.58, ARD −0.01, 95 % CI −0.08 to 0.07).
Functional outcome
Four studies reported the Harris hip score after total follow-up (13, 15-17). The Harris hip 
sc re ranges from 0 to 100 points and include function, pain, deformity and the range 
of motion. The weighted mean HHS was 81 (weighted mean SD 11) versus 77 (12) for 
THA and HA, respectively  A difference was found for the total score of this specific hip 
score (mean difference, MD 5.12, 95 % CI 2.81–7.42). Patients treated with THA reported 
statistically significantly higher Harris hip Scores. Heterogeneity across the studies was 
0 % (P=0.46) (Figure 7).
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Figure 5. Forest plot comparing risk ratios of major complications (as defined in Appendix 2) after Total Hip 
Arthroplasty versus HemiArthroplasty in displaced femoral neck fractures in the healthy elderly. Mantel-
Haenszel statistical method was used with the ‘random effects’ analysis method for dichotomous data.
M-H, Mantel-Haenszel; THA, Total Hip Arthroplasty; HA, HemiArthroplasty
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Figure 6. Forest plot comparing risk ratios of minor complications (as defined in Appendix 2) after Total Hip 
Arthroplasty versus HemiArthroplasty in displaced femoral neck fractures in the healthy elderly. Mantel-
Haenszel statistical method was used with the ‘random effects’ analysis method for dichotomous data.
M-H, Mantel-Haenszel; THA, Total Hip Arthroplasty; HA, HemiArthroplasty
From two papers it was possible to calculate separately the pain subdomain of the 
Harris hip score (13, 15). The weighted mean score for the pain subdomain of the HHS 
was 42 (weighted mean SD 2) versus 39 (3) for THA and HA, respectively. A significant 
difference was found favouring this score after treatment with THA (MD 2.62, 95 % CI 
0.18–5.05) (Figure 8). Two studies (10, 28) reported pain in categories mild to no pain 
(with no analgesia) after total follow-up. No to mild pain was reported in 75 % after THA 
and in 56 % after HA. These pooled data also showed a significant difference in favour 
of the THA group (RR 1.36, 95 % CI 1.20–1.54. Heterogeneity across studies was 0 % 
(P=0.39) (Figure 9).
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Figure 7. Forest plot comparing risk ratios of total Harris Hip Score after Total Hip Arthroplasty versus Hemi-
Arthroplasty in displaced femoral neck fractures in the healthy elderly. Inverse variance statistical method 
was used with the ‘random effects’ analysis method for continuous data.
IV, Inverse Variance; THA, Total Hip Arthroplasty; HA, HemiArthroplasty
Pain
One study (16) separately showed the results of pain as scored with the Western 
Ontario and McMaster Universities Osteoarthritis Index questionnaire (WOMAC). The 
calculated mean difference was 16.60 points (THA 94.4, SD 6.8 versus HA 77.8, SD 20.9; 
95 % CI 5.00–28.20, P=0.005) favouring THA (Figure 10).
Quality of life
Two European studies measured the quality of life with the EuroQol-5 Dimensions ques-
tionnaire at the final follow-up at one and two years respectively (10, 15). The weighted 
mean EQ-5D score was 0.69 (weighted mean SD 0.28) versus 0.57 (0.48) for THA and HA, 
respectively. A difference was found favouring THA (MD 0.13, 95 % CI 0.03–0.23, P=0.01). 
Heterogeneity across the studies was 0 % (P=0.33) (Figure 11).
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Figure 8. Forest plot comparing risk ratios of Harris Hip Score pain section after Total Hip Arthroplasty ver-
sus HemiArthroplasty in displaced femoral neck fractures in the healthy elderly. Inverse variance statistical 
method was used with the ‘random effects’ analysis method for continuous data.
IV, Inverse Variance; THA, Total Hip Arthroplasty; HA, HemiArthroplasty
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Figure 9. Forest plot comparing risk ratios of no-to-mild pain after Total Hip Arthroplasty versus HemiAr-
throplasty in displaced femoral neck fractures in the healthy elderly. Mantel-Haenszel statistical method 
was used with the ‘random effects’ analysis method for dichotomous data. M-H, tel-Haenszel; THA, To-
tal Hip Arthroplasty; HA, HemiArthroplasty
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Figure 10. Forest plot comparing risk ratios of WOMAC pain score after Total Hip Arthroplasty versus Hemi-
Arthroplasty in displaced femoral neck fractures in the healthy elderly. Inverse variance statistical method 
was used with the ‘random effects’ analysis method for continuous data. IV, Inverse Variance; THA, Total Hip 
Arthroplasty; HA, HemiArthroplasty
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Figure 11. Forest plot comparing risk ratios of Quality of lifederived from the EQ-5D after Total Hip Arthro-
plasty versus HemiArthroplasty in displaced femoral neck fractures in the healthy elderly. Inverse variance 
statistical method was used with the ‘random effects’ analysis method for continuous data. IV, Inverse Vari-
ance; THA, Total Hip Arthroplasty; HA, HemiArthroplasty
dIsCussIoN
Revision surgery rates and mortality rates were similar after THA and HA treatment for 
displaced femoral neck fractures in healthy elderly. None of these treatment options 
appeared to be superior with respect to postoperative minor or major complications. 
Risk of dislocation favoured HA. Estimates for function, pain and quality of life are less 
clear, but tend to be in favour of THA. The first debate on the management of selected 
displaced hip fractures started in the 70s and the question is still valid, as is illustrated 
by the flow of publications with expert opinions, experiences and reviews. In the last 
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three years two systematic reviews were published (21, 30), and the Cochrane review 
was recently updated (2), yet the question has still not been resolved.
Goh et al. performed a meta-analysis published in 2007 including three studies total-
ing 407 patients (10, 28, 29). In summary, no differences were found for revision surgery, 
mortality and dislocation rates. Significantly less pain was reported for patients with THA 
after one year of follow-up. It was concluded that for a subgroup of healthy patients with 
a good prefracture mobility THA might be considered as primary surgical treatment (30).
Hopley et al. concluded in their extensive analysis with four randomized, three quasi-
randomized and eight retrospective cohort studies that patients treated with total hip 
arthroplasty for intracapsular hip fractures may obtain better outcomes than those 
treated with HA (21). In addition, they concluded that advantages with THA must be 
traded off against a slightly higher risk of dislocations and general complications.
From the latest Cochrane review on this topic including the same seven randomized 
trials as in the article by Hopley et al. it was concluded that although dislocation was 
more common with THA, there was a general trend towards better functional outcome 
scores for those treated with THA (2).
Data from the “ARTHRO trial” (13) were not included in the above-mentioned manu-
scripts. Beyond revision outcomes, this methodological well-designed trial provided 
new data on functional outcomes not previously available. Adding data from the 250 
patients from this trial resulted in a 34 % increase in total population from randomized 
trials. The present analysis provides important new insights. First, our estimates of func-
tional outcomes and pain suggest that patient-based results after THA may be better 
than that reported in previous meta-analyses. Also, our estimate of the difference in 
dislocation rates is less pronounced than previously reported. The overall mortality rate 
of 14 % as found in this study is lower than the frequently reported 20–25 %; this may be 
due to the relatively healthy patients that were included in the individual trials.
study limitations
The present review has some limitations. The published individual trials were generally 
of low methodological quality (I). For example, the methods of allocating participants 
to a treatment were not all strictly randomized (e.g., hospital record number, order of 
admission, and day of the week). Also, the method of data analysis was not specified in 
three studies. Different outcome parameters and methods of reporting the results were 
used. Consequently, interesting parameters could not be analysed, for example, the 
30-day mortality. In addition, the studies meeting the inclusion criteria were individual 
trials with a small sample size without an adequate power calculation.
The total number of available randomized trials is still small, however they jointly 
involve almost 1,000 patients. Although definitive conclusions cannot be drawn from 
these results, there seems to be a more prominent and beneficial role for total hip ar-
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throplasty over hemiarthroplasty in the growing group of selected patients with femoral 
neck fractures.
Implications for future research
Although there is a growing awareness of the possibility of better results for selected pa-
tients treated with THA for displaced femoral neck fractures, a randomized trial is needed 
to definitively answer this long-lasting controversy in trauma surgery. One such unique 
international collaborative initiative (IHFRC; www.ihfrc.ca) is currently actively en-rolling 
patients in a multinational trial comparing revision surgery, functional outcome and 
quality of life after THA versus HA in elderly patients who sustained a displaced femoral 
neck fracture (31). This study would allow further assessment of the clinical relevance 
of the relatively small differences in pain and functional outcome found in the present 
study. This trial is important because it has the potential to substantially change surgical 
practice for the management of femoral neck fractures (32).
CoNClusIoN
This review, including the most recent evidence, shows that total hip arthroplasty may be 
advantageous over hemiarthroplasty in a selected group of patients suffering displaced 
femoral neck fractures. Ultimately, only large, well designed and well conducted studies 
will result in improvements in the outcomes of treatment and resolve the long-standing 
controversy of whether total hip arthroplasty or hemiarthroplasty is the preferred treat-
ment modality for this common fracture.
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APPeNdIx 1. lAsT seARChes CARRIed ouT: 22-2-2011
Pubmed: N=211
(hip fractures[mesh] OR hip fracture*[tw] OR femoral neck fractures[mesh] OR femoral 
neck fracture*[tw] OR femur neck fracture*[tw] OR femoral collum fracture*[tw] OR femur 
collum fracture*[tw] OR intracapsular hip fracture*[tw] OR subcapital hip fracture*[tw] 
OR intracapsular collum fracture*[tw] OR subcapital collum fracture*[tw] OR intracap-
sular neck fracture*[tw] OR subcapital neck fracture*[tw]) AND (arthroplasty[mesh] OR 
arthroplast*[tw] OR hemiarthroplast*[tw] OR hip replace*[tw] OR hip prosthe*[tw]) AND 
random*[tw] NOT (animals[mesh] NOT humans[mesh])
embase: N=121
(‘ femur neck fracture ‘/syn OR ((‘femoral neck’ OR ‘femur neck’ OR ‘femoral collum’ OR 
‘femur collum’ OR ‘intracapsular hip’ OR ‘subcapital hip’ OR ‘intracapsular collum’ OR ‘sub-
capital collum’ OR ‘intracapsular neck’ OR ‘subcapital neck’) NEAR/3 fracture*):ti,ab,de) 
AND (‘hip arthroplasty’/syn OR hemiarthroplast*:ti,ab,de OR (hip NEAR/3 (replace* OR 
prosthe*)):ti,ab,de) AND random*:ti,ab,de NOT (animal/de NOT human/de)
Wos: N=774
(hip fracture* OR femoral neck fracture* OR femur neck fracture* OR femoral collum frac-
ture* OR femur collum fracture* OR intracapsular hip fracture* OR subcapital hip frac-
ture* OR intracapsular collum fracture* OR subcapital collum fracture* OR intracapsular 
neck fracture* OR subcapital neck fracture*) AND (arthroplast* OR hemiarthroplast* OR 
hip replace* OR hip prosthe*) AND random* NOT (animal* NOT human*)
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APPeNdIx 2
Minor complications included all reported cases of:
Anemia
Ileus
Superficial Wound infect
Urinary tract infection
Deep venous trombosis
Bloodtransfusion
Atrial fibrilation
Pneumonia
Decubitus
Hart failure
Post operative confusion
Other infection
Major complications included all reported cases of:
Myocardial infarction
Deep infection
Stroke
Pulmonary embolism
Sepsis
Hematemesis
Re-operation (not revision)
GI bleeding

Chapter 5
Central coordination of a multicenter 
randomized trial as an alternative for 
payment per patient: experience from 
the HEALTH trial
Ned Tijdschr Traum. 2012;20:2-8
P.T.P.W. Burgers, R.W. Poolman, S.Culgin, T.A.Einhorn, M. Bhandari, P. Patka, E.M.M. 
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ABsTRACT
Objective: Different strategies can be used for the organization of multicenter clini-
cal trials. Multiple sites participated in the HEALTH trial (Hip Fracture Evaluation with 
ALternatives of Total Hip Arthroplasty versus Hemi-Arthroplasty). For the Dutch sites 
all trial-related tasks are managed by a central trial coordinator, whereas the sites in 
Canadian and the US have local study coordinators. The aim of this study was to analyze 
how these strategies affected trial performance.
Design: Prospective, observational study.
Method: Data related to obtaining ethics approval, trial start-up time, inclusion rate, 
and percentage of completed follow-ups were collected for each hospital and compared. 
Data from pre-trial screening were compared with actual inclusion rates.
Results: The median start-up time of the trial after obtaining ethics approval was 
shorter in the Netherlands than in Canada/US (4.6 versus 11.6 weeks). The inclusion rate 
was similar in both groups (0.62 versus 0.64/month). The median percentage of enrolled 
patients in the Netherlands was 27.3% versus 17.0% in Canada/US. The actual inclusion 
rates were lower than expected from pre-trial screening. The percentage of effectuated 
follow-up visits was > 90% in both groups.
Conclusion: In this study, central trial coordination contributed to faster trial start-up 
and higher inclusion rates, but had no effect on the effectuated follow-up visits. Central 
coordination is therefore a suitable alternative for appointing these tasks to local re-
search assistants and per patient payment. Central coordination enables non-academic 
hospitals to participate in clinical trials. Limiting conditions for central coordination 
are budget availability, a manageable number of patients, and a manageable distance 
between participating sites.
Funding: Grants from the Netherlands Organization for Health Research and Devel-
opment (ZonMw, project number 170.882.503), Canadian Institute of Health Research 
(CIHR; project number MCT-90168) and a grant from the National Institute of Health 
(NIH; project number 1R011AR055130-01A1) were received. The funders had no role 
in study design, data collection and analysis, decision to publish, or preparation of the 
manuscript.
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INTRoduCTIoN
Feasibility of clinical studies largely depends on the required sample size (1-3). A mul-
ticenter trial can be used in order to reduce the inclusion period. Such a design also 
has the advantage of better generalizability of the results (4,5). However, multicenter 
clinical trials require a complex logistic organization, especially for international trials 
(6). Coordination is critical to obtaining a good trial infrastructure and to make the study 
a success with reliable results (3, 7-10).
In multicenter research the local principal investigator is responsible for carrying 
out the trial in his/her hospital. Traditionally, local coordination has been the standard 
method; the local investigator has to organize everything by himself. A research assis-
tant or research nurse may support in obtaining ethics approval, patient recruitment, 
and data collection. Especially in industry-sponsored studies, the research team receives 
financial compensation. However, the availability of support often outweighs any finan-
cial compensation in deciding whether or not to participate in a clinical trial (11-13). 
Most university hospitals have access to research assistance. Community hospitals often 
lack this support, while the patient volume is generally bigger in those hospitals.
Currently, central coordination method is increasingly used as an alternative to local 
coordination. A physician-researcher performs almost all tasks in all participating hospi-
tals in a restricted geographical area. Participating centers do not receive any financial 
compensation. The central coordinator carries out the study tasks on behalf of and in 
close cooperation with the local principal investigator, who remains ultimately respon-
sible. In order to ensure independency, the central coordinator may not be involved in 
obtaining informed consent. The goal of central coordination is a faster ethics approval 
process, a faster trial start-up, and improved data quality.
In the HEALTH Trial (Hip Fracture Evaluation of Alternatives with Total Hip Arthroplasty 
Versus Hemi Arthroplasty), an international randomized controlled trial (RCT) in hip frac-
ture patients, both central and local trial coordination methods were used. The trial has 
been initiated by the International Hip Fracture Research Collaborative (IHFRC; www.
ihfrc.ca) (14). The primary aim of the HEALTH trial is to compare revision rates after total 
hip arthroplasty and hemi-arthroplasty for femoral neck fractures in the elderly. In the 
Netherlands, central coordination is used, while sites in Canadian and the US use local 
coordinators.
The aim of this study was to analyze how central and local coordination have influ-
enced the progress of the HEALTH trial.
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PATIeNTs ANd meThods 
heAlTh trial Characteristics
In the Netherlands the 14 participating sites started between December 15, 2008 and 
January 6, 2011. On February 14, 2011 the anticipated sample size of 150 patients 
was reached. In Canada five sites participated. These started between January 7 and 
December 14, 2009. On October 30, 2010 the target number of 36 patients was reached. 
In the US eleven sites participated and their start was between October 16, 2009 and 
November 12, 2010. In the US, the inclusion period is not yet complete. Patients with a 
dislocated femoral neck fracture who could not be included, were recorded. A distinc-
tion was made between excluded and missed patients.
Prior to the trial, seven sites also participated in a pre-trial screening period, with the aim 
to get an estimation of the number of eligible patients and thus the feasibility of the trial.
In the HEALTH trial two different coordination strategies are used: in the Netherlands, 
the trial is coordinated centrally from Erasmus MC. The central trial coordinator, who was 
funded by an external grant, was authorized by all principal investigators in the partici-
pating centers to carry out local study tasks. Ethics approval was centrally coordinated, 
in close cooperation with the local centers. These sites were responsible for patient 
screening and obtaining informed consent, and the central coordinator was responsible 
for collecting follow-up data. The maximum one-way distance from the coordinating 
site was 125 km. Sites received no fee for their participation. Sites in Canada and the 
US had a local research assistant and all study tasks were carried out by local staff. As 
compensation these sites received payment per enrolled patient.
data
Until April 1, 2011, the following data were collected for each hospital:
- Basic characteristics (hospital type and method of research coordination);
- Ethics approval process (date of submission and date of approval, number and 
nature of revisions);
- Pre-trial screening period (start and end date, and number of screened and eligible 
patients);
- trial period (start and end dates, number of enrolled, excluded, and missed patients, 
and number of completed follow-ups).
data analysis
All data were analyzed using the Statistical Package for the Social Studies version 16.0 
(SPSS Inc., Chicago, IL, USA). Data of the centrally coordinated sites (the Netherlands) 
were compared with locally coordinated sites (Canada/US). Continuous variables are 
expressed as median with quartiles, and tested using a Mann-Whitney U-test. Categori-
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cal variables are expressed as number of percentage and tested using a Chi-squared or 
Fisher’s Exact test. A p-value <0.05 was considered statistically significant.
ResulTs
Characteristics of participating sites
In the Netherlands 50% of the participating centers were non-academic, non-teaching 
hospitals, while in Canada and the US 69% of the centers were non-academic, teaching 
hospitals (p = 0.022; Figure 1).
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 Central 
coordination 
(n=14) 
Local 
coordination 
(n=16) 
p-value 
Time between ethics approval and trial 
start (weeks) 
4.6 (1.0-9.1) 11.6 (6.0-54.4) 0.011 
Duration of enrolment period (weeks) 89.9 (39,3-108,1) 36.5 (25.8-49.3) n.v.t. 
Included patients (number) 9 (6-15) 6 (1-9) n.v.t. 
Figure 1. Hospital type in the countries participat-
ing in the HEALTH trial: the Netherlands (central 
coordination; 14 sites) and in Canada and the US 
(local coordination; 16 sites).
ethics approval process
The median duration for obtaining ethics approval was 10.1 weeks in the Netherlands 
versus 10.3 weeks in Canada/US (p = 0 .810; Table 1). In the Netherlands, two of the 14 
ethics boards had requested to adapt trial documents: one time additional information 
had to be added to the patient information folder and two times language corrections 
were requested. In Canada/US, six of the sixteen Institutional Review Boards (IRBs) 
requested adjustments; two asked for additional information, two for language correc-
tions in the patient information folder, and two for additional information for the study 
protocol. Five IRBs asked for an explanation of study procedures in the protocol (Table 1).
Pre-trial screening period
Three Canadian, five American and two Dutch sites participated in the pre-trial patient 
screening. The median duration of this screening period in the Netherlands was 7.8 
weeks (P25-P75 7.3-8.3 weeks) versus 8.3 weeks (P25-P75 7.7-10.2 weeks) in Canada/US. The 
cumulative screening period, calculated by a summation of screening times per center, 
was 3 months for the Netherlands versus 17 months in Canada/US.
In the Netherlands, 17 patients were evaluated, of whom 10 (58.8%) were found eli-
gible for participation. In Canada/US 93 patients were assessed (median 10 per center; 
P25-P75 3-19), of whom 41 (44.1%) were found eligible for participation. Based on these 
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data the expected inclusion number in the Netherlands was 2.78 per month (10 in 3.6 
months) versus 2.40 patients in Canada/US (41 patients in 17.1 months).
Table 1. Data concerning the process of obtaining ethics/IRB approval of sites participation in the HEALTH 
trial by coordination strategy
Central coordination 
(n=14)
local coordination 
(n=16)
p-value
Time needed for ethics/IRB approval1 (weeks) 10.1 (5.8-19.2) 10.3 (7.0-18.7) 0.810+
Resubmission rounds1 0 (0-0) 0 (0-1) 0.145+
Type of revisions requested:
– Patient information folder: add information2 1 (7.1) 2 (12.5) 1.000++
– Patient information folder: change wording2 2 (14.3) 2 (12.5) 1.000 ++
– Protocol: add information2 0 (0.0) 2 (12.5) 0.485++
– Protocol: explain procedures 2 0 (0.0) 5 (31.2) 0.045++
The numbers in the headers represent the number of sites.
1 Data are presented as median with P25-P75 given between brackets; 2 data are presented as number with 
percentages between brackets; + Mann-Whitney U-test; ++ Fisher exact test.
Inclusion
The median time between the ethics approval and the start of the trial in the Netherlands 
was 4.6 weeks; this was significantly shorter than in Canada/US (11.6 weeks, p= 0.011; 
Table 2). In the Netherlands, the overall inclusion period was longer than in Canada/US 
(median 89.9 versus 36.5 weeks). Dutch and Canadian sites stopped enrolling since they 
reached the targeted population size. In the US 84% of target enrolment was achieved 
on that date.
During a cumulative enrolment period of 240 months, 150 Dutch patients were 
enrolled, which is 0.62 inclusions per month. In Canada/US 90 patients were enrolled 
in a cumulative period of 140 months, which is 0.64 patients per month. The centers 
that participated in the pre-trial screening enrolled 29 patients in 51 months (0.57 per 
month) in the Netherlands versus 64 patients in 90 months (0.71 per month) in Canada/
US.
In all centers, more patients were excluded than included. The median percentage of 
patients included in the Netherlands was 10% higher than in Canada/US (Table 2). In the 
Netherlands, relatively fewer patients were excluded (64.2% versus 78.5% in Canada/
US). Less than 5% of patients were missed for inclusion.
Follow-up
Follow-up data were collected at seven time points: at the outpatient department (1 and 
10 weeks, and 6, 12, 24 months after surgery) or by telephone (9 and 18 months). The 
rate of completed follow-ups within the predefined acceptable time window was 91% in 
the Netherlands and 92% in Canada/US (Table 2).
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Table 2. Characteristics of the enrolment and follow-up period of the HEALTH-trial by coordination strategy
Central coordination 
(n=14)
local coordination 
(n=16)
p-value
Time between ethics approval and trial start 
(weeks)
4.6 (1.0-9.1) 11.6 (6.0-54.4) 0.011
Duration of enrolment period (weeks) 89.9 (39,3-108,1) 36.5 (25.8-49.3) n.v.t.
Included patients (number) 9 (6-15) 6 (1-9) n.v.t.
Excluded patients (number) 26 (15-48) 14 (3-42) n.v.t.
Missed patients (number) 2 (0-5) 0 (0-0) n.v.t.
Included patients (% of total) 27.3 (15.5-30.9) 17.0 (8.1-33.6) 0.124
Excluded patients (% of total) 64.2 (55.9-69.9) 78.5 (53.6-91.9) 0.081
Missed patients (% of total) 4.4 (0.0-8.2) 0.0 (0.0-0.0) 0.023
Completed follow-ups (%) 91.2 (79.5-95.5) 92.3 (75.0-100.0) 0.631
Numbers in the headers represent the number of sites. Data are represented as median with P25-P75 be-
tween brackets. Data are analyzed with Mann-Whitney U-test
dIsCussIoN
Central coordination of the HEALTH trial resulted in better trial progress. In the Nether-
lands, where a central trial coordinator conducted virtually all tasks for the participat-
ing sites, the startup-time after obtaining ethics approval was shorter and inclusion 
progress was better than in Canada and the US, where local research assistants were 
appointed at individual sites. The rates of completed follow-ups were equally good in 
both coordination systems.
The process of obtaining ethics approval can be time-consuming and stressful and 
may result in diverse responses from review ethics committees (8-13). Despite proce-
dural differences between the two regions, the duration of the review process for the 
HEALTH trial was similar for both groups. In the Netherlands, a central ethics committee 
performs a full review of the submitted study documents. Subsequently, this central 
committee approves the participation of other sites, upon receipt of a ‘declaration of 
local feasibility’ signed by the local Board of Directors. In Canada and the US, the IRB 
at each individual site performs a full review of trial documents. The IHFRC, initiator of 
the trial, had prepared all the trial documents and provided them to all center for ethics 
review. Given the small number of needed revisions, these documents proved to be of 
high quality. The high quality of study documents clearly contributed positively to the 
relatively short review time.
The start-up phase in the Netherlands took about one month. The longer start-up 
phase in Canada/US had a financial reason. In the Netherlands, a grant was available and 
each center could start immediately after obtaining ethics approval and an initiation 
visit. Unlike Dutch sites, sites in Canada and the US received financial compensation for 
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each enrolled patient. The contract negotiations took place after obtaining IRB approval 
and prior to trial start-up. This has significantly delayed the start-up process in Canada/
US. Apart from these procedural differences between countries, the focused activities 
and actions of the central trial coordinator may have contributed positively to a more 
efficient and speedy start-up in the Netherlands.
Interestingly, the inclusion rate was 10% higher in the Netherlands than in Canada 
and the US (p> 0.05). Several factors may have contributed to this difference. In the 
Netherlands, more general hospitals participated. These hospitals treat more patients 
with a femoral neck fracture than university hospitals. Using central trial coordination al-
lowed these centers, which often do not have a research infrastructure, to participate in 
the trial. The relatively low (administrative) costs for staff and assistants were of eminent 
importance to most Dutch site principal investigators in their decision to participate.
In addition, cultural differences contributed to differences in trial progress. In Canada 
and the US orthopedic trauma surgeons are responsible for the care of patients with a 
femoral neck fracture; they perform both hemi-arthroplasty and total hip arthroplasty. 
In the Netherlands, the care for these patients is provided by both general orthopedic 
surgeons (20-25% trauma duty) and general and trauma surgeons (75-80% trauma 
duty). In the Netherlands, total hip implantation is restricted to orthopedic surgeons; 
consequently, centers could only participate if at least the orthopedic surgeons par-
ticipated. At four sites general and trauma surgeons participated. Participation of all 
surgical departments could have shortened the inclusion period in the Netherlands.
Based upon the screening data, the number of inclusions was much lower than was 
expected. Although disappointing, this was consistent with a previous study, which 
demonstrated that retrospective screening is more likely to give a reliable assessment 
than prospective screening (15). Prospective screening may be useful to motivate local 
staff and give awareness for future trial participation, but it has no predictive value for 
trial progression. The rate of completed follow-up visits was independent from the co-
ordination strategy; both central and local coordination resulted in excellent follow-up 
performance, with > 90% of follow-ups being completed.
This study has some limitations. Many of the results of this study were multifactorially 
influenced. Legislation, health care and insurance systems differed in the participating 
countries. As a result, not all observed differences may be attributable to the difference 
in coordination strategy.
Central trial coordination strategy is compliant to the recently tightened require-
ments of Good Clinical Practice (16). Moreover, this strategy facilitates trial participation 
of general hospitals, which adds to the feasibility of performing randomized surgical 
trials in the Netherlands as well as to the participation in international research. In ad-
dition, generalizability is higher when general hospitals participate as well. Important 
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conditions are the availability of sufficient funds to cover costs for the salary and travel 
expenses of the coordinating investigator.
CoNClusIoN
Results of this study showed that central coordination of a multicenter trial is a suitable 
alternative for local coordination. The strategy with a centrally funded trial coordinator 
enables high-volume hospitals to participate, thus improving the trial progression, com-
pared with local trial coordination combined with per patient payment. Both strategies 
resulted in similar, high quality follow-up data. The feasibility of central coordination 
depends upon the size of the study population, the availability of sufficient budget for 
salary and travel expenses of the coordinator, and the distance between the participat-
ing sites. If these aspects are adequately taken into account, the central coordination 
approach for the management of multicenter trials should be considered. Given the 
restricted geographical area of the Netherlands, this concept can be very promising for 
future multicenter studies in our country.
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ABsTRACT
Background: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
has been extensively evaluated in groups of patients with osteoarthritis, yet not in patients 
with a femoral neck fracture. This study aimed to determine the reliability, construct validity, 
and responsive ness of the WOMAC compared with the Short Form-12 (SF-12) and the EuroQol 
5D (EQ-5D) questionnaires for the assessment of elderly patients with a femoral neck fracture.
Methods: Reliability was tested by assessing the Cronbach alpha. Construct validity 
was deter mined with the Pearson correlation coefficient. Change scores were calculated 
from ten weeks to twelve months of follow-up. Standardized response means and floor 
and ceiling effects were determined. Analyses were performed to compare the results 
for patients less than eighty years old with those for patients eighty years of age or older.
Results: The mean WOMAC total score was 89 points before the fracture in the younger 
patients and increased from 70 points at ten weeks to 81 points at two years postopera-
tively. In the older age group, these scores were 86, 75, and 78 points. The mean WOMAC 
pain scores before the fracture and at ten weeks and two years postoperatively were 92, 76, 
and 87 points, respectively, in the younger age group and 92, 84, and 93 points in the older 
age group. Function scores were 89, 68, and 79 points for the younger age group and 84, 
71, and 73 points for the older age group. The Cronbach alpha for pain, stiffness, function, 
and the total scale ranged from 0.83 to 0.98 for the younger age group and from 0.79 to 
0.97 for the older age group. Construct validity was good, with 82% and 79% of predefined 
hypotheses confirmed in the younger and older age groups, respectively. Responsiveness 
was moderate. No floor effects were found. Moderate to large ceiling effects were found 
for pain and stiffness scales at ten weeks and twelve months in younger patients (18% to 
36%) and in the older age group (38% to 53%).
Conclusions: The WOMAC showed good reliability, construct validity, and responsive-
ness in both age groups of elderly patients with a femoral neck fracture who had been 
physically and mentally fit before the fracture. The instrument is suitable for use in future 
clinical studies in these populations.
Clinical Relevance: The results are based on two clinical trials. The questionnaires used 
concern pure, clinically relevant issues (ability to walk, climb stairs, etc.). Moreover, the 
results can be used for future research comparing clinical outcomes (or treatments) for 
populations with a femo ral neck fracture.
Funding: Research grants were received from Stichting NutsOhra, the Netherlands 
(project num ber T-0602-43) and the Netherlands Organization for Health Research and 
Development (ZonMw, the Netherlands, project number 170.885.607 and 170.882.503). 
These funding sources had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report.
Level of Evidence: Diagnostic studies, level I
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INTRoduCTIoN
The problem in assessing quality of care for patients with a hip fracture is the complex 
assortment of issues related to their care, including baseline health and frailty, social 
isolation and support, mental status, and joint function and pain. Different constructs 
can be assessed in the evaluation of hip fracture treatment. A frequently used disease-
specific patient-reported outcome measure is the WOMAC (Western Ontario and 
McMaster Universities Osteoarthritis Index) (1). To also cover the complexity of issues, 
the SF-12 (Short Form-12) and the EQ-5D (EuroQol 5D) are used for evaluating general 
health and health-related quality of life (2-5).
The WOMAC is a disease-specific twenty-four-item questionnaire (scored on a 5-point 
Likert scale) measuring three domains: pain, stiffness, and function. The WOMAC was 
designed for patients with osteoarthritis of the hip and knee (6). Translation and cross-
cultural validation were performed for different countries, including the Netherlands 
(7-10). The WOMAC has frequently been used for orthopaedic patients, including those 
with a hip fracture (11-13). It has been extensively validated in patients who underwent 
knee and hip arthroplasty because of osteoarthritis, but measurement properties in 
patients with a hip fracture are undetermined.
The aim of this study was to determine the reliability, validity, and responsiveness of 
the WOMAC compared with the SF-12 and EQ-5D questionnaires for the assessment of 
elderly patients who sustained a femoral neck fracture.
mATeRIAls ANd meThods 
Patients
Between March 3, 2008, and February 14, 2011, 400 patients with a femoral neck fracture 
were enrolled in two multicenter trials. One hundred and fifty patients were enrolled in 
the Dutch branch of the HEALTH (Hip Fracture Evaluation with ALternatives of Total Hip 
arthroplasty versus hemiarthroplasty) trial (ClinicalTrials.gov identifier NCT00556842; 
fourteen hospitals), and 250 were enrolled in the FAITH (Fixation using Alternative Im-
plants for the Treatment of Hip fractures) trial (ClinicalTrials.gov identifier NCT00761813; 
fourteen hospitals). Adult patients (fifty years of age or older) with a low-energy femoral 
neck fracture without other major trauma who were able to walk before the fracture 
were considered eligible. Patients with a suspected pathological fracture, associated 
major injuries of the lower extremities, retained hardware or infection around the hip, a 
bone metabolism disorder other than osteoporosis, cognitive impairment, dementia, or 
Parkinson disease as well as patients who were not likely to be able to complete follow-
up were excluded. Data on sex, age, American Society of Anesthesiologists (ASA) clas-
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sification (14), walking status, and living situation were collected. The ethics committees 
approved this study, and all patients provided signed informed consent.
Questionnaires
All 400 patients were asked to complete the three multidimensional questionnaires—
the WOMAC, SF-12, and EQ-5D—in the hospital and at each visit to the outpatient 
department.
The SF-12 score ranges between 0 and 100 (best) and consists of a Physical Component 
Summary (PCS-12) and Mental Component Summary (MCS-12) (2). The SF-12 represents 
a plausible alternative to the larger thirty-six-item SF-36 for measuring health status, es-
pecially in large-scale studies with a need to reduce questionnaire length. The reliability 
and validity were determined in different populations (2) and countries, including the 
Netherlands (3). The EQ-5D is a reliable and valid instrument for assessing health-related 
quality of life for elderly patients with a femoral neck fracture (4). The mobility, self-care, 
daily activities, pain, and anxiety domains are tested on a 3-point Likert scale, resulting 
in a utility score (EQ-US) that ranges from 0 to 1 (maximum) (5). In addition, patients 
scored their health status on a visual analog scale (EQ-VAS) that ranged from 0 (indicat-
ing worst possible health) to 100 (indicating best possible health) (5).
Data about the prefracture status were gathered during visits within one week after 
surgery, and other follow-up visits were at ten weeks and at six, twelve, and twenty-four 
months after surgery. Questionnaires were also completed during a telephone interview 
at nine and eighteen months. Patients did not receive any assistance in completing the 
questionnaires and did not consider the burden of completion too high. If necessary (e.g., 
due to physical status early in recovery), interviewer-administered versions were used.
data analysis 
Data were analyzed with SPSS software (version 20.0; IBM SPSS Statistics for Windows; 
IBM, Armonk, New York). Data are reported using the COSMIN (COnsensus-based Stan-
dards for the selection of health status Measurement INstruments) checklist (15).
Outcome scores for each follow-up visit for all instruments and subdomains were 
calculated. Unless mentioned otherwise, all further analyses were performed for two 
age groups (i.e., less than eighty years old and eighty years of age or older) and for ten 
weeks and twelve months.
The reliability of the WOMAC instrument was tested by determining the Cronbach 
alpha as a measure of internal consistency. The Cronbach alpha was used as a reliability 
parameter as there was no repetition of measurement by different observers or at differ-
ent follow-up times. Questionnaires aimed at measuring the same construct (WOMAC 
pain, SF-12 pain, and EQ-Pain) were used as repetition measurement (16,17). A Cronbach 
alpha within the range of 0.70 to 0.90 was considered acceptable (16).
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In the absence of a gold standard for the assessment of hip function after a hip 
fracture, construct validity was determined by calculating the Pearson correlation coef-
ficient. Construct validity refers to the extent to which scores on a particular measure 
relate to other measures in a manner that is consistent with theoretically derived hy-
potheses concerning the concepts being measured (17). Only questionnaires for which 
the WOMAC total score was available were included. Hypotheses for construct validity 
were defined before data analysis (see Appendix). Correlation coefficients of 0.1 to 0.3 
were considered weak; 0.3 to 0.6, moderate; and >0.6, strong (18).
Responsiveness is the ability of a questionnaire to detect clinically important changes 
over time (17). Change scores of the instruments were calculated from ten weeks to 
twelve months of follow-up. To assess responsiveness, standardized response means were 
calculated by dividing the mean change by the standard deviation of this change. Effect 
estimates were interpreted according to Cohen: a standardized response mean of 0.2 to 
0.4 was considered a small effect; 0.5 to 0.7, a moderate effect; and 0.8, a large effect (19).
A floor or ceiling effect was considered present if >15% of the patients in a sample size 
of fifty patients achieved the lowest or highest possible score (17).
missing data
As the raw data for individual items were analyzed, missing data were not imputed.
ResulTs
Population
Of all 400 included patients, 275 were less than eighty years old and 125 were eighty 
years of age or older (Table 1); 251 patients (62.8%) were female and 386 (96.5%) lived 
independently. This was similar in both age groups. Before the fracture, 325 patients 
(81.3%) walked without aid; they included 248 (90.2%) of those in the younger age 
group and seventy-seven (61.6%) of those in the older age group. Of the total group, 
289 patients (72.3%) were categorized as ASA class 1 or 2; they included 223 (81.1%) of 
those in the younger age group and sixty-six (52.8%) of those in the older age group. 
The dominant treatment was internal fixation in the younger age group (199 patients; 
72.4%) and arthroplasty in the older age group (eighty-three patients; 66.4%).
outcome scores
Patients who were less than eighty years old had a mean WOMAC total score (and stan-
dard deviation) of 89 ± 15 points before the fracture, 70 ± 22 points at ten weeks after 
the fracture, and 81 ± 20 points after twenty-four months (see Appendix). In the older 
age group, the corresponding scores were 86 ± 16, 75 ± 21, and 78 ± 18 points. Similar 
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changes in scores were reported for WOMAC stiffness, WOMAC pain, and WOMAC func-
tion (see Appendix).
SF-12 PCS scores decreased after the fracture and increased again over time (see Ap-
pendix), yet SF-12 MCS scores remained more stable over time (see Appendix). Likewise, 
EQ-US scores decreased after the fracture and increased again over time (see Appendix), 
whereas EQ-VAS scores remained more stable over time (see Appendix).
Table 1. Demographic data on the study group according to age group
Total
(N=400)
Age <80 years
(N=275)
Age ≥ 80 years
(N=125)
Female 251 (62.8%) 173 (62.9%) 78 (62.4%)
Mean age (years) 74 (10) 69 (8) 85 (4)
ASA I/II 289 (72.3%) 223 (81.1%) 66 (52.8)
Walking without aids prefracture 325 (81.3%) 248 (90.2%) 77 (61.6%)
Living independently prefracture 386 (96.5%) 268 (97.5%) 118 (94.4%)
Treatment: internal fixation 241 (60.3%) 199 (72.4%) 42 (33.6%)
hemiarthroplasty 92 (23.0%) 48 (17.5%) 44 (35.2%)
total hip arthroplasty 67 (16.8%) 28 (10.2%) 39 (31.2%)
SD, standard deviation; ASA, American Society of Anesthesiologists.
Data are shown as number (%) or as mean (SD).
WOMAC reliability
The Cronbach alpha for the domains of pain, stiffness, function, and the total scale were 
between 0.83 and 0.98 for the younger group and between 0.79 and 0.97 for the older 
group (Table 2)
Table 2. Reliability of the WOMAC instrument at ten weeks and twelve months for patients who had a 
femoral neck fracture, according to age group
WomAC 
domain
Number
of items
Cronbach’s alpha (N)
Age <80 years (N=275) Age ≥ 80 years (N=125)
10 weeks 12 months 10 weeks 12 months
stiffness 2 0.83 (229) 0.83 (204) 0.79 (113) 0.79 (95)
Pain 5 0.92 (191) 0.92 (186) 0.85 (67) 0.83 (70) 
Function 17 0.97 (107) 0.97 (130) 0.97 (22) 0.93 (36) 
Total scale 24 0.98 (105) 0.98 (128) 0.97 (21) 0.94 (35) 
N; number of available questionnaires with all items completed per domain and with all items completed. 
The Cronbach’s alpha is given with the number of patients included in the analysis between brackets.
Construct validity
All Pearson correlations were significant at p < 0.01 (two-tailed; Table 3). In six main hy-
potheses, twenty-eight components were predicted, of which twenty-three (82%) were 
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correctly hypothesized a priori in the younger age group and twenty-two (79%), in the 
older age group. Unconfirmed predictions were mainly underestimations (hypothesis 3; 
see Appendix). WOMAC stiffness correlated moderately (r > 0.35 to 0.55) with all other 
scores, while weak correlations (r = 0.1 to 0.3) were expected. WOMAC pain correlated 
strongly with EQ-US (r = 0.74 in the younger age group and 0.72 in the older age group), 
whereas moderate correlation (r = 0.3 to 0.6) was expected.
Responsiveness
Descriptive statistics and responsiveness are presented in Table 4. The standardized 
response mean was moderate for WOMAC function (0.64) and the WOMAC total score 
(0.66) for the younger age group. WOMAC subscales for stiffness and pain showed small 
standardized response means, ranging from 0.21 to 0.30 in the younger age group.
Table 4. Responsiveness of the WOMAC domains and WOMAC Total score, according to age group
Age <80 years (N=275) Age ≥ 80 years (N=125)
10 
weeks
mean 
(sd)
12 
months
mean 
(sd)
Change
mean (sd)
sRm (N) 10 
weeks
mean 
(sd)
12 
months
mean 
(sd)
Change
mean 
(sd)
sRm (N)
WomAC stiffness 67 (24) 74 (23) 5.5 (25.5) 0.21 (185) 80 (22) 81 (20) -0.3 (25.2) -0.01 (93)
WomAC Pain 76 (23) 85 (20) 6.9 (22.8) 0.30 (184) 84 (22) 91 (16) 5.1 (19.4) 0.26 (92)
WomAC Function 68 (24) 80 (21) 11.7 (18.2) 0.64 (145) 71 (24) 79 (18) 5.0 (19.1) 0.26 (54)
WomAC Total score 70 (22) 80 (20) 10.8 (16.4) 0.66 (144) 75 (21) 82 (15) 4.1 (16.6) 0.24 (54)
Scores at 10 weeks and at 12 months as well as the difference between these scores (change), are shown 
as median with SD.
The Standardized Response Mean (SRM) is given with the number of patients used in the analysis between 
brackets.
Table 5. Ceiling effect of the WOMAC domains and WOMAC Total score, according to age group
Age <80 years (N=275) Age ≥ 80 years (N=125)
N 10 weeks
N (%)
12 months
N (%)
N 10 weeks
N (%)
12 months
N (%)
WomAC stiffness 224 40 (17.9%) 72 (35.6%) 112 43 (38.4%) 50 (52.6%)
WomAC Pain 229 46 (20.1%) 53 (26.1%) 113 48 (42.5%) 38 (40.0%)
WomAC Function 179 7 (3.9%) 26 (13.7%) 73 3 (4.1%) 8 (10.3%)
WomAC Total score 179 2 (0.1%) 13 (6.9%) 73 2 (2.7%) 7 (9.0%)
The number of patients reporting the maximum score of 100 points are given with the percentage given 
in brackets. N represents the total number of questionnaires used for the analysis. None of the instruments 
demonstrated a floor effect (i.e., 0 points).
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Floor and ceiling effects
None of the WOMAC domains or the total score showed a floor effect. No ceiling ef-
fects were found for the function domain or the total score in either of the age groups 
(Table 5). Pain and stiffness showed a ceiling effect at ten weeks and twelve months 
postoperatively for the younger age group (18% to 36%) as well as for the older age 
group (38% to 53%).
dIsCussIoN
The present study was the first to determine the reliability, validity, and responsiveness of 
the WOMAC compared with the SF-12 and EQ-5D for the assessment of elderly patients 
who sustained a femoral neck fracture and who had been physically and mentally fit 
before the fracture. The results indicated that the WOMAC is a reliable and valid patient-
reported outcome measure for patients who are less than eighty years old and for those 
who are eighty years of age or older. Responsiveness was also sufficient, indicating the 
instrument can be used for measuring changes in scores over time.
Subscores of all patient-reported outcome measures showed similar patterns over 
time. The scores reduced (most likely immediately) after surgery; from ten weeks after 
surgery onward, a gradual increase over time was noted. After two years, the scores 
approximated the prefracture scores, indicating a small residual decrease in mental and 
physical functioning. Due to differences in symptom evolution, the clinimetric results 
from groups of patients with osteoarthritis are not readily applicable to groups with a hip 
fracture. The minimal clinically important change (MIC) for patients with a hip fracture 
has not been reported, yet changes in WOMAC pain and function were larger than the 
MIC reported for hip replacement after osteoarthritis (10 points for pain and 8 to 9 points 
for function) (20,21). There may be two reasons that changes in the mean WOMAC over 
time were smaller than those observed after hip replacement for osteoarthritis (from 53 
points at baseline to 94 points two years after surgery for pain and from 50 to 92 points, 
respectively, for function) (22). First, true baseline scores for patients with a hip fracture 
(i.e., scores between fracture and surgery) would have been much lower. Although these 
scores are unknown (as asking patients to complete questionnaires before surgery is not 
feasible), we expect these scores to be even lower than preoperative scores in patients 
with osteoarthritis (22). Calculating changes in WOMAC scores relative to baseline would 
have resulted in much larger changes over time. Second, at the first follow-up visit (at 
ten weeks), rehabilitation likely has progressed considerably already in the majority of 
patients, as participation required patients to be fit before the fracture.
The construct validity of the WOMAC instrument was good, with 82% (patients less 
than eighty years old) and 79% (patients eighty years or older) of the predefined hypoth-
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eses being true. In particular, the strong correlations of the WOMAC function and total 
score with the SF-12 PCS, SF-12 total score, and EQ-US support the preferred use of the 
WOMAC for assessing functional recovery in this population.
The responsiveness of the WOMAC instrument as a whole was moderate for patients 
less than eighty years old, as the standardized response mean was 0.66. In the older age 
group, the standardized response mean was small (0.24). For patients with a hip fracture, 
the standardized response mean has not been shown before. However, for patients with 
hip osteoarthritis, the standardized response mean of the WOMAC exceeded 1.0 (23,24), 
which was mainly due to much larger changes in scores between the two measure-
ments. Larger changes for those patients are expected, as the WOMAC score is at the 
lowest point prior to the hip replacement. These true baseline scores cannot be deter-
mined for patients with a hip fracture. The Dutch version of the non-hip-specific Short 
Musculoskeletal Function Assessment questionnaire (SMFA) appeared to be moderately 
responsive (standardized response means for subscales, 0.17 to 0.47) for patients with a 
variety of musculoskeletal disorders (25). In different Swedish patient groups with a hip 
fracture, the standardized response means were moderate to large (0.76 to 0.96) for the 
SMFA and small to large for the non-disease-specific instruments EQ-5D (0.01 to 1.14) 
and Nottingham Health Profile questionnaire (0.09 to 0.98) (26,27).
There was no evidence for any floor effect of the WOMAC instrument or for a ceiling 
effect of WOMAC function and total score. In contrast, moderate to large ceiling effects 
(18% to 53%) were found for pain and stiffness at ten weeks and twelve months in both 
age groups, which is similar to that reported in other studies (28-30). It may reflect the 
narrow discriminating capacity of these WOMAC domains in the studied population. 
Some selection bias might have played a role, as patients had to be physically and men-
tally fit to participate. Participants were able to walk and lived independently before the 
fracture.
The WOMAC has been used previously for assessing functional outcomes and quality 
of life for patients with a hip fracture (31,32). In the current study, it was validated for the 
first time in a group of patients with a hip fracture. We consider the novelty of validating 
the WOMAC for patients with a hip fracture to be a strength of our study. Moreover, we 
consider the studied groups to be representative of patients with a hip fracture seen in 
daily practice and believe the results apply to generally fit patients with a hip fracture. 
Whether the WOMAC is also valid for use in frail elderly patients remains unknown, as 
patients who were not able to walk before the fracture and patients with other disorders, 
e.g., Parkinson disease, pathological fractures, and dementia, were excluded. Another 
strength of the study was the built-in, very short period, only several days after fracture, 
for the self-reported, preinjury disability evaluation to be completed, minimizing the 
risk of recall bias (33).
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The sample size of the present study was not large enough to analyze the effect of 
complications on the results. The occurrence of complications, especially those resulting 
in revision surgery, may have affected the crude questionnaire scores, but that applies 
to all three instruments used. An association between the occurrence of complications 
and the validity of the WOMAC instrument seems unlikely and has never been reported 
in the literature before as far as we know.
One limitation could be the use of arbitrary hypotheses for construct validation, 
although they were predefined in compliance with clinimetric evaluation guidelines 
(15). Second, some selection bias might have led to overestimation of the outcomes, 
especially ceiling effects. This effect is also known from the Harris hip score, which is 
frequently used in orthopaedic research, but no gold standard exists for functional 
evaluation of patients with a hip fracture (34,35).
Third, data completeness was not 100% at each time point. One can imagine that 
patients were not able to complete the forms, especially if they were in poor condition. 
The 36% of the items that were missing, which caused a missing WOMAC total score, 
might have influenced the outcomes, resulting in the present, more favorable, mean 
outcome scores and large ceiling effects.
In conclusion, the WOMAC, a widely used disease-specific questionnaire, shows 
adequate reliability and construct validity for patients fifty years of age or older with 
a femoral neck fracture who had been physically and mentally fit before the fracture. 
Responsiveness was better for younger patients than for patients eighty years of age or 
older. It is therefore a suitable instrument for use in future clinical studies in this popula-
tion.
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ABsTRACT 
Purpose: Modern management of the elderly with a hip fracture is complex and costly. 
The aim of this study was to compare the treatment-related hospital length of stay 
(HLOS) before and after implementing a clinical pathway for patients undergoing hip 
fracture surgery.
Methods: Retrospective, before-and-after study. The first period ranged from June 21, 
2008 to November 1, 2009 (N= 212), the second was from January 7, 2010 to July 7, 
2011 (N= 314). The electronic hospital system and patients records were reviewed for 
demographics, HLOS, mortality, complications and readmissions.
Results: In the first period 53% had a femoral neck fracture, of which 57% was treated 
with hemiarthroplasty. In the second period this was 46% and 71%. Pertrochanteric 
fractures were treated with a Gamma nail in 85% in the first period, 92% in the second 
period. The median HLOS decreased from nine to six days (p<0.001). For the hemiarthro-
plasty group HLOS de creased from nine to seven days (p<0.001), for internal fixation 
there was no significant differ ence (five versus six days, p=0.557) and after Gamma nail-
ing it decreased from ten to six days (p<0.001). For mortality no statistically significant 
difference was found (6% versus 5%, p= 0.698). Complications decreased for the Gamma 
nail group (44% versus 31%, p= 0.049). Readmissions for the total group were not differ-
ent (16% versus 17%, p= 0.720).
Conclusions: Implementing a clinical pathway for hip fractures is a safe way to reduce 
the HLOS and it improves the quality of care.
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INTRoduCTIoN
Optimal modern management of the elderly with a hip fracture is complex and costly. 
The incidence of hip fractures increases exponentially with age, resulting in a 1-year 
incidence of 1% in women aged 80 years in Western countries (1). An expected increase 
in life expectancy, higher activity levels of the elderly and a subsequent higher risk of 
falling, cause hip fractures to be an increasing challenge for health care systems (1, 2).
The total costs of health care for hip fractures in 2007 in the Netherlands were €378 
million, of which 54% was generated during the in-hospital stay (3). Over 40% of the 
patients, admitted from their home setting are not able to return to their home setting 
after surgery (4). Waiting lists for medical rehabilitation facilities and nursing homes 
result in prolonged hospital stay and associated increasing costs (3).
To reduce these health care costs the Dutch Ministry of Health, Welfare and Sport 
propagates an early transfer to medical rehabilitation facilities (4). Implementing a mul-
tidisciplinary clinical pathways may improve the logistic management of the growing 
population of elderly patients with a hip fracture. It tends to have positive effects on 
mortality, postoperative complications, and in-hospital stay, consequently leading to 
reduced costs (5, 6). The aim of this study was to compare the treatment-related hospital 
length of stay before and after implementing a clinical pathway for all patients undergo-
ing hip fracture surgery.
PATIeNTs ANd meThods
study
A retrospective single-center before-and-after study. The first period ranged from June 
21, 2008 to November 1, 2009. The second period was from January 7, 2010 to July 7, 
2011.
Clinical pathway
The clinical pathway was developed by a multidisciplinary team and adapted to the lo-
cal needs and circumstances. The team consisted of trauma surgeons, an anesthesiolo-
gist and a geriatrician, a physiotherapist, the unit coordinator and team leaders of the 
surgical ward, a representative of the emergency department, the head of the hospital 
logistic department and of the department for patient education and the managers of 
the rehabilitation centers involved. This team was responsible for training and imple-
menting the pathway per stage on the different departments. Five stages were defined: 
pre-, peri-, post-operative, transfer and follow-up. The primary goal was to reduce the 
hospital length of stay. The standardized protocol covered the emergency department 
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(ED) with a rapid assessment of the patient, immediate video assisted education for 
patient and relatives about recommended treatment and prognosis. Other medical 
disciplines should be consulted preoperatively on the ED if necessary. The protocol 
continues on the clinical ward with consulting supportive disciplines such as physical 
therapists and a geriatrician. It also includes appointments with three surrounding re-
habilitation facilities aiming at transferring the patient to a patient-centered destination 
as soon as possible. This pathway was standard of care from November 2, 2009 onwards.
Patients
All patients admitted to the department of surgery of the IJsselland Ziekenhuis, Capelle 
aan den IJssel, the Netherlands for fractures of the proximal femur were included. 
Patients were identified by searching the electronic hospital database for CTG Code 
(Centraal orgaan Tarieven Gezondheidszorg; CTG38565 hemiarthroplasty; CTG38533 
internal fixation for proximal femoral fracture (IF); CTG38535 internal fixation for pertro-
chanteric fracture. Pathologic fractures and treatments with total hip arthroplasty were 
excluded. The following data were collected from the electronic patient files:
– Patient characteristics: gender, date of birth, date of fracture, date and time of admis-
sion, date and length of surgery, ASA classification (American Society of Anesthesi-
ologists).
– Treatment characteristics: use of cancellous screws (Synthes, Paoli, USA), sliding hip 
screw (Synthes, Paoli, USA), Thompson hemiarthroplasty (Stryker, Newbury, United 
Kingdom), (Long) Gamma3TM nail (Stryker, Schönkirchen, Germany), specialty of sur-
geon (trauma surgeon, general surgeon or surgical resident). The type of treatment 
was determined by the (supervising) surgeon.
– Post-surgery characteristics: re-admission date, date and type of complications 
categorized by: superficial wound infection, deep wound infection with or without 
re-operation, revision surgery, implant removal, death, neurologic complications, 
cardiac complications, miscellaneous (e.g., delirium, medication related, urinary tract 
infection, pneumonia, etc.), date and cause of death.
statistical analysis 
Data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 16.0 
(SPSS Inc. Released 2007, SPSS for Windows, Chicago, SPSS Inc). Normality of continuous 
data was assessed by frequency histograms (Q-Q plots). Descriptive analysis was per-
formed for describing patient-, fracture and treatment-related variables. Continuous vari-
ables were all non-parametric and are shown as medians with the first and third quartiles. 
Categorical variables are presented as numbers with percentages. Differences between 
the two periods were compared using a Mann-Whitney U-test (continuous data) or a Chi-
squared test (categorical data). A p-value <0.05 was considered statistically significant.
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ResulTs
Patient demographics, fracture and treatment characteristics 
In total 526 patients were admitted, 212 in the first period and 314 in the second. Patient 
characteristics are shown in Table 1. The median age was 84 years (P25-P75 78-89 years) 
and 391 patients were woman (74%). Two-hundred ninety one patients were classified 
as ASA class II (55%) and 181 as ASA class III (34%). The median age (p= 0.512), gender 
(p=0.919) and pre-operative ASA class (p=0.366) did not differ. In the first period 53% of 
the patients had sustained a femoral neck fracture, in the second period this was 46% 
(p=0.110). In the first period 57% of the patients were treated with a Thompson hemi-
arthroplasty versus 71% in the second period (p=0.024). Of the population with a per-
trochanteric fracture 85% was treated with a Gamma Nail, 8% with a Long Gamma Nail, 
and 7% with a SHS. In the second period these rates were 92%, 7%, and 1% (p=0.062).
Table 1. Patient, fracture and treatment characteristics before and after the implementation of the clinical 
pathway
Characteristic Total Before After p-value
N 526 212 314
Female gender1 391 (74) 157 (74) 234 (75) 0.919
Age2  84 (78-89) 84 (77-89)  84 (79-89) 0.512
Pre-operative ASA-score 1
ASA I 39 (7) 19 (9) 20 (6) 0.366
ASA II 291 (55) 130 (61) 161 (51)
ASA III 181 (34)  60 (28) 121 (39)
ASA IV 12 (2) 1 (1) 11 (4)
Unknown  3 (1) 2 (1)  1 (0)
Fracture type1
Femoral Neck 255 (48) 112 (53) 143 (46) 0.110
Pertrochanteric 271 (52) 100 (47) 171 (54)
Surgical procedure1
Femoral Neck
Hemiarthroplasty 166 (65) 64 (57) 102 (71) 0.024
Internal fixation 89 (35) 48 (43)  41 (29)
Pertrochanteric
SHS 9 (3) 7 (7)  2 (1) 0.032
Gamma nail 242 (89) 85 (85) 157 (92)
Long Gamma nail 20 (7) 8 (8) 12 (7)
1 Patient numbers are displayed, with the percentages given within brackets;
2 Data are displayed as median, with the first and third quartile given within brackets
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hospital length of stay 
Table 2 shows the median hospital length of stay (HLOS), which for the total group was 
nine versus six days (p<0.001). For patients treated with hemiarthroplasty the median 
HLOS was two days shorter (nine versus seven days, p<0.001). For the IF group no differ-
ence was found (median HLOS: five versus six days, p=0.557). For patients treated with 
Gamma nail it was four days shorter (ten versus six days, p<0.001).
Table 2. Median hospital length of stay in days by type of fracture, treatment and period
Total Before After p-value
Total 7 (5-10) 9 (5-14) 6 (5-8) <0.001
Femoral neck 7 (7-4) 8 (4-12) 6 (4-8) 0.024
Hemiarthroplasty  8 (5-10.25) 9 (6-14) 7 (5-8.25) <0.001
Internal Fixation 5 (3-9)  5 (3-10.5) 6 (4-7.50) 0.557
Pertrochanteric 7 (5-11) 10 (6-16) 6 (5-8) <0.001
SHS  9 (6-13)  9 (7-10) 15 (3-15) 1.000
Gamma nail  7 (5-10) 10 (5-17) 6 (4-8) <0.001
Long Gamma nail 10 (7-12)  10 (11-16)  8 (6-10) 0.014
Data are displayed as median, with the first and third quartile given within brackets
mortality
Detailed mortality rates are shown in Table 3. No statistically significant difference was 
found for the 30-day mortality (6 versus 5%, p= 0.698). None of the patients treated with 
SHS for pertrochanteric fractures died within 30 days after admission.
Table 3. Mortality within 30 days after admission by type of fracture, treatment and study period
Total Before (N= 212) After (N= 314) p-value
Total 29/ 526 (6) 13/ 212 (6) 16/ 314 (5) 0.698
Femoral neck 18/ 255 (7) 6/ 112 (5) 12/ 143 (8) 0.462
Hemiarthroplasty 15/ 166 (9) 4/ 64 (6) 11/ 102 (11) 0.411
Internal Fixation 3/ 89 (3) 2/ 48 (4) 1/ 41 (2) 1.000
Pertrochanteric 11/ 271 (4) 7/ 100 (7) 4/ 171 (2) 0.106
SHS 0/ 9 (0) 0/ 7 (0) 0/ 2 (0) 1.000
Gamma nail 9/ 242 (4) 7/ 85 (8) 2/ 157 (1) 0.010
Long Gamma nail 2/ 20 (10) 0/ 8 (0) 2/ 12 (17) 0.495
Patient numbers are displayed, with the percentages given within brackets
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Complications
Tables 4 and 5 show the post-operative complications. A total of 214 (41%) patients had 
at least one complication. Ninety-five patients had a complication in the first period and 
119 in the second period (45 vs 38%, p=0.124). The complication occurred within 30 
days after admission for 54 patients in the first period and for 73 patients in the second 
period (57 vs 61%, p=0.576).
In patients treated with hemiarthroplasty, 69 (42%) had a post-operative complica-
tion. No difference was found between the two periods (41 versus 42%, p=0.873). Forty 
six complications (67%) occurred within 30 days after surgery, which was similar for 
both periods (65 versus 67%, p=1.000). Of the IF group 48% developed a complication 
in the first period versus 51% in the second period (p=0.833). Thirty four percent of 
complications occurred within 30 days after surgery, which was similar for both periods 
(26% versus 43%, p=0.342). For hemiarthroplasty surgical site infections were the main 
hip-related complication (31%). Implant removal and conversion surgery accounted for 
71% of the complications after internal fixation for femoral neck fratcures.
A complicated course was found in 85 patients (35%) treated with a Gamma nail. In 
the second period a reduction was found for complication rates (44% versus 31%, p= 
0.049). Fifty-six complications (67%) occurred within 30 days after surgery, which was 
similar for both periods (65 vs 67%, p=1.000).
Table 4. Complication rate by type of treatment and study period
Characteristic Total Before After p-value
Total 214/ 526 (41) 95/ 212 (45) 119/ 314 (38) 0.124
Femoral Neck 113/ 255 (44) 49/ 112 (44) 64/ 143 (45) 0.237
Hemiarthroplasty 69/ 166 (42) 26/ 64 (41) 43/ 102 (42) 0.873
Internal fixation 44/ 89 (49) 23/ 48 (48) 21/ 41 (51) 0.833
Pertrochanteric 101/ 271 (37) 46/ 100 (46) 55/ 171 (32) 0.027
SHS 3/ 9 (33) 2/ 7 (29) 1/ 2 (50) 1.000
Gamma nail 85/ 242 (35) 37/ 85 (44) 48/ 157 (31) 0.049
Long Gamma nail 13/ 20 (65) 7/ 8 (88) 6/12 (50) 0.158
Patient numbers are displayed, with the percentages given within brackets
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Table 5. Rate of complications within 30 days after surgery by type of treatment and study period
Characteristic Total Before After p-value
Total 127/ 214 (59) 54/ 95 (57) 73/ 119 (61) 0.576
Femoral Neck  61/113 (54)  23/ 49 (47) 38/ 64 (59) 0.253
Hemiarthroplasty 46/ 69 (67) 17/ 26 (65) 29/ 43 (67) 1.000
Internal fixation 15/ 44 (34) 6/ 23 (26) 9/ 21 (43) 0.342
Pertrochanteric 66/ 101 (65) 31/ 46 (67) 35/ 55 (64) 0.834
SHS 2/ 3 (67) 2/ 2 (100) 0/1 (0) 0.333
Gamma nail 56/ 85 (66) 24/ 37 (65) 32/ 48 (67) 1.000
Long Gamma nail 8/ 13 (62) 5/ 7 (71) 3/ 6 (50) 0.592
Patient numbers are displayed, with the percentages given within brackets
Readmissions
Readmission rates are shown in Tables 6 and 7. In total, 86 patients (16%) were readmit-
ted, without difference between the two periods (16% vs 17%, p= 0.720). The readmission 
rate within 30 days after discharge was higher in the second period (18 vs 43%, p= 0.020). 
The readmission rate after hemiarthroplasty was not significantly different between the 
periods (16 vs 21%, p= 0.540). No significant difference was found for the readmission 
rate within 30 days after hemiarhtroplasty (50 vs 62%, p= 0.701). After IF no difference 
was found in the total readmission rate (33% vs 44%, p= 0.383) nor in the readmission 
rate within 30 days (6 vs 33%, p= 0.090). After Gamma nail treatment six patients were 
readmitted in the first period and 12 in the second period (7 vs 8%, p=1.000). None of the 
patients in the Gamma nail group was readmitted within 30 days in the first period, but 
four patients were readmitted in the second period (0 vs 33%, p= 0.245).
Table 6. Readmission rate by type of fracture, treatment and study period
Characteristic Total Before After p-value
Total 86/ 526 (16) 33/ 212 (16) 53/ 314 (17) 0.720
Femoral Neck 65/ 255 (25) 26/ 112 (23) 39/ 143 (27) 0.474
Hemiarthroplasty 31/ 166 (19) 10/ 64 (16) 21/ 102 (21) 0.540
Internal fixation 34/ 89 (38) 16/ 48 (33) 18/ 41 (44) 0.383
Pertrochanteric 21/ 271 (8) 7/ 100 (7) 14/ 171 (8) 0.817
SHS  1/ 9 (11) 0/ 7 (0)  1/ 2 (50) 0.222
Gamma nail 18/ 242 (7) 6/ 85 (7) 12/157 (8) 1.000
Long Gamma nail  2/ 20 (10) 1/ 8 (13)  1/ 12 (8) 1.000
Patient numbers are displayed, with the percentages given within brackets
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Table 7. Rate of readmission within 30 days after discharge by type of fracture, treatment and study period
Characteristic Total Before After p-value
Total 29/ 86 (34) 6/ 33 (18) 23/ 53 (43) 0.020
Femoral Neck 25/ 65 (38) 6/ 26 (23) 19/ 39 (49) 0.043
Hemiarthroplasty 18/ 31 (58) 5/ 10 (50) 13/ 21 (62) 0.701
Internal fixation  7/ 34 (21) 1/ 16 (6)  6/ 18 (33) 0.090
Pertrochanteric  4/ 21 (19) 0/ 7 (0)  4 /14 (29) 0.255
SHS  0/ 1 (0) 0/ 0 (0)  0/ 1 (0) 1.000
Gamma nail  4/ 18 (22) 0/ 6 (0)  4/ 12 (33) 0.245
Long Gamma nail  0/ 2 (0) 0/ 1 (0)  0/ 1 (0) 1.000
Patient numbers are displayed, with the percentages given within brackets
dIsCussIoN
Implementing a clinical pathway for the treatment of patients with a proximal femoral 
fracture is efficient and safe. It resulted in a significant reduction of the median hospital 
length of stay by three days, without significantly influencing the rates of mortality, 
complications, and readmissions.
To streamline the increasing demand for beds for patients with proximal femoral 
fractures, these results are of importance. Findings from a previous study (1996) showed 
a mean hospital stay of 21 days for these patients (7). In 2002, Van Balen et al. reported 
a reduction of the median hospital stay from 18 to 11 days after implementing an 
“early discharge regimen” in the same geographical area (8). The British national audit 
report described a 5% reduction in average hospital stay between 2011 and 2012 (9). 
In contrast, the current study showed a 33% reduction of HLOS. This difference cannot 
solely be explained by “natural reduction” as found by the audit, which itself might be 
partly caused by the increase in use of clinical pathways for hip fracture patients. The 
comparison with only the clinical pathway as a variable, consistency of the findings with 
literature and the explicable underlying mechanism jointly support causality.
Literature on effects of clinical pathways for hip fractures generally shows positive 
results, although some publication bias cannot be excluded (10-13). A recent review 
by Leigheb et al. showed similar reductions in the hospital length of stay in eight out of 
twelve studies (6). Three studies reported a longer hospital stay (14-16) and one did not 
find any difference after implementing a clinical pathway (17).
The main strength of the current study is that it is one of the first to report differences 
per treatment subgroup of a hip fracture population. The median age of the IF group 
was almost 10 years younger compared to the other treatment groups (77 versus 85 and 
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86 years, respectively). These younger patients were likely in better physical and mental 
condition and thus sooner fit for discharge to their own house. They had no waiting time 
for rehabilitation at all. In contrast, Hommel et al. did not find any significant differences 
between patients with different kind of operation types (15).
The total number and percentage of patients primarily treated with total hip arthro-
plasty was very small and did not contribute substantially to the total group. Moreover 
these patients were treated on another ward and by the orthopedic surgical team. For 
these reasons this small group was not taken into account in the current analysis. Hemi-
arthroplasty was used more frequently in the second period despite similar patient char-
acteristics and relative frequency of femoral neck fractures. Participation in an internal 
fixation randomized trial during the first period could have led to a lower threshold for 
applying internal fixation (18). Other known variables that may influence the choice of 
treatment (e.g. membership of the supervising staff, internal hospital procedures, daily 
ward affairs and procurement of medical supplies) did not change during the study. 
Moreover, the fact that people treated with hemiarthroplasty had a longer HLOS would 
rather have led to an underestimation of the effects. It is very unlikely that potential 
unknown or unmeasured changes have influenced the outcomes of this order. Therefore 
the clinical pathway seems to be responsible for the changes in HLOS.
The unchanged readmission and complication rates (decreased from 45 to 38%) sup-
port the safety of the implemented care pathway. The observed difference in type of 
treatment did not influence the complication rates as the treatment-related complica-
tion rates were the same in both groups. For a major part this was due to the decreasing 
rate in the Gamma nail group. This observation lacks a clear clarification in view of the 
implementation. The rate of complications within 30 days was also unchanged between 
the periods. The total complication rates were comparable with rates found in literature 
(19). The safety of implementing a clinical pathway for hip fractures is further supported 
by a meta-analysis of nine studies (involving 4637 patients), focusing on co-morbidities 
and postoperative complications (20). It was found that complications during hospital-
ization in patients with hip fractures be treated in a clinical pathway were less prevalent. 
A third parameter for safety would be mortality. Due to the low mortality rate within 30 
days after surgery, no definitive conclusions can be drawn on the effect of the clinical 
pathway on this parameter. However, the 30-day mortality rates (6% versus 5%) are in 
accordance with those from the meta-analysis. The combined in-hospital/ 30-day mor-
tality was reported 8% (118 of out 1520 patients) in the pathway group and 9% (141 out 
of 1522 patients) in the non-pathway group (20).
In the current study, the majority of complications after hemiarthroplasty (72%) and 
Gamma nail (75%) occurred within 30 days after surgery, whereas only a minority of 
complications after IF (32%) occurred early after surgery. General complications such as 
delirium, urinary tract infection, and medication related complications occurred most 
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frequently (53%) after treatment with Gamma nail. These data can inform patients and 
their relatives about what clinical outcomes and problems they may expect after sur-
gery. The type of surgeon: general surgeon, trauma surgeon, or surgical resident did not 
influence the complication rates (data not shown), which is also reported in literature 
(21). Moreover, the same brand and type of materials were used for all standardized 
surgical procedures during the entire study period.
This study had a few limitations. Although multiple digital hospital systems and 
patient files were used to identify complications, a slight underestimation due to the 
retrospective design of the study cannot be ruled out. Secondly, some interesting pa-
rameters, such as long term follow up, functional recovery by patient reported outcome 
measures, costs and total duration of institutionalization could not be investigated due 
to the retrospective design. Van Balen et al. found no reduction in total costs after imple-
mentation of an early discharge regimen, with a shift from the hospital to the nursing 
home. However, they reported in 2002 a median total hospital stay of 26 days (8).
Despite these limitations, the study provides evidence that in our institute implement-
ing the clinical pathway has led to a higher level of organisation and improvement of the 
quality of care for patients with a fracture of the proximal femur.
CoNClusIoN
Implementing a clinical pathway for proximal femoral fractures resulted in a significant 
reduction of hospital length of stay for patients treated with hemiarthroplasty or Gamma 
Nail but not after treatment with internal fixation. No differences were found for rates of 
mortality, complication and readmission. The use of a clinical pathway for hip fractures 
is a safe way to reduce the hospital length of stay and it contributes to improvement of 
quality of care of this fragile population.
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ABsTRACT 
Purpose: The absolute number of hip fractures is growing and increases the already 
signifi cant burden on society. The aim of this study was to determine the mean total 
medical costs per patient for treating displaced femoral neck fractures with hemi- or 
total hip arthroplasty in fit elderly patients.
Methods: The population was the Dutch sample of an international randomized 
controlled trial relating to femoral neck fracture patients treated with hemi- or total 
hip arthroplasty. Pa tient data and health care utilization were prospectively collected 
during a total follow-up pe riod of two years. Costs were separated into costs for hospital 
costs during primary stay, costs for clinical follow-up, and costs generated outside the 
hospital during rehabilitation. Multiple imputation was used to account for missing data.
Results: Data of 141 participants (mean age 81 years) were included in the analysis. 
The 2-year mortality rate was 19%. The mean total costs per patient after ten weeks of 
follow-up were €15,216. After one and two years of follow-up the cumulative mean costs 
were €23,869 and €26,398, respectively. Rehabilitation was the main cost determinant, 
and accounted for 46%. Primary admission days accounted for 22% of the total costs, 
index surgery for 11% and physical therapy for 7%.
Conclusions: The main determinants for the mean total costs (€26,398 per patient 
until two years) for arthroplasty after treatment of displaced femoral neck fractures 
were rehabilitation and nursing homes. Most of the costs were made in the first year. 
Reducing costs after hip fracture surgery should focus on improvements of the duration 
and efficiency of the rehabilita tion phase.
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INTRoduCTIoN 
The major complication of osteoporosis is the clinical manifestation of hip fractures. 
Based upon global trends and demographic changes the world-wide number of 
hip fractures is assessed to be over 7.3 million patients in the year 2050 (1, 2). In the 
Netherlands the number of patients sustaining a hip fracture since 1981 has more 
than doubled to almost 19,000 patients in 2012 (3). Almost 60% of all proximal femoral 
fractures concern femoral neck fractures, of which 80% are displaced (4). The Garden 
classification is frequently used to describe femoral neck fractures in the elderly. Garden 
type 3 and 4 represent displaced fractures. Femoral neck fractures can be treated using 
a non-operative approach, internal fixation, or arthroplasty. The arthroplasty group can 
further be divided into hemi-arthroplasty and total hip arthroplasty. Approximately 62% 
of patients aged 65 years or older are primarily treated with arthroplasty; hemi-arthro-
plasty is performed in this group in 78% of patients on average (5). Different insights into 
the preferred treatment of femoral neck fractures is subject of ongoing international 
debate (6). An international survey revealed that primary arthroplasty was for 75% of 
the responding surgeon’s the preferred treatment for patients over 60 years of age with 
a displaced fracture. For patients under 60 years of age with a displaced fracture (Garden 
type 3 or 4) hemi-arthroplasty was preferred by 11% and 25% of respondents, respec-
tively (6). Despite the higher initial costs compared with internal fixation, arthroplasty 
has been proven to be a cost-effective therapy (7-10).
According to data of the Dutch Ministry of Health care, Welfare and Sports, hip frac-
ture associated crude total costs in 2011 in the Netherlands were 471.5 million euro (11). 
Insight into health care use and associated costs is gaining importance as the burden 
of health care costs threatens to exceed the financial resources available. Such insight 
may reveal options for cutting down health care expenses. Although surgeons are ex-
pected to have a general idea about the costs for treatments they provide, these data 
are not easily available (12-14). Recently data came available of the total medical costs 
of femoral neck fracture patients treated with internal fixation in the Netherlands (15). 
To the best of our knowledge, detailed analysis of the costs of arthroplasty for femoral 
neck fractures in the Netherlands has not been published before. Therefore the aim of 
this study was to provide a detailed overview of the costs of patients with a femoral neck 
fracture treated with arthroplasty.
PATIeNTs ANd meThods 
This cost study was conducted as a cohort study alongside the Dutch sample of the 
HEALTH trial (Hip Fracture Evaluation with ALternatives of Total Hip Arthroplasty ver-
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sus Hemi-Arthroplasty, NCT00556842), an international randomized controlled trial 
comparing total hip arthroplasty and hemi-arthroplasty on revision surgery and quality 
of life in patients with a displaced femoral neck fracture. The local Medical Research 
Ethics Committees of all participating centers approved the study. Informed consent 
was obtained from all individual participants included in the study.
Population 
In the Netherlands 14 hospitals participated and enrolled 150 patients between De-
cember 2008 and January 2011. Patients were eligible if they: 1) were adults aged ≥50 
years, 2) had a (radiologically confirmed) displaced femoral neck fracture (ICD-10 code 
S72.0; Garden type 3 and 4) after a low energy impact and no other major trauma, 3) 
had operative treatment within three days of presenting to the emergency room, and 
4) were ambulatory pre-fracture (with or without aid). Patients or proxies provided 
informed consent. Patients were excluded if they 1) were not suitable for treatment with 
arthroplasty (i.e., inflammatory arthritis, rheumatoid arthritis, pathologic fracture, or se-
vere osteoarthritis of the hip), 2) had infection or retained hardware around the affected 
hip, 3) had a bone metabolism disorder other than osteoporosis, 4) were moderately 
or severely cognitively impaired pre-fracture, 5) had dementia or Parkinson’s disease 
severe enough to compromise the rehabilitation process, or 6) were not likely to be able 
to complete follow-up.
Treatment and follow-up 
Medical optimization was warranted for all included patients before surgery. Within 72h 
after presenting to the Emergency Department, patients were treated with arthroplasty 
(i.e., hemiarthroplasty or total hip replacement). The exact treatment including material 
choice (cemented or uncemented and unipolar or bipolar prosthesis) was left to the 
treating surgeon. Thromboprophylaxis were prescribed to all patients according to the 
local protocols. Post-operative weight bearing was as tolerated and early mobilization 
was encouraged. All patients were advised to be screened and treated for osteoporosis 
if deemed necessary. Follow-up measurements were performed at 10 weeks and at 6, 9, 
12, 18, and 24 months after the primary surgery.
Cost measurement 
This study included the following categories for hip related costs; (1) hospital costs dur-
ing primary hospital stay, including emergency department visit, diagnostic evaluations, 
surgery, and admission days; (2) hospital costs during follow-up, including diagnostic 
evaluations, outpatient clinic visits, diagnosis and treatment of adverse events, revision 
surgery, and admission days; and (3) non-hospital costs of rehabilitation and aids.
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Data on health care use were collected prospectively at each scheduled follow-up 
contact and at the close-out visit at the end of the study. Data were collected from the 
study case report forms (items are listed in Electronic supplementary material (ESM) 
Supplemental Table 1) and from the patient’s hospital file. At each follow-up contact, 
patients were asked to complete a questionnaire on their health care use. This question-
naire was a customized version of the ‘Trimbos and iMTA questionnaire on Costs associ-
ated with Psychiatric illness’ (Tic-P), which has been validated for use in health care cost 
studies (15, 16). An English version of the TicP questionnaire is available online (17). The 
questionnaire included questions on stay in a hospital, rehabilitation center or nursing 
facility, number of contacts with an intramural medical specialist or paramedical worker 
during admission and follow-up, medication use, co-morbidity and use of walking aids. 
Any missing data were completed during a close out visit at each hospital.
The total number of consumption units per cost category was multiplied by the unit 
prices. All unit prices were indexed with the national consumer price index to 2012 and 
are presented in Table 1. Costs for the index surgery, including time spent in the operat-
ing room, theatre personnel, overhead, anesthesia, and implant material and general 
equipment, was provided by two teaching hospitals and one academic hospital. Data 
from the teaching hospitals were averaged in order to obtain a realistic estimation of 
the average prices in the participating teaching hospitals. The Dutch manual on cost 
research, methods and standard costs in economic healthcare evaluations was used for 
reference cost prices of most other health care resources (18). The NZa (Nederlandse 
Zorgautoriteit; Dutch Healthcare Authority) is the Dutch market regulator in care and 
advises the Minister on healthcare costs. This institute provided the unit prices for 
intramural diagnostic procedures. Costs of medication were derived from the CVZ (Col-
lege voor zorgverzekeringen; Health Care Insurance Board), online accessible on www.
medicijnkosten.nl. Costs of rehabilitation aids were obtained from a local home care firm 
that is a represention of national practice. Costs of aids were calculated according to the 
annuity method, applying an interest rate of 4.5% and a 10-year write off period. With 
over 90% of the patients in the study being retired, the costs for production losses were 
considered of limited importance for this population, and were thus excluded. Home 
care was also excluded, since it was impossible to determine which proportion of the 
total home care received was due to the hip fracture. As done previously in a similar 
study on internal fixation of femoral neck fractures, costs of osteoporosis screening were 
included in radiology/diagnostic studies costs, costs of visits to an osteoporosis special-
ist were included in outpatient clinic visits costs, and costs for osteoporosis treatment 
were included in medication costs.
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Medical costs
statistical analysis
Data were analyzed using SPSS (version 20.0, SPSS Inc., Chicago, IL, USA). Replacement 
of missing values for cost items was done with multiple imputation following the predic-
tive mean matching method, using ten imputations (19). The following variables were 
included in the imputation model: sex, age, ASA at baseline, walking independently at 
baseline, treatment, costs of initial surgery and all other cost categories at 10 weeks, 
6, 9, 12, 18 and 24 months. Each of the ten complete datasets were further analyzed 
by non-parametric bootstrapping using 1,000 bootstraps per dataset (20). The 95% 
confidence interval around the mean costs was determined by taking the 2.5th and 
the 97.5th percentile of these bootstrap replications. Costs were calculated for the total 
study population.
ResulTs 
demographics
The participating departments in the 14 hospitals registered 592 consecutive patients 
with a femoral neck fracture, of whom 181 were eligible and 150 (25%) subsequently 
gave informed consent (Figure 1). One withdrew consent immediately, one patient 
died before surgery and seven patients were treated with internal fixation rather than 
arthroplasty. A total of 141 patients remained for the current cost analysis, of whom 74 
were treated with hemiarthroplasty and 67 with a total hip arthroplasty. The mean age 
was 81 (SD 7; range 57-100) years, 2 patients (1%; both females) were younger than 60 
years of age. A total of 96 patients (68%) were female. The mean age was 80 (SD 8; range 
57-100) years for females and 81 (SD 6; range 69-91) years in males. No patients (0%) had 
ASA class 1, 67 (48%) ASA class 2, 46 (33%) ASA class 3 and 2 (1%) ASA class 4 and 26 
(18%) ASA 5. A total of 136 (97%) were not institutionalized before the fracture, and 102 
(72%) patients were independent ambulatory before the fracture.
Clinical outcome and health care consumption 
The mean hospital length of stay was 10 days (SD 8). One patient with a complicated 
clinical course was discharged 90 days after the initial surgery. Within 14 days, 87% 
(N=123) of the patients was discharged. The discharge destination was in a rehabilita-
tion or nursing facility in 56%, and 44% of the patients went to their own house. Median 
stay in a rehabilitation facility was 10 (SD 28) days, in a nursing facility 14 (SD 42 ) days, 
and in an elderly home 18 (SD 62) days. During rehabilitation, patients had a mean of 52 
(SD 5) physical therapy sessions.
A total of 118 adverse events (AEs) occurred and 77 patients (55%) had no AE at all. 
The most frequent AEs were a subsequent fracture (N= 19; 13%), superficial wound 
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infections (N= 11; 8%) and dislocations (N= 10; 7%). Less than ten patients had other 
AEs including pulmonary embolus, myocardial infarction, cerebral vascular accident, 
pneumonia, urinary tract infection, delirium and decubitus. A total of 18 revision surger-
ies were performed in 10 patients of which seven closed reductions were performed in 
the emergency department (Table 2). One patient had four times a reoperation because 
of recurrent dislocations. One patient had three times arthrotomy and joint lavage 
because of deep infection, reduction was performed two times closed and one time 
32 
 
Analyzed 
Assessed for eligibility (N= 592)  Excluded  (N= 411) 
Not meeting inclusion criteria : 
♦ < 50 years of age (N= 12) 
♦ no confirmed femoral neck fracture (N=2) 
♦ No displaced fracture not repairable with 
internal fixation (N= 76) 
♦ Not likely to be treated < 72 hours (N=28)  
♦ Not ambulant prefracture (N= 8) 
♦ No medical optomalisation before 
surgery (N= 4) 
♦ High energy trauma (N= 1) 
♦ Other major trauma (N= 2) 
♦ No expertise present for total hip or 
   hemiarthroplasty (N= 2) 
 
Meeting exclusion criteria  
♦ Not suitable for arthroplasty (N= 16) 
♦ Infection around the hip (N= 2) 
♦ Bone metabolism disease (N= 5) 
♦ Dementia (N= 158) 
♦ Parkinson (N= 76) 
♦ Likely follow-up problems (N= 173) 
♦ Enrolled in other study (N= 3) 
      Other reason (N= 41) N=141 
 Received arthroplasty (N= 141) 
¨ Treated with internal fixation (N= 7) 
♦ Dead before surgery (N= 1) 
♦ Immediate withdrawal informed consent 
(N= 1)  
Enrolled (N= 150) 
H8	  
	  
	  
	  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
	  
 
 
Figure 1. Flow-chart of patient enrollment process
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open, two cups were reimplanted, one periprosthetic fracture was treated with plating 
and one conversion was performed. The mortality after ten weeks was 5% (N= 7), the 
1-year mortality was 11% (N=16) and the 2- year mortality was 19% (N=27). Patients died 
mainly due to cancer (N= 9), cardiovascular diseases (N= 6), neurological diseases (N= 
3) and the bone cement implantation syndrome (N=2). The mean duration of follow-up 
was 22 months (SD 9).
Costs 
Table 3 shows the calculated mean costs after multiple imputation of the missing data. 
The overall percentage of missing data was 17.8% and the relative efficiency of the mul-
tiple imputation was 0.98. In the first 10 weeks after the fracture the mean total costs 
were €15,216, which was 58% of the total costs. The most important cost category was 
the primary hospital stay accounting for €9,026. From this category costs were predomi-
nantly related to hospital admission (€5,732) and to the index surgery (€2,915). Other 
important costs were made for rehabilitation facilities and nursing homes (€4,068).
After 1 year of follow-up the cumulative mean total costs per patient were €23,869 
(95% CI 19,157- 30,136), this was 90% of the overall total costs. The single most contrib-
uting costs (55%) were related to rehabilitation and changes in living situation with a 
total amount of €13,139. Rehabilitation centers/ nursing homes (€11,694) and physical 
therapy at the outpatient clinic (€13,340) were the main items of expenditure. After 2 
years of follow-up the total rehabilitation related costs (€14,429) still accounted for 55% 
of the total costs. The hospital costs for follow-up almost doubled from €1,705 (7% of the 
total costs) after 1 year to €2,943 (11%) after two years of follow-up. The main items were 
costs related to adverse events which increased with 181% from €581 to €1,052 and an 
increase of 204% for revision surgery from €480 to €980 (Figure 2).
 
Table 2. List of revision surgeries performed
Revision surgery 1 Revision surgery 2 Revision surgery 3 Revision surgery 4
Patient 1 Conversion to THA Closed reduction ED Closed reduction ED Closed reduction ED
Patient 2 Arthrotomy and 
joint lavage
Arthrotomy and 
joint lavage
Arthrotomy and joint lavage
Patient 3 Closed reduction ED Closed reduction ED Plate fixation periprosthetic frx
Patient 4 Closed reduction OR Closed reduction ED
Patient 5 Conversion to THA
Patient 6 Open reduction
Patient 7 Closed reduction ED
Patient 8 Arthrotomy
Patient 9 Conversion to THA
Patient 10 Closed reduction OR
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THA, total hip arthroplasty; ED, emergency department; OR, operating room
Table 3. Mean costs of femoral neck fracture patients treated with arthroplasty (N=141)
Cost categories Cost until 10 weeks (€) Costs until 1 year (€) Costs until 2 years (€)
Hospital costs – primary stay
Emergency department visit 160 (160- 160) 160 (160- 160) 160 (160- 160) 
Radiology/Diagnostic modalities 219 (206- 232) 219 (206- 232) 219 (206- 232) 
Surgery 2,915 (2,798-3,023) 2,915 (2,798-3,023) 2,915 (2,798-3,023) 
Admission days 5,732 (4,452- 7,966) 5,732 (4,452- 7,966) 5,732 (4,452- 7,966) 
Total 9,026 (7,706- 11,295) 9,026 (7,706- 11,295) 9,026 (7,706- 11,295) 
Hospital costs – follow-up
Radiology/Diagnostic modalities 115 (103- 128) 240 (212- 270) 344 (278- 427) 
Out-patient clinic visits 120 (109- 133) 297 (263- 336) 416 (355- 494) 
Adverse events 200 (66- 392) 581 (280- 1056) 1,052 (568- 1,781) 
Revision surgery 396 (61- 990) 480 (112- 1100) 980 (345- 1940) 
Medication 82 (74- 92) 106 (93- 121) 151 (125- 182) 
Total 914 (499- 1541) 1,705 (1,102- 2,563) 2,943 (1,894- 4,308) 
Costs related to rehabilitation / changes in living situation
Rehabilitation center/Nursing home 4,707 (3,627- 5,874) 11,694 (8,132- 16,350) 12,240 (8,542- 17,008) 
Physical therapy (outpatient) 549 (470- 640) 1,340 (1,162- 1,537) 1,975 (1,627- 2,370) 
Use of aids 20 (17- 25) 105 (78- 139) 214 (166- 270) 
Total 5,276 (4,200- 6,467) 13,138 (9,486- 17,956) 14,429 (10,461- 19,552) 
Total costs 15,216 (13,051- 18,323) 23,869 (19,157-30,136) 26,399 (21,101- 33,213)
40 
 
	  
Figure 2. Relative contribution of costs categories to the total treatment costs of patients until two years 
follow-up
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Medical costs
Costs are presented as mean costs at each follow-up moment with 95 % uncertainty interval between brackets
The data have been imputed. If a patient had not consumed health care, costs for that item were recorded as €0
dIsCussIoN 
The cumulative mean costs per patient after treatment with arthroplasty for femoral 
neck fracture were after 1 year €23,869 (95% CI €19,157- €30,136) and €26,398 (95% CI 
€21,101- €33,213) after 2 years.
These costs are in line with the range of €12,952 to €43,671 (as adjusted to 2012) found 
in literature (7-9, 21-25). This broad range can be explained by different variables used 
in the studies. All studies were performed in western countries, but with different health 
systems, mean length of hospitals stays, reference costs and rehabilitation facilities. The 
populations studied were relatively small with 32 to 180 patients. One study, based on 
19,808 patients, used a Markov decision model (25). Although most of the costs are 
generated in the first year, the two studies with the lowest costs had a follow-up of one 
year (21, 23), not taking into consideration the late and costly complications. One study 
(8) did not include treatment with hemiarthroplasty and two studies only reviewed the 
costs for patients treated with hemiarthroplasty (21, 22). Also, different types of costs 
were calculated in previous studies, e.g., in-hospital costs only (7), the included popula-
tions differed in age, or included only women (23). The current results correspond best 
with the results (adjusted costs €29,834 and €29,807, respectively) of the two largest 
studies, both including both types of arthroplasty (9, 25).
Additionally, from a prospective cohort study of 10,275 Dutch people the estimated 
incremental cost of medical care the first year after a hip fracture was $9,540 (adjusted 
to €, 2012: €11,715) and $1,017 (€1,248) in the subsequent year (26). These incremental 
costs are comparable with the €14,844 (first year) and €2,529 (subsequent year) found in 
the current study De Laet et al. (26) found higher costs, but in that study detailed costs of 
adverse events, revision surgeries and costs of diagnostic modalities were not included. 
The in-depth method of our study can be considered more specific as the total costs are 
presented in more detail.
Recently a similar study was published for Dutch elderly patients with a femoral neck 
fracture (50 years or older) primarily treated with internal fixation (15). Both studies 
had the same design and used identical research methods, questionnaires, statistics. 
and resources, making it suitable for direct comparison. After two years of follow-up 
the costs, adjusted to 2012 for the total internal fixation group were €20,368 (original 
data: €19,425; 95% CI €5,237-€58,874). The relative contributions of the different cost 
categories were very comparable with respect to rehabilitation (46% of total costs for 
arthroplasty and 49% ( for internal fixation) and admission days (both 22%), with higher 
absolute costs in the current arthroplasty study. These differences can be explained by 
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the general older population in the arthroplasty group based on baseline characteris-
tics. In the current study, the mean age was 10 years older (81 versus 71), patients were 
more often ASA 3-4 (54% versus 13%), used aids prefracture more often (28% versus 
13%), and had a displaced fracture more often (100% versus 46%). It is likely that older 
patients require more and longer rehabilitation facilities. Besides, the mean HLOS (10 
versus 7 days) were longer in the arthroplasty group. Subgroup analysis of 67 patients 
(27%) who underwent revision to arthroplasty after primary internal fixation resulted in 
adjusted costs of: €28,031 (€26,733; 95% CI €9,465- €80,029), which exceeds the costs of 
primary arthroplasty. This emphasizes the need to carefully select the primary treatment 
for hip fractures as conversion from internal fixation to arthroplasty is even more costly 
than primary arthroplasty.
This study had some limitations. First, the population has been selected, based upon 
the eligibility for arthroplasty. Therefore it is a specific subset of the total population 
which was presented at the emergency departments of participating hospitals. The 
patients were relatively healthy, fit, and most were independent walkers before the 
fracture. Patients with dementia or Parkinson’s disease were excluded. As they repre-
sent a substantial part of the general hip fracture population. These patients may have 
complex needs and incur higher costs, consequently leading to an underestimation of 
the mean costs presented. Costs are based on Dutch prices and may vary depending on 
the health care system used. However, we believe and have shown by comparing with 
published costs from other Western countries that the results are applicable to other 
settings as well. Secondly, the actual costs are expected to be even higher as costs for 
pre-hospital care, costs for routine blood analysis at the emergency department and 
wards, and perioperative consultation by other medical specialists and, although not 
routinely applied, forensic autopsy were not included. On the other hand, the number 
of visits for follow-up and X-rays are lower in general practice compared to a trial setting. 
Also, the amounts used in the manuals may differ from the actual costs. However, these 
costs are not expected to be substantial. Finally, costs for home care were not included 
as for most patients it was impossible to discriminate which part of the post-fracture 
home care was actually due to the hip fracture and not due to home care they already 
received for pre-fracture conditions. With these limitations in mind the results are in line 
with previous international publications.
In conclusion, the treatment of displaced femoral neck fractures with arthroplasty 
is costly with cumulative mean costs after one year of €23,869 and €26,398 after two 
years of follow-up. Rehabilitation and nursing homes accounts for almost half of the 
total medical costs, revision surgery and adverse events not even ten percent. Focus on 
improvements of the rehabilitation phase can result in reducing costs.
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Summary
This thesis covers three topics related to hip fracture patients. Part 1 comprises three 
chapters in which epidemiological data are analyzed. The results of these studies pro-
vide answers to the following questions:
- What were the incidence rates of hip fractures in the older Dutch population, based 
on historical data from 1981 to 2008? (Chapter 2)
- What is the cumulative incidence of non-simultaneous bilateral femoral neck frac-
tures in the Netherlands, based on data from 14 Dutch hospitals? (Chapter 3)
- Is hemiarthroplasty (HA) or total hip arthroplasty (THA) the preferred treatment for 
dis placed femoral neck fractures in fit elderly, based on randomized trials? (Chapter 
4)
Part 2 consists of two chapters focusing on research techniques. Here, the research 
questions are:
- What is the preferred coordination strategy for conducting a multicenter study in the 
Netherlands? (Chapter 5)
- Is the WOMAC also a valid patient reported outcome measure (PROM) in a hip frac-
ture population? (Chapter 6)
Part 3 contains two chapters on clinical and economic questions:
- What is the impact of the implementation of a clinical pathway for patients with a hip 
fracture admitted to a Dutch teaching hospital? (Chapter 7)
- What are the direct medical costs for patients treated with a prosthesis for a hip 
fracture, in the Netherlands? (Chapter 8)
PART 1
Chapter 2 describes the absolute numbers of hip fracture patients in the Dutch elderly 
population between 1981 and 2008. In this period, the absolute number of patients 
more than doubled from 7,614 to 16,049. The crude incidence rate increased from 46.4 
per 10,000 older adults in 1981 to a peak in 1995 (70.4 per 10,000 older adults), and 
subsequently gradually decreased to 66.5 in 2008. Although no real explanation could 
be found, this pattern is comparable with the trends reported from several Western 
countries. Furthermore, the total length of stay decreased by a fifth, as in all age groups 
the average length of stay decreased (from an average 37 days in 1981 to 14 in 2008).
Patients sometimes fracture the contralateral hips after a first hip fracture. Chapter 3 
aims to determine the cumulative incidence of non-simultaneous, bilateral hip fractures 
in the Netherlands. Data were available from 1,250 consecutive hip fracture patients, 
who were admitted to 14 Dutch hospitals between February 2008 and August 2009. The 
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number of patients with a non-simultaneous bilateral hip fracture was 109 (9%). The me-
dian interval between the two fractures was 25 months. With an identical fracture type, 
the type of treatment was also the same in 88%. The relatively high risk for a second 
femoral neck fracture points out the importance of secondary prevention, particularly in 
patients with a previous wrist or vertebral fracture. Chapter 4 is a systematic review with 
meta-analysis of eight randomized trials (between 1986 and 2010) with a total of 986 pa-
tients. In all studies, patients were randomized between HA and THA and the follow-up 
was at least 1 year. A non-significantly revision rate difference was found: 4% (HA) versus 
7%. The dislocation rate was higher in the THA group: 3% versus 9%. The 1-year mortality 
did not differ significantly: 15% (HA) versus 13%. Rates of major complications, 24% (HA) 
versus 25%, and minor complications, 14% (HA) versus 13% were equal in both groups. 
Patient satisfaction measured with different patients reported outcome measures were 
statistically significantly better after THA. However, because these individual studies 
did not meet the modern quality standards, the heAlTh trial was designed. This is an 
international, randomized trial comparing HA with THA for the treatment of displaced 
femoral neck fractures in the fit elderly (N = 1,434).
PART 2
Chapter 5 describes the analysis of two different coordination strategies that are used 
to coordinate the above mentioned heAlTh trial. Traditionally, multicenter research is 
coordi nated with a local coordination strategy. The local principal investigator organizes 
everything himself in his hospital. Assistance for procedures to obtain ethics approval, 
patient recruitment, and data collection is sometimes available. With the central coordi-
nation strategy, one funded coordinator conducts all tasks for the participating hospitals. 
Central coordination re sulted in a shorter startup time (median 7 weeks) and a higher 
inclusion rate (median 10%), with comparable high quality and an excellent follow-up 
rate (> 90%). Central coordination provides, under certain conditions, non-academic, 
high-volume hospitals the opportunity to participate to major orthopedic trauma trials.
Nowadays, in clinical research and in modern practice, validated questionnaires are 
used to measure patient satisfaction for a certain treatment. Such a questionnaire is 
the Western Ontario and McMaster Universities Arthritis Index (WOMAC). It is frequently 
used since 1982 and it has been extensively studied in patients with hip and knee wear 
(osteoarthritis) who are treated with artificial joints. Chapter 6 describes the validation 
results of the WOMAC in a total different population: patients without clinical relevant 
osteoarthritis, but with a hip fracture. With osteoarthritis complaints (pain) continues to 
increase until surgery is performed. Contrary, patients with a fracture generally have no 
symptoms of the hip joint until the femoral neck fracture. This study demonstrates for 
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the first time that the WOMAC is valid, reliable and also detects well clinically relevant 
changes in the hip fracture population.
PART 3
The modern treatment of patients with a hip fracture requires multidisciplinary involve-
ment. Basic requirements include adequate pain relief, a short stay at the emergency de-
partment, emergency surgical treatment, complication prevention (decubitus, delirium, 
infections, etc.), adequate postoperative mobilization and subsequent rehabilitation, 
including osteoporosis screening. All these necessities in a frail population and taking 
into account the physical and psychological co-morbidities and polypharmacy. A clinical 
care pathway provides structure to healthcare professionals in order to achieve this op-
timal care for all patients. Chapter 7 describes the effect of the introduction of a clinical 
pathway for hip fracture patients in a Dutch teaching, the Netherlands. The analysis of 
212 patients during the period preceding the introduction (June 21, 2008 to November 
1, 2009) and 314 patients after the care pathway introduction (January 7, 2010 to July 
7, 2011) resulted in a decrease in admission days up to 4 days, depending on the type 
of surgery. The death rate (6 versus 5%) and complication rate (45 versus 38%) did not 
differ significantly. There was also no difference in the overall rate of readmissions (16 
versus 17%). In conclusion, the introduction of a clinical care pathway proved to be a 
safe way to shorten the length of stay and contributes to improving the quality of care 
for this vulnerable population. The results described in Chapter 8 answer the question: 
What are the direct medical costs of a treatment with prosthesis for a hip fracture in 
the Netherlands? The care trajectories of the Dutch HEALTH trial participants were 
closely moni tored. To each component a unit price was linked and eventually a mean 
amount could be calculated. The indexed costs were available from financial data kindly 
provided by several participating hospitals, the Dutch Healthcare Authority (NZa) and 
the Dutch Manual for Costing: Methods and Reference Prices for Economic Evaluations 
in Healthcare by the Institute for Medical Technology Assessment commissioned by the 
Healthcare Insurance Board (CVZ, College voor zorgverzekeringen). These are the usual 
sources for calculating direct medical costs of treatment in healthcare. Rehabilitation 
(46%) and admission days (22%) accounted for the main part of the total costs per 
patient. The cumulative average price after one year follow-up was € 23,869 and after 
two years € 26,398.
Finally, Chapter 9 is the Dutch summary and Chapter 10 is the English summary. Chap-
ter 11 is the general discussion of the results described in this thesis. Future perspectives 
on the treatment with a prosthesis for a hip fractured are included.

Chapter 10
Nederlandse samenvatting

139
Samenvatting
Dit proefschrift beschrijft onderzoek over patiënten met een “gebroken heup” en bestaat 
uit drie delen. deel 1 bestaat uit drie hoofdstukken waarin epidemiologische gegevens 
zijn onder zocht.
De resultaten van de onderzoeken geven antwoorden op de volgende vragen :
- Hoe is het verloop van het aantal nieuwe patiënten met een gebroken heup in Ned-
erland, gebaseerd op historische gegevens vanaf 1981? (hoofdstuk 2)
- Hoe vaak komt het beiderzijds, maar niet-simultaan breken van heupen voor in 
Nederland, gebaseerd op gegevens van 14 Nederlandse ziekenhuizen? (hoofdstuk 
3) 
- Heeft een totale heupprothese of een kop-halsprothese de voorkeur in behandeling 
voor verplaatste heupfracturen bij fitte ouderen, gebaseerd op de resultaten van 
gerandomiseerde klinische studies? (hoofdstuk 4) 
deel 2 beslaat twee hoofdstukken over onderzoekstechnieken. De geformuleerde 
onderzoeksvragen zijn hier:
- Welke coördinatiestrategie heeft de voorkeur bij het verrichten van een multicenter 
onderzoek in Nederland? (hoofdstuk 5)
- Is de WOMAC ook een valide vragenlijst voor de follow-up van patiënten die behan-
deld zijn aan een gebroken heup? (hoofdtsuk 6) 
deel 3 bevat twee hoofdstukken met klinisch-economische vragen:
- Welke invloed heeft de invoering gehad van een klinisch pad voor patiënten die met 
een gebroken heup werden opgenomen in een regionaal opleidingsziekenhuis in 
Nederland? (hoofdstuk 7)
- Wat zijn in Nederland de direct medische kosten van patiënten met een gebroken 
heup, die behandeld zijn met een prothese? (hoofdstuk 8)
deel 1
hoofdstuk 2 beschrijft het totaal aantal nieuwe patiënten met een gebroken heup in de 
Neder landse 65+ populatie tussen 1981 en 2008. Het absolute aantal patiënten verdub-
belde van 7.614 naar 16.049 in deze periode. In een eerste periode steeg de incidentie 
van 46,4 per 10.000 ouderen tot een piek van 70,4 in 1995, waarna de incidentie afnam 
tot 66,5 in 2008. Een eensluidende verklaring is hiervoor niet gevonden. Dit patroon 
komt wel goed overeen met het patroon dat in andere westerse landen voorkomt. Verder 
nam het totaal aantal ligdagen met een vijfde af, doordat de gemiddelde opnameduur 
in alle leeftijdsgroepen verminderde (van gemiddeld 37 dagen in 1981 tot 14 in 2008).
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Echter, na een eerste breuk van de heup kan ook de andere zijde breken. Bij ouderen 
gaat het dan vaak om een nieuwe val. Het doel van hoofdstuk 3 is het bepalen van 
de frequentie van dit beiderzijds, niet-simultaan breken van heupen in Nederland. Uit 
14 Nederlandse ziekenhuizen waren de gegevens beschikbaar van alle 1.250 patiënten 
die tussen februari 2008 en august 2009 opgenomen werden met de diagnose “ge-
broken heup”. Het aantal patiënten met een niet-simultane breuk van beide heupen 
was 109 (9%). Het mediane interval tussen de twee breuken was 25 maanden. Bij een 
identiek breuktype was de behandeling in 88% ook hetzelfde. Het relatief hoge risico 
voor een tweede dijbeenhalsbreuk benadrukt het belang van secundaire preventie, 
vooral bij patiënten met een eerdere pols- of wervelfractuur. hoofdstuk 4 beschrijft 
het samenvoegen van de resultaten van 8 eerder (tussen 1986 en 2010), onafhankelijk 
van elkaar uitgevoerde, gerandomiseerde onderzoeken met in totaal 986 patiën ten. De 
behandeling van een patiënt met een gebroken heup hangt van veel factoren af. Wan-
neer gekozen wordt voor een prothese zijn hier grofweg in het algemeen 2 typen van. 
Een kop-halsprothese (KHP) vervangt de dijbeenhals en heupkop van de patiënt. Bij een 
totale heupprothese (THP) wordt ook de kom vervangen. Welke van deze twee opera-
ties voor de patiënt beter is, is nog niet duidelijk. In de 8 onderzoeken lootten patiënten 
tussen KHP en THP en vervolgens vond minimaal 1 jaar follow-up plaats. Dit review met 
meta-analyse resulteerde in een revisiepercentage dat niet-significant groter was bij de 
KHP- groep: 4% versus 7%. Het percentage “uit de kom schieten” (luxatie) was bij de THP- 
groep hoger: 3% versus 9%. De 1-jaarsmortaliteit verschilde niet significant: 15% na een 
KHP versus 13% na een THP. Grote complicaties, 24% (KHP) versus 25% en kleine com-
plicaties, 14% (KHP) versus 13% waren in beide groepen gelijk. Patiëntentevredenheid 
gemeten met verschillende door patiënten ingevulde vragenlijsten was beter na een 
THP. Echter, omdat de onderzoeksmethoden van de individuele studies niet voldoen 
aan moderne methodologische standaarden is de heAlTh trial opgezet. Dit is een 
internationaal, gerandomiseerde trial die KHP vergelijkt met THP voor de behandeling 
van verplaatste dijbeenhalsfracturen (N= 1.434).
deel 2
In hoofdstuk 5 staat de analyse beschreven van twee verschillende coördinatiestrat-
egieën die gebruikt zijn voor het coördineren van de heAlTh trial. Traditioneel wordt 
bij multicenter onderzoek gekozen voor lokale coördinatie. Hierbij organiseert de lokale 
hoofdonderzoeker alles zelf in zijn ziekenhuis. Soms is assistentie beschikbaar voor de 
procedure bij de medisch ethische toetsingscommissie (METC), patiëntenrekrutering 
en dataverzameling. Bij centrale coördinatie verricht een centraal aangestelde, betaalde 
studiecoördinator voor alle deelnemende ziekenhuizen deze taken. Centrale coördi-
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natie resulteerde in een kortere opstarttijd (mediaan 7 weken) en een hoger inclusie-
percentage (mediaan 10% meer) met vergelijkbare hoge kwaliteit en een uitstekend 
follow-uppercentage (>90%). Centrale coördinatie biedt, onder randvoorwaarden, 
niet-academische, hoog-volume ziekenhuizen de mogelijkheid deel te nemen aan grote 
orthopedisch- traumachirurgische studies.
Bij de follow-up van patiënten wordt, zeker in onderzoeksverband, maar ook in de 
moderne klinische praktijk, veel gebruikt gemaakt van gevalideerde vragenlijsten. Deze 
door de patiënt gerapporteerde uitkomstmaten geven de belangrijkste informatie over 
het effect van de behandeling. hoofdstuk 6 beschrijft de resultaten van het onderzoek 
naar een vragenlijst (WOMAC), die sinds 1982 veel wordt afgenomen en uitgebreid is 
onderzocht bij patiënten met heup- of knieslijtage (artrose). Met deze lijst wordt de 
patiëntentevredenheid na behandeling met kunstgewrichten van deze aandoeningen 
gemeten. De populatie van patiën ten met gewrichtsslijtage verschilt echter belangrijk 
met die van patiënten met een gebroken heup. Bij artrose nemen (pijn)klachten steeds 
verder toe bij vorderende slijtage van het gewricht, tot een moment waarop besloten 
wordt te opereren. Patiënten met een fractuur daarentegen hebben over het algemeen 
geen klachten van het heupgewricht zelf en hebben van het ene op het andere mo-
ment een dijbeenhalsbreuk en veel pijn. Daarom is het niet vanzelfsprekend dat deze 
vragenlijst ook gebruikt kan worden in de beenbreukpopulatie. Met dit onderzoek is 
voor de eerste keer aangetoond dat de WOMAC vragenlijst geldig en betrouwbaar is en 
bovendien klinisch relevante veranderingen goed detecteert in de heupfractuurpopu-
latie.
deel 3
De moderne behandeling van patiënten met een gebroken heup vereist vele handelin-
gen met betrokkenheid van meerdere disciplines. Basale vereisten zijn bijvoorbeeld ad-
equate pijnstilling, een vlotte doorstroom op de spoedeisende hulp en snelle operatieve 
behandeling, valanalyse, decubitus-, val- en delierpreventie, adequate postoperatieve 
mobilisatie en verdere revalidatie, dit alles rekening houdend met fysieke en psychische 
comorbiditeit en polyfarmacie. Een klinisch zorgpad geeft structuur aan zorgprofession-
als om deze optimale zorg voor alle (fractuur)patiënten te bereiken. hoofdstuk 7 bes-
chrijft het effect van de introductie van een klinisch zorgpad voor heupfractuurpatiënten 
in een regionaal opleidingsziekenhuis in Nederland. De analyse van 212 patiënten met 
een operatie voor een heupfractuur in de periode vóór het zorgpadgebruik (21 juni 2008 
tot 1 november 2009) en 314 patiënten met het zorgpadgebruik (7 januari 2010 tot 7 juli 
2011) resulteerde in een daling van de gemiddelde opnameduur van 10 tot 6 dagen, 
afhankelijk van het type operatie. Het overlijdenspercentage (6 versus 5%) en compli-
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catiepercentage (45 versus 38%) verschilden niet wezenlijk. Ook was er geen verschil in 
het totale percentage heropnames (16 versus 17%). Concluderend is de introductie van 
een klinisch zorgpad een veilige manier gebleken om de opnameduur te bekorten en 
het draagt bij aan verbetering van de kwaliteit van zorg voor deze kwetsbare populatie.
De in hoofdstuk 8 beschreven resultaten geven antwoord op de vraag: wat kost 
een behandeling met een prothese voor een gebroken heup in Nederland? De zorgt-
rajecten van de Neder landse heAlTh trial deelnemers zijn nauwkeurig gevolgd. Aan 
elk onderdeel van deze zorg werd een bedrag gekoppeld en uiteindelijk kon hier een 
gemiddelde van berekend worden. De geïndexeerde kostprijzen waren beschikbaar 
uit de financiële administratie van verschillende, participerende ziekenhuizen, de 
Nederlandse Zorgautoriteit (NZa) en uit de handleiding voor kostenonderzoek van het 
Instituut voor MedicalTechnology Assessment in opdracht van het college van zorgver-
zekeringen (CvZ). Voor het berekenen van direct medische kosten van een behandeling 
zijn dit gebruikelijke bronnen. Het revalidatietraject (46%) en de opnamedagen (22%) 
maakten samen het belangrijkste deel uit van de totale kosten per patiënt. Het cumula-
tieve gemiddelde bedrag na 1 jaar follow-up was € 23.869 en na 2 jaar € 26.398.
Tot slot bevat hoofdstuk 9 de Nederlandse samenvatting en hoofdstuk 10 de 
Engelse samenvatting. hoofdstuk 11 is een algemene discussie over de bevindingen 
beschreven in dit proefschrift en de plaats hiervan in zowel de praktijk als de literatuur. 
Tevens bevat het een toekomstperspectief over de behandeling van een “gebroken 
heup” met een prothese.
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Hip fracture care must be well organized in order to achieve the best medical and logis-
tic results for the 20,000 Dutch patients who sustain such a fracture annually. In order to 
optimize healthcare planning, knowledge of accurate numbers in hip fracture incidence 
rate and population structure are needed (Chapter 2). A trend break in the incidence 
rates of hip frac ture-related hospitalizations was observed in the Netherlands around 
1994. This study was performed over the period from 1981-2008. The incidence peak 
was in 2010 for the first time more than 20,000 patients (20,254 registered cases, 65+ 
population: 17,184, Figure 1).
Since 1981 a fairly stable 85% (ranges: 81-89%) of hip fractures occur in the 65+ popula-
tion. The Dutch 65+ population has almost doubled since 1981 from 1.6 million (12% of 
total popula tion) to more than 3 million (18%), with a steep increase since 2010 (Figure 
2).
A parallel steep increase of the hip fracture incidence in the future might better be 
prevented. So what must be the major effort in hip fracture prevention in the Nether-
lands?
Although clear Dutch primary and secondary preventive guidelines exist (1-3), it has 
repeatedly been shown that the adherence to these guidelines is generally poor (4-8). 
Two aspects are crucial for fracture prevention. First, the focus should be on primary 
prevention of falls (9, 10). Leading activities for sustaining a fracture indoors are walk-
ing, standing, and sitting; common outdoor activities are walking and cycling (11). Key 
aspects of such prevention programs should include individual patient assessment, 
evaluation of risks around the house, safety intervention (12-14), physical exercise train-
ing to improve body balancing (15, 16) and follow-up (17). However, it is good to realize 
that patients themselves are not always motivated to follow these prevention strategies 
(18, 19).
Hip protectors, for example, probably reduce the risk of hip fractures (but not falls) in 
selected patients in nursing homes, but its effect is minimal due to poor acceptance and 
adherence particularly in the long term (20). Elderly persons increasingly use a mobility 
aid. Using such mobility aids can lead to substantial accidents (21, 22). The second as-
pect in fracture prevention is screening for osteoporosis and treating this risk factor can 
be an effective strategy in fracture prevention (23, 24). Bisphosphonates have shown a 
clinically important benefit, especially in secondary prevention (25-27). On the other 
hand, it is known that patient compliance and persistence with treatment for optimal 
fracture prevention is mandatory, but low (28). The role of vitamin D suppletion is still 
debated (29), but there is lacking evidence for a positive effect of supplementation 
on fractures or fall prevention (30). So, the use of pharmacotherapy should always be 
outweighed against the possible side effects (31-35). The importance of short-term sec-
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ondary prevention is emphasized by the fact that recurrent fallers have poorer physical 
performance and quality of life than single fallers (36). These data support the results 
as described in Chapter 3. The cumulative incidence of non-simultaneous bilateral 
femoral neck fractures was 9 % and the median interval between the two fractures was 
25 months (37). These numbers are in accordance with previous published Dutch results 
(38). In conclusion, primary and secondary hip fracture prevention is challenging and 
important in daily practice to achieve improvement.
When prevention fails and the older person falls, a displaced femoral neck fracture can 
be the result. Traditionally, these fractures have been treated with hemiarthroplasty and 
later with total hip arthroplasty, also other options exist, e.g., conservative treatment 
(only with short life expectancy) and internal fixation (39). Both in literature (40-43) and at 
morning rounds (the characteristics of ) these patients and their fractures are frequently 
discussed. Mostly the conclusion is that the preference of the surgeon is decisive for 
treatment. The supposed advantage of total hip arthroplasty is superior function and 
patient satisfaction, proponents of hemiarthroplasty emphasize shorter surgery times, 
reduced blood loss and lower costs (44, 45). It is good to realize that the discussion is 
about a subgroup of the total population, namely the elderly patient who is cognitive 
unimpaired and who was physically fit before the fracture (46, 47). In literature there is a 
trend towards better functional outcomes in patients treated with total hip arthroplasty. 
For example, the Cochrane review in 2001 (48) and its updates by Parker et al. in 2004 
(49) and 2006 (50) concluded that the role of total hip arthroplasty in the treatment of 
displaced femoral neck fractures was uncertain. The most recent update in 2010 states 
that there is some evidence for better functional outcomes, against more dislocations 
after total hip arthroplasty than after hemiarthroplasty (51). In our systematic review 
and meta-analysis (Chapter 4) we also found similar rates for postoperative minor and 
major complications, revision surgery rates and mortality. Risk of dislocation favored 
HA. Estimates for function, pain and quality of life are less clear, but tend to be in favor 
of THA . Other recent reviews and cost-effectiveness analysis confirms these conclusions 
(52-55), also without a greater risk for mortality (56). The moderate methodological 
quality of the trials, which form the base of the reviews and analyses, is the reason why 
controversy persist (57). The results of the international HEALTH trial (N= 1,434, see ap-
pendix) aims to provide better evidence for the preferred type of arthroplasty for active 
elderly patients with a displaced femoral neck fracture (58). The follow-up of this trial is 
two years and 91% (1,302/1,434) of the participants was included in November 2016. 
This trial has the potential to have an important impact on the confidence in the effect 
estimate and to substantially change surgical practice for the modern management of 
femoral neck fractures, for instance in the Netherlands. Combining available data from 
Statistics Netherlands (http://statline.cbs.nl) and the Annual Report of the Dutch Arthro-
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plasty Register (www.LROI.nl) results only in a stable 3.5% primary total hip arthroplas-
ties for acute fracture management in 2010, 2011, and 2012 (Table 1).
On the other hand, a study from the American Board of Orthopaedic Surgery found an 
increase on the use of total hip arthroplasty over time from 0.7% (1999) to 7.7% (2011)
(59). A nationwide study in Finland found an increase from 4.9% (1998) to even 9.2% 
(2011)(60).
Considering total hip arthroplasty more often potentially results not only in better 
patient outcomes but it also can have a positive influence on costs (61). Another inter-
esting trial (currently recruiting patients) aims to compare total hip arthroplasty and 
hemiarthroplasty for displaced femoral neck fracture specifically in patients aged 80 
years and over (62). Besides the type of implant other surgery related uncertainties exist, 
for example: is there a “best approach”(63), use cement or not for new design implants 
(64, 65), what is the role of large-head (≥36-millimeters) total hip implants and which 
patient characteristics are essential to make correct patient-based-decisions on the 
treatment of the femoral neck fracture in a particular patient?
Table 1. Total number of patients treated with primary total hip arthroplasty (THA) in relation to the num-
ber of all types of hip fractures in the Netherlands, divided per year (www.LROI.nl).
Year N (total hip fractures) N (ThA for fractures) %
2012 18,863 628 3.3
2011 19,136 624 3.2
2010 20,254 831 4.1
Research in the field of management of hip fractures requires large numbers of par-
ticipating patients. These numbers can best be achieved in multicenter research, which 
brings logistical and regulatory challenges. Several coordination strategies can be used. 
Chapter 5 describes a comparison of a strategy with a centrally-funded trial coordinator 
enabling high-volume hospitals to participate, thus improving trial progression, with lo-
cal trial coordination combined with per patient payment. Limiting conditions for central 
coordination are budget availability, a manageable number of patients, and a manage-
able distance between participating sites. The same results were found in a comparable 
trial, including even 250 hip fracture patients in the Netherlands (66). Although inclu-
sion rates were similar for both coordination strategies there was a higher enrollment 
rate with central coordination. Kendall et al. also found a positive association between 
site visiting coordinators and the assessed recruitment-related study milestones (67).
Traditionally, objective determinants like mortality, complications, and revision sur-
gery were used for evaluating quality of care in clinical research. Nowadays, methods 
to measure the subjective patient’s perspective of treatment results are gaining impor-
tance (68). These perspectives are quantified using patient-reported outcome measures 
(PROMs), which are available for assessing functional outcome and quality of life. In 
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Chapter 6 it is shown, for the fi rst time, that a well-known disease specifi c questionnaire, 
the WOMAC, is valid and reliable in a generally fi t hip fracture population. It is therefore 
a suitable instrument for use in future clinical studies in this population (69). Great ef-
forts are made by the Netherlands Orthopaedic Association and Dutch Trauma Society 
to make PROMs part of standard of arthroplasty and hip fracture care. Implementing 
PROMs to the Dutch Arthroplasty Register (www.LROI.nl) and the Dutch Hip Fracture 
Audit aims to evaluate quality and further improve patient care. A successful stepwise 
introduction of such a comprehensive program was previously shown in Sweden (70).
As outlined above, the care for patients with hip fractures is complex and, especially 
in the frail subpopulation, outcomes depend on multidisciplinary collaboration (71). A 
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Figure 1. Absolute numbers of hip fractures in the Dutch 65+ population (available data until 2012: http://
statline.cbs.nl).
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Figure 2. Rates of the Dutch 65+ population in relation to the total population (available data until 2015: 
http://statline.cbs.nl).
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hospital specific clinical pathway is a tool for care professionals to ensure optimal care 
through the whole process without skipping essential steps. Pathways can have a posi-
tive effect on clinical outcomes (72, 73). The results from Chapter 7 show the same effect 
in a before-and-after study. The pathway describes interdisciplinary appointments and 
rules regarding the five clinical stages: pre-, peri-, post-operative, transfer to surround-
ing rehabilitation centers and follow-up. Successful implementation of such pathways 
can contribute to reducing healthcare costs as propagated by the Dutch Ministry of 
Health, Welfare and Sport (74). Namely, health expenditure has increased continuously 
since 1972, from 8% to 13% of gross domestic product (GDP). Based on the trend of the 
past decade, different scenarios assess healthcare expenditure between 19% and 31% 
of GDP in 2040. Insight in healthcare costs may reveal options for cutting down health 
care expenses. Chapter 8 reveals for the first time the Dutch costs for arthroplasty for 
the treatment of displaced femoral neck fractures in active elderly patients. The mean 
total medical costs of treating femoral neck fracture patients with arthroplasty were 
after one year € 23,869 and after two year € 26,399. The main cost determinants were 
rehabilitation and nursing homes. Reducing costs after hip fracture surgery should focus 
on improving the duration and efficiency of the rehabilitation phase.
Hip fracture care in the Netherlands is well organized. However, results from clinical 
research are able to better finetune the details of hip fracture management. A pivotal 
role is for the treating clinician whose task is to have a helicopter view and look after 
the optimal, individual, pre-operative preparation, timely surgery, eye for peroperative 
detail and to be interested in the patient after surgery and at the outpatient clinic.
In summary, a dedicated orthopedic trauma surgeon is not solely dependent on im-
plant mate rial, but should be able to achieve good clinical results and satisfied patients.
FuTuRe PeRsPeCTIVes
Figure 3 summarizes the impact of results from this thesis on clinical practice. Future 
research should focus on the following topics, in order to further improve hip fracture 
care in the Netherlands.
First, the most important aspect of optimal hip fracture care is primary fall prevention. 
There fore, increasing national awareness for fall incidents by public campaigns is neces-
sary. Recur rent falling, especially in the 65+ population cannot be accepted by neither 
healthcare professionals nor family members. Different types of fall prevention strate-
gies exist and this health topic deserves more attention. Fall prevention (number and 
cause(s) of falls, living circumstances, polypharmacy, etc.) is primarily a task for general 
practitioners and nursing homes physicians.
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Hospitals in cooperation with general practitioners should organize the secondary 
fracture prevention. First because in the Netherlands fractures are diagnosed and 
treated in hospitals. Secondly, this type of prevention is time consuming, needs good 
follow-up structure, blood sampling and DEXA scanning. In the cases that prevention 
has failed and the hip fracture is a fact, the appropriate treatment must be chosen for 
that particular patient by shared decision making. The first question should be: osteo-
synthesis or arthroplasty? The definitive results from the HEALTH and FAITH trial will 
soon provide important data on the type of implant preference and on risks of revision 
surgery, complication rates and costs. Multiple options are available for arthroplasty and 
some clinical questions are unanswered. Future research should also focus on clinical 
important differences and costs when comparing different options for arthroplasty. 
For example, does the surgical approach (and the surgeons’ experience) substantially 
influence postoperative function, pain and rates of dislocation? Does the use of ce-
ment substantially influence postoperative function, pain and rates of periprosthetic 
fractures, infection and death in the hip fracture population? When performing total 
hip arthroplasty in this population, what are the disadvantages of using large diameter 
heads (>36 mm)? Discussions and critical reviews from meta-analyses from randomized 
controlled trials and observational studies, answering the above mentioned questions 
will support the decision making for treatment of individual patients. The results from 
future (randomized) studies will be of more clinical value when a high volume of patients 
are included and when the follow-up time, depending on the subject of course, is longer 
(at least five year) than customary (1 or 2 years). Also, clinical hip fracture related studies 
without using patient reported outcome measures (PROMs) should not be planned, car-
ried out, sponsored or approved by medical research ethics committees. PROMs are not 
only of importance for the results in individual studies, but also the continuation of the 
PROMs program (including the hip fracture populations) related to the Dutch Arthro-
plasty Register, involving all disciplines treating hip fractures, is essential in improving 
quality of hip fracture care. Study results can be compared with national standard values 
and geographic important variations can be detected. Also, in order to improve qual-
ity of hip fracture care it is possible to discuss and to monitor if treatment trends from 
literature are reflected in clinical practice. This kind of scientific support for treatment 
changes has been proven to be successful, an example is the Swedish National Patient 
Register (75). Another aspect for future investment in the care for hip fractures, based 
among other publications and on the outcomes described in Chapter 7, is to stimulate 
the use of dedicated care pathways and to evaluate the results of surgery, complications, 
admission days, secondary prevention, and follow up.
Especially the mean hospital admission days has been reduced in the last decade. This 
can be regarded as an important advance. However, in Chapter 8 it is described that 
about half of the costs for hip fracture treatment is needed for rehabilitation facilities/ 
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nursing homes. Reducing this length (and thus costs) would be a next step in optimizing 
treatment. Most rehabilitation centers, hospitals and physiotherapists have their own 
protocols. But no uniform national protocol exists. It would be useful to develop such 
a program with specific exercises and points. The Dutch concept guideline “Proximal 
femoral fractures” advices, based on the NICE and AAOS guidelines, to offer at least 
once daily in-hospital therapy and evaluate functional recovery. To start therapy on 
the day of surgery is part of optimal hip fracture care. Early mobilization is preferred 
as it reduces complications and has positive influence on the functional recovery. As 
a consequence hip fracture patients ideally are treated in the morning, before the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Relation between chapters from this thesis and the clinical course of displaced femoral neck frac-
tures. Green blocks represent new information from study results in this thesis, which can be used in clinical 
practice. Yellow blocks represent information from study results in this thesis, which can confirm previously 
published results, without direct effect on clinical practice.
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regular operative theater program. In most hospitals however, the daily practice is that 
hip fractures patients are operated at the end of the regular program (after 16:00). To 
implement morning hip fracture surgery would have major logistic consequences. After 
discharge intensive home therapy (at least 3x / week) is preferred over no physiotherapy 
and it equals therapy at the outpatient department. Alternatively, therapy is performed 
in rehabilitation facilities. There is no evidence on the optimal duration or discharge 
criteria from physiotherapy. The standard rehabilitation duration of 12 months needs to 
be further evaluated.
In conclusion, for the preferred early mobilization of hip fracture patients surgery in 
the morn ing can help to achieve even better patients outcomes. The length, type of 
exercises, evaluation methods and location (at home or rehabilitation center) of the 
physiotherapy in the Netherlands needs to be further evaluated with a cost analysis and 
development of a national protocol.
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Mini abstract
WhAT Is AlReAdY kNoWN oN ThIs ToPIC?
- Since the mid-nineties there are decreasing incidence rates for hip fracture-related 
hospitalizations in several, but not all, western countries (Chapter 2).
- The cumulative incidence of non-simultaneous proximal femur fractures is about 
2-20% and the median interval is about 2-5 years (Chapter 3).
- The most beneficial type of arthroplasty (per patient) for displaced femoral neck 
fractures is not known (Chapter 4).
- Patient reported outcome measures are the modern way of treatment evaluation 
(Chapter 6), a well- known example is the WOMAC questionnaire, frequently used in 
arthritis populations.
- Cost analysis are important, but are country dependent due to different healthcare 
and economic systems around the world (Chapter 8).
WhAT ThIs ThesIs Adds?
- Chapter 2 shows a decrease in hip fracture incidence rates since 1994, also in the 
Netherlands.
- Chapter 3 shows for femoral neck fractures a specific cumulative incidence of 9% 
and an interval of 2 years. In this population osteoporosis screening was performed 
in only 19%, although 28% had had a prior fracture and 5-7% had a concomitant 
fracture. Surgeons generally agreed on the use of internal fixation or arthroplasty for 
the different types of femoral neck fractures.
- The review of the most recent available evidence (Chapter 4) shows that total hip 
arthroplasty may be advantageous over hemiarthroplasty in a selected group of 
patients suffering displaced femoral neck fractures.
- The results in Chapter 6 show for the first time that the WOMAC is also suitable for 
use in future clinical studies in hip fracture populations.
- For the first time in the Netherlands the total medical costs of treating femoral neck 
fracture patients with hemi- or total hip arthroplasty are calculated: € 26,399 per 
patient until 2 years postoperatively (Chapter 8).
WhAT do We hAVe To ChANGe?
- Efforts to minimize hip fractures and the length of hospital stay after a hip fracture 
must be continued (Chapter 2).
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- Use the results from Chapter 3 for patient education to increase awareness of the 
relatively high risk of a second hip fracture in the near future. Doctors should better 
adhere to the national secondary osteoporosis prevention guideline (and refer all 
50+-patients with a fracture for screening).
- Total hip arthroplasty should more frequently be considered in the treatment of 
displaced femoral neck fractures (Chapter 4) and without any type of delay this 
treatment for fracture care should be available at all times.
- PROMs should be obligatory in future hip fracture treatment evaluation research 
(Chapter 6).
- With the expected increase of the total absolute numbers of hip fractures in the near 
future, efforts need to be made to reduce the total medical costs (Chapter 8).
WhAT Needs FuRTheR ReseARCh?
- For appropriate healthcare planning and follow-up, it would be advisable to repeat 
the study from Chapter 2 in 2020.
- Further identifying risk factors for other fractures after a hip fracture with a prospec-
tive study or database. Measurements of hip fracture treatment results from a patient 
perspective (PROMs), also after a second fracture (Chapter 3).
- Research on the effect sizes of the types of arthroplasty after displaced hip fracture 
and further fine tuning of the national guideline on this topic. Although several 
randomized controlled trials have already been performed or are recruiting patients, 
results of more large, well-designed and well-conducted studies are needed (Chap-
ter 4).
- Future research in the field of PROMs for hip fracture populations should focus on 
the found ceiling effects and possible redundant questions, to finally develop an 
optimal hip fracture specific WOMAC questionnaire (Chapter 6).
- As rehabilitation and nursing homes accounted for almost half of the total medical 
costs after treatment with arthroplasty for displaced femoral neck fractures, focus on 
improvements of the rehabilitation phase can result in reducing costs (Chapter 8).
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Summary HEALTH protocol
INTRoduCTIoN
Worldwide, 4.5 million persons are disabled from hip fractures yearly with an expected 
increase to 21 million persons living with disability in the next 40 years. Hip fractures are 
associated with a 30% mortality rate and the number of hip fractures is expected to be 
over 6 million patients annually by 2050.
Despite these impressive numbers, definitive standard surgical management of 
displaced femoral neck fractures is lacking. Current evidence suggests the use of arthro-
plasty; advocates of hemi-arthroplasty (HA) focus upon reduced dislocation rates, lower 
rates of deep vein thrombosis, shorter operating times, less blood loss, and a technically 
less demanding procedure. Surgeons supporting total hip arthroplasty (THA) perceive 
benefits in improving patient function and improving quality of life. Methodological 
limitations of previous studies, as well as their small sample sizes and resulting wide 
confidence intervals, have left the optimal operative approach unresolved.
objective
The HEALTH trial compares revision rates at 24 months following THA versus HA in 
patients 50 years of age or older with displaced femoral neck fractures. Secondary 
outcome measures include mortality, complications, health-related quality of life (Short 
Form-12, SF-12), functional outcomes (Western Ontario McMaster Osteoarthritis Index, 
WOMAC), and health outcome (EuroQol-5D, EQ-5D).
hypothesis
It is hypothesized that total hip arthroplasty will have similar or lower rates of revision 
surgery (primary outcome) and higher functional outcome scores (secondary outcome) 
at 24 months compared with hemi-arthroplasty.
meThods ANd ANAlYsIs
In a multicenter, randomised controlled trial, 1,434 patients 50 years of age or older, 
with displaced femoral neck fractures from international sites are randomised to receive 
either THA or HA. Exclusion criteria include associated major injuries of the lower ex-
tremity, hip infection(s) and a history of frank dementia. Minimisation is used to ensure 
balance between intervention groups for the following factors: age, prefracture living, 
prefracture functional status, American Society for Anesthesiologists (ASA) Class and 
center number. Data analysts and the HEALTH Steering Committee are blinded to the 
surgical allocation throughout the trial. Outcome analysis will be performed using a χ2 
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test (or Fisher’s exact test) and Cox proportional hazards modelling estimate. All results 
will be presented with 95% CIs.
ResulTs
In the Netherlands 14 participating sites started between December 15, 2008 and Janu-
ary 6, 2011. On February 14, 2011 the anticipated sample size of 150 patients was reached. 
Patients were recruited for the Dutch HEALTH trial if they (1) were adults aged ≥50 years; 
(2) had a radiologically confirmed displaced femoral neck fracture, were aged at least 
50 years (and were not candidates for osteosynthesis); (3) had a low energetic fracture 
without other major trauma; and (4) were ambulatory pre-fracture (with or without aid). 
Patients were excluded if they; (1) had a pathological fracture; (2) had associated major 
injuries of the lower extremities; (3) had retained hardware around the hip; (4) had an 
infection around the hip; (5) had a bone metabolism disorder other than osteoporosis; 
(6) were moderately or severely cognitively impaired pre-fracture; (7) had dementia or 
Parkinson’s disease severe enough to compromise the rehabilitation process; or (8) were 
not likely to be able to complete follow-up. These eligibility criteria did not interfere with 
national treatment guidelines.
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Abbreviations
lIsT oF ABBReVIATIoNs
CVZ College voor zorgverzekeringen 
(tegenwoordig:Zorginstituut Nederland)
euroQol-5d/ eQ-5d Europe Quality of Life- 5 dimensions (questionnaire)
GdP Gross domestic product
FAITh Fixation using Alternative Implants for the Treatment of 
Hip fractures
hA Hemi-Arthroplasty
heAlTh Hip fracture Evaluation with ALternatives of Total hip 
arthroplasty versus Hemi-arthroplasty (NCT00556842)
NZa Nederlandse Zorg Autoriteit
khP Kop-halsprothese
meTC Medisch ethische toetsingscommissie
PRom Patient Reported Outcome Measure
sF-12 Short Form 12 (questionnaire)
ThA Total Hip Arthroplasty
ThP Totale heupprothese
WomAC Western Ontario McMaster Osteoarthritis Index (question-
naire)
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Lieve Caroline, ontzettend bedankt voor alles wat je mij gegeven hebt. Mede door 
jouw steun en inzet hebben we ook dit project kunnen afronden. Ik houd van jou en zal 
dat blijven doen.
Lieve Janne, sven en Nils. Wat zijn jullie een prachtig team met z’n drieen. Altijd 
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